Covered_Recipient_Type,Teaching_Hospital_ID,Teaching_Hospital_Name,Physician_Profile_ID,Physician_First_Name,Physician_Middle_Name,Physician_Last_Name,Recipient_Primary_Business_Street_Address_Line1,Recipient_Primary_Business_Street_Address_Line2,Recipient_City,Recipient_Zip_Code,Physician_Primary_Type,Physician_Specialty,Submitting_Applicable_Manufacturer_or_Applicable_GPO_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,658.84,12/31/2015,In-kind items and services,254936860,,,"Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab MEDI-563 in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,HOLOGIC INC,100000010400,HOLOGIC INC,MA,9375.00,10/21/2015,Cash or cash equivalent,239738556,,,Protocol 15 01 ALARA2015 1,,A prospective program to collect clinical image data from both 2D FFDM and 3D tomosynthesis mammograms for use in testing and refining the performance of a supervised pixel based machine learning SPML technique to reduce noise and artifacts in FFDM and tomosynthesis images acquired at a reduced xray radiation dose
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,HOLOGIC INC,100000010400,HOLOGIC INC,MA,5000.00,11/12/2015,Cash or cash equivalent,239738560,,,Protocol 15 01 ALARA2015 1,,A prospective program to collect clinical image data from both 2D FFDM and 3D tomosynthesis mammograms for use in testing and refining the performance of a supervised pixel based machine learning SPML technique to reduce noise and artifacts in FFDM and tomosynthesis images acquired at a reduced xray radiation dose
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314-3017,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,24850.43,01/13/2015,Cash or cash equivalent,254909914,BRILINTA,,A Multinational  Randomised  Double Blind  Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death  Myocardial Infarction or Stroke in Patients with Type 2 Diabetes,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,45546.90,12/31/2015,In-kind items and services,254938724,,,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,13612.25,01/14/2015,Cash or cash equivalent,254941378,BRILINTA,,"A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo in Addition to Existing Acetyl Salicylic Acid ASA Therapy in Patients with History of Myocardial Infarction and Risk of Thrombotic Even",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,5454.14,04/30/2015,In-kind items and services,254939708,,,High dose ICS LABA 2ndController Study SIROCCO,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314-3017,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1008.26,12/31/2015,In-kind items and services,254949428,BYDUREON,,Exenatide Study of Cardiovascular Event Lowering EXSCEL A Placebo controlled Double blind Trial Examining the Effect of Exenatide QW Treatment on Major Macrovascular Events in Patients with Type 2 Diabetes with Elevated CV Risk,,
Covered Recipient Teaching Hospital,2938,Mercy Medical Center-Des Moines,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,39050.00,07/15/2015,Cash or cash equivalent,254943524,BRILINTA,,Affordability and Real world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication patient adherence and clinical outcomes,,
Covered Recipient Teaching Hospital,2815,Trinity Bettendorf,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,17634.74,01/13/2015,Cash or cash equivalent,254933524,FARXIGA,,"Dapagliflozin Effect on Cardiovascular Events  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,49510.15,05/19/2015,Cash or cash equivalent,254932720,,,A randomised double blind placebo controlled parallel group multicentre phase III study to evaluate the efficacy and safety of 2 doses of benralizumab MEDI 563 in patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD with a history of COPD exacerbations GALATHEA,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314-3017,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,13170.00,10/19/2015,Cash or cash equivalent,254929860,BYDUREON,,Exenatide Study of Cardiovascular Event Lowering EXSCEL A Placebo controlled Double blind Trial Examining the Effect of Exenatide QW Treatment on Major Macrovascular Events in Patients with Type 2 Diabetes with Elevated CV Risk,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,Ste 3262,Des Moines,50314-3027,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2227.54,04/30/2015,In-kind items and services,254952022,BYDUREON PEN,,Exenatide Study of Cardiovascular Event Lowering EXSCEL A Placebo controlled Double blind Trial Examining the Effect of Exenatide QW Treatment on Major Macrovascular Events in Patients with Type 2 Diabetes with Elevated CV Risk,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,4548.78,04/30/2015,In-kind items and services,254950760,SYMBICORT,,A Phase IIIB 6 Month Doubleblind Double dummy Randomized Parallel group  Multicenter Exacerbation Study of Symbicort pMDI 160 45 g  2 Actuations Twice daily Compared to Formoterol Turbuhaler 45 g  2 Inhalations Twice daily in COPD Patients,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,12.07,04/30/2015,In-kind items and services,254977317,SYMBICORT,,LABA Safety Study,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,4.92,04/30/2015,In-kind items and services,254975190,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Suite West 4,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,5994.30,01/29/2015,Cash or cash equivalent,254976046,BRILINTA,,A Randomised Double Blind Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin ASA in Patients with Acute Ischaemic Stroke or TIA,,
Covered Recipient Teaching Hospital,2815,Trinity Bettendorf,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,16415.00,01/22/2015,Cash or cash equivalent,254965202,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,46048.11,07/07/2015,Cash or cash equivalent,254965212,,,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,14418.25,12/08/2015,Cash or cash equivalent,254964376,,,"Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab MEDI-563 in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Beta2 Agonist BORA",,
Covered Recipient Teaching Hospital,2938,Mercy Medical Center-Des Moines,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,23.55,04/30/2015,In-kind items and services,254962500,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,2815,Trinity Bettendorf,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,22.42,04/30/2015,In-kind items and services,254962574,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,2815,Trinity Bettendorf,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,7136.50,01/16/2015,Cash or cash equivalent,254965480,BRILINTA,,"A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo in Addition to Existing Acetyl Salicylic Acid ASA Therapy in Patients with History of Myocardial Infarction and Risk of Thrombotic Even",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Amarin Pharma Inc.,100000010379,Amarin Pharma Inc.,NJ,11158.00,12/17/2015,Cash or cash equivalent,274740606,AMR101,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,966.50,12/31/2015,In-kind items and services,257603260,,,"STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1,  A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1398.73,12/31/2015,In-kind items and services,257603268,,,A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease COPD Patients While on Maintenance Therapy,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3877.59,04/06/2015,Cash or cash equivalent,257603276,BYDUREON,,Real World Evidence Bydureon Project EQW BCB402 MTC registry,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,2500.00,12/29/2015,In-kind items and services,257604494,,,Beta lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime avibactam CAZ AVI for the treatment of complicated urinary tract infections cUTIs,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,7000.00,06/26/2015,In-kind items and services,257604610,,,Molecular beta lactamase characterization of aerobic Gram negative pathgens recovered from patients enrolled in phase II trials for ceftazidime avibactam  Efficacy analyze against resistant subsets,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,14500.00,12/31/2015,Cash or cash equivalent,257603286,,,"STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1,  A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist",,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,5000.00,06/03/2015,In-kind items and services,257605380,,,Beta lactamase characterization of baseline Enterobacteriaceae from a phase 3 trial of ceftazidime avibactam for the treatment of infections caused by CAZ nonsuspectible pathogens,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,44122.39,08/03/2015,Cash or cash equivalent,257603412,,,Ph2a Montherapy RCC study,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,2500.00,06/03/2015,In-kind items and services,257605774,,,Beta lactamase characterization of Enterobacteriaceae baseline pathogens from two phase 3 trials of ceftazidime avibactam,,
Non-covered Recipient Entity,,,,,,,345 Beaver Kreek Ctr,Ste A,North Liberty,52317-9258,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,8750.00,11/26/2015,In-kind items and services,257606456,,,The in vitro activity of ceftazidime avibactam Gram negative pathogens isolated from patients with hospital acquired and ventilator associated bacterial pneumonia,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242-1007,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,1083.30,03/18/2015,Cash or cash equivalent,257606680,BYDUREON,,Real World Evidence Bydureon Project EQW BCB402 MTC registry,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,30126.13,08/07/2015,Cash or cash equivalent,257606712,,,A Phase III Open Label Randomised Multi centre International Study of MEDI4736 Given as Monotherapy or in Combination With Tremelimumab Determined by PD L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242-1007,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3500.00,01/14/2015,Cash or cash equivalent,257603658,BRILINTA,,US Clopidogrel study PCI with Bivalirudin,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242-1007,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3237.50,04/30/2015,In-kind items and services,257603690,BRILINTA,,US Clopidogrel study PCI with Bivalirudin,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,Ste E321gh,Iowa City,52242-1009,,,AstraZeneca Pharmaceuticals LP,100000000169,"MedImmune, LLC",MD,79630.04,08/20/2015,Cash or cash equivalent,254961344,,,"A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3277.50,07/09/2015,Cash or cash equivalent,257603102,TUDORZA,,Double blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,24223.60,02/05/2015,Cash or cash equivalent,257603302,EPANOVA,,A Long Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Riask Patients with Hypertriglyceridemia STRENGTH,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,11398.38,01/23/2015,Cash or cash equivalent,257603170,BRILINTA,,A Randomised Double Blind Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin ASA in Patients with Acute Ischaemic Stroke or TIA,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,47.20,07/15/2015,In-kind items and services,257603208,TUDORZA,,Double blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,20936.95,01/23/2015,Cash or cash equivalent,257603214,FARXIGA,,"Dapagliflozin Effect on Cardiovascular Events  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,6700.00,11/12/2015,Cash or cash equivalent,254971132,BRILINTA,,Affordability and Real world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication patient adherence and clinical outcomes,,
Covered Recipient Teaching Hospital,2938,Mercy Medical Center-Des Moines,,,,,1111 6th Ave,,Des Moines,50314,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,18850.00,01/22/2015,Cash or cash equivalent,254970337,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,Ste 3262,Des Moines,50314-3027,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,29035.00,01/26/2015,Cash or cash equivalent,254970636,BYDUREON,BYDUREON PEN,Exenatide Study of Cardiovascular Event Lowering EXSCEL A Placebo controlled Double blind Trial Examining the Effect of Exenatide QW Treatment on Major Macrovascular Events in Patients with Type 2 Diabetes with Elevated CV Risk,,
Non-covered Recipient Entity,,,,,,,1515 Delhi St,Ste 100,Dubuque,52001-6320,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1512.50,10/28/2015,Cash or cash equivalent,254971812,SYNAGIS,,The SENTINEL 1 Study An Observational  Non Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,27269.60,03/10/2015,Cash or cash equivalent,254969940,,,High dose ICS LABA 2ndController Study SIROCCO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,10703.17,06/15/2015,In-kind items and services,269270842,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,160.00,12/08/2015,In-kind items and services,269270844,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,199.00,12/08/2015,In-kind items and services,269270848,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,25.00,12/08/2015,In-kind items and services,269270850,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,79.00,12/08/2015,In-kind items and services,269270852,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,195.00,12/08/2015,In-kind items and services,269270854,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,7995.00,12/08/2015,In-kind items and services,269270856,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,195.00,03/30/2015,In-kind items and services,269270858,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,199.00,03/30/2015,In-kind items and services,269270860,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,260.00,03/30/2015,In-kind items and services,269270862,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,49.00,03/30/2015,In-kind items and services,269270864,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,7995.00,03/30/2015,In-kind items and services,269270866,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,79.00,03/30/2015,In-kind items and services,269270868,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,25.00,03/30/2015,In-kind items and services,269270870,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1200.00,04/08/2015,In-kind items and services,269270872,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,325.00,04/08/2015,In-kind items and services,269270874,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,7995.00,04/08/2015,In-kind items and services,269270876,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,25.00,11/05/2015,In-kind items and services,269271198,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,79.00,11/05/2015,In-kind items and services,269271200,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,195.00,11/05/2015,In-kind items and services,269271202,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,7995.00,11/05/2015,In-kind items and services,269271204,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,79.00,04/08/2015,In-kind items and services,269270878,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,36.00,04/08/2015,In-kind items and services,269270880,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,69.00,04/08/2015,In-kind items and services,269270882,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,49.00,04/08/2015,In-kind items and services,269270884,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,195.00,04/08/2015,In-kind items and services,269270886,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,160.00,04/08/2015,In-kind items and services,269270888,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,260.00,04/08/2015,In-kind items and services,269270890,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,195.00,04/08/2015,In-kind items and services,269270892,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,25.00,04/08/2015,In-kind items and services,269270894,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,120.00,04/08/2015,In-kind items and services,269270896,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,170.00,04/08/2015,In-kind items and services,269270898,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,199.00,04/08/2015,In-kind items and services,269270900,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,120.00,04/13/2015,In-kind items and services,269270902,,,,,Equipment for research support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,618.00,01/08/2015,Cash or cash equivalent,269270904,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,618.00,06/19/2015,Cash or cash equivalent,269270906,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,Study support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1375.00,03/03/2015,Cash or cash equivalent,269270908,,,Clinical Study of the Nucleus Hybrid Cochlear Implant  Hybrid S12,,Study support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,165.00,02/06/2015,Cash or cash equivalent,269270910,,,Clinical Study of the Nucleus Hybrid Cochlear Implant  Hybrid L24,,WIRB fees
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,165.00,05/11/2015,Cash or cash equivalent,269270912,,,Clinical Study of the Nucleus Hybrid Cochlear Implant  Hybrid L24,,WIRB fees
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,405.00,04/20/2015,Cash or cash equivalent,269270914,,,Clinical Study of the Nucleus Hybrid Cochlear Implant  Hybrid L24,,Study support
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,165.00,07/01/2015,Cash or cash equivalent,269270916,,,Implantation of the Cochlear Nucleus System in Adults with Single-Sided Deafness,,WIRB fees
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1400.00,08/13/2015,Cash or cash equivalent,269270918,,,Nucleus Hybrid L24 Implant System Post Approval Study  Extended Duration,,WIRB fees
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cochlear Ltd,100000005734,Cochlear Americas,CO,1400.00,09/19/2015,Cash or cash equivalent,269270920,,,Nucleus Hybrid L24 Implant System Post Approval Study  Extended Duration,,WIRB fees
Non-covered Recipient Entity,,,,,,,1225 S Gear Ave,Ste 255,West Burlington,52655,,,"Acclarent, Inc",100000010475,"Acclarent, Inc",CA,1850.00,09/11/2015,Cash or cash equivalent,263725734,,,OASIS Registry,,
Non-covered Recipient Entity,,,,,,,1225 S Gear Ave,Ste 255,West Burlington,52655,,,"Acclarent, Inc",100000010475,"Acclarent, Inc",CA,275.00,10/12/2015,Cash or cash equivalent,263725736,,,OASIS Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Thoratec Corporation,100000000296,Thoratec Corporation,CA,4228.00,12/29/2015,Cash or cash equivalent,263663142,,,MOMENTUM 3,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Thoratec Corporation,100000000296,Thoratec Corporation,CA,50.00,04/02/2015,Cash or cash equivalent,263662860,,,SSI STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Thoratec Corporation,100000000296,Thoratec Corporation,CA,1470.00,04/16/2015,Cash or cash equivalent,263662874,,,SSI STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,ZOLL Services LLC (A/K/A ZOLL LifeCor Corp),100000000178,ZOLL Services LLC (A/K/A ZOLL LifeCor Corp),PA,5000.00,05/07/2015,Cash or cash equivalent,239723350,,,HOSPITAL WEARABLE DEFIBRILLATOR INPATIENT STUDY PROTOCOL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,ZOLL Services LLC (A/K/A ZOLL LifeCor Corp),100000000178,ZOLL Services LLC (A/K/A ZOLL LifeCor Corp),PA,3250.00,08/27/2015,Cash or cash equivalent,239723352,,,HOSPITAL WEARABLE DEFIBRILLATOR INPATIENT STUDY PROTOCOL,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,4850.00,11/13/2015,Cash or cash equivalent,263665038,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,7800.00,03/04/2015,Cash or cash equivalent,263665040,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,11100.00,08/18/2015,Cash or cash equivalent,263665042,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,15350.00,06/08/2015,Cash or cash equivalent,263665044,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,200.00,05/28/2015,Cash or cash equivalent,263665578,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,1200.00,06/10/2015,Cash or cash equivalent,263665580,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,1350.00,11/26/2015,Cash or cash equivalent,263665582,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,3150.00,03/04/2015,Cash or cash equivalent,263665584,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,8550.00,08/18/2015,Cash or cash equivalent,263665586,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,16700.00,06/05/2015,Cash or cash equivalent,263665588,,,"Short, Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses",,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,1550.00,03/06/2015,Cash or cash equivalent,263665024,,,General Outcomes Registry,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,10400.00,03/18/2015,Cash or cash equivalent,263665026,,,General Outcomes Registry,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,11675.00,07/20/2015,Cash or cash equivalent,263665028,,,General Outcomes Registry,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,12725.00,11/25/2015,Cash or cash equivalent,263665030,,,General Outcomes Registry,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,12800.00,09/15/2015,Cash or cash equivalent,263665032,,,General Outcomes Registry,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,600.00,11/25/2015,Cash or cash equivalent,263665034,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,ONE EDMUNDSON PLSUITE 500,,COUNCIL BLUFFS,51503,,,DePuy Synthes Sales Inc.,100000005706,DePuy Orthopaedics Inc.,IN,700.00,03/13/2015,Cash or cash equivalent,263665036,,,DePuy Outcomes Tracking  Sigma High Performance Partial Knee System,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,305.20,04/30/2015,In-kind items and services,257604150,,,A Phase III Randomised Double blind Placebo controlled Multi centre International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer Stage III Who Have Not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,6379.41,06/30/2015,In-kind items and services,257604212,BRILINTA,,US Clopidogrel study PCI with Bivalirudin,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,9965.00,12/01/2015,Cash or cash equivalent,257605100,,,A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease COPD Patients While on Maintenance Therapy,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,21162.30,12/31/2015,In-kind items and services,257605138,,,Ph2a Montherapy RCC study,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,150.68,04/30/2015,In-kind items and services,257604346,FARXIGA,,"Dapagliflozin Effect on Cardiovascular Events  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes",,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,11596.10,02/05/2015,Cash or cash equivalent,257604376,EPANOVA,,A Long Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Riask Patients with Hypertriglyceridemia STRENGTH,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1400.00,02/06/2015,Cash or cash equivalent,257605214,,,A Phase III Randomised Double blind Placebo controlled Multi centre International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer Stage III Who Have Not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy,,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803-2448,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,50455.75,01/23/2015,Cash or cash equivalent,257604546,BRILINTA,,A Multinational  Randomised  Double Blind  Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death  Myocardial Infarction or Stroke in Patients with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,13367.80,02/02/2015,Cash or cash equivalent,257605316,,,A Phase II Non comparative Open Label Multi centre International Study of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum based Chemotherapy Regimen,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3569.63,04/30/2015,In-kind items and services,257606268,,,A Phase II Non comparative Open Label Multi centre International Study of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum based Chemotherapy Regimen,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,5104.00,03/11/2015,Cash or cash equivalent,257606294,,,A Phase III Open Label Randomised Multi centre International Study of MEDI4736 Given as Monotherapy or in Combination With Tremelimumab Determined by PD L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,Po Box 3014,Ames,50010-3014,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3168.54,01/29/2015,Cash or cash equivalent,257605404,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242-1007,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,560.34,03/02/2015,In-kind items and services,257605456,TUDORZA,,Double blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,1840.66,04/30/2015,In-kind items and services,257603916,EPANOVA,,A Long Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Riask Patients with Hypertriglyceridemia STRENGTH,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,Po Box 3014,Ames,50010-3014,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,9.74,04/30/2015,In-kind items and services,257606506,SYMBICORT,,LABA Safety Study,,
Non-covered Recipient Entity,,,,,,,1753 W Ridgeway Ave,Ste 112,Waterloo,50701-4588,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,102.08,04/30/2015,In-kind items and services,257606622,,,A Phase III Open Label Randomised Multi centre International Study of MEDI4736 Given as Monotherapy or in Combination With Tremelimumab Determined by PD L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,6896.75,05/22/2015,Cash or cash equivalent,257604044,BRILINTA,,US Clopidogrel study PCI with Bivalirudin,,
Covered Recipient Teaching Hospital,2815,Trinity Bettendorf,,,,,4500 Utica Ridge Rd,,Bettendorf,52722,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,126.73,04/30/2015,In-kind items and services,254958260,FARXIGA,,"Dapagliflozin Effect on Cardiovascular Events  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes",,
Covered Recipient Teaching Hospital,2946,Genesis Medical Center,,,,,1227 E Rusholme St,,Davenport,52803,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,9500.00,10/15/2015,Cash or cash equivalent,254960200,BRILINTA,,Affordability and Real world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication patient adherence and clinical outcomes,,
Non-covered Recipient Entity,,,,,,,1515 Delhi St,Ste 100,Dubuque,52001-6320,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,2975.00,10/28/2015,Cash or cash equivalent,254968810,SYNAGIS,,The SENTINEL 1 Study An Observational  Non Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,16455.60,04/24/2015,Cash or cash equivalent,254967092,SYMBICORT,,A Phase IIIB 6 Month Doubleblind Double dummy Randomized Parallel group  Multicenter Exacerbation Study of Symbicort pMDI 160 45 g  2 Actuations Twice daily Compared to Formoterol Turbuhaler 45 g  2 Inhalations Twice daily in COPD Patients,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3372.00,03/02/2015,Cash or cash equivalent,254967106,BRILINTA,,Randomised double blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease EUCLID Examining Use of tiCagreLor In paD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Amarin Pharma Inc.,100000010379,Amarin Pharma Inc.,NJ,690.00,07/15/2015,Cash or cash equivalent,274740092,AMR101,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Amarin Pharma Inc.,100000010379,Amarin Pharma Inc.,NJ,10866.00,06/09/2015,Cash or cash equivalent,274739918,AMR101,,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio",,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,7970.00,02/04/2015,Cash or cash equivalent,254954574,,,An Observational Study to Assess Respiratory Syncytial Virus RSV-associated Illness in Adults With Chronic Obstructive Pulmonary Disease COPD andor Congestive Heart Failure CHF,,
Non-covered Recipient Entity,,,,,,,933 E Pierce St,Ste 501,Council Bluffs,51503-4626,,,AstraZeneca Pharmaceuticals LP,100000000146,AstraZeneca Pharmaceuticals LP,DE,3908.30,03/19/2015,Cash or cash equivalent,254954252,SYMBICORT,,LABA Safety Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2850.00,10/19/2015,Cash or cash equivalent,263674738,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2492.00,07/27/2015,Cash or cash equivalent,263674740,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3860.00,07/27/2015,Cash or cash equivalent,263674742,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4837.00,02/27/2015,Cash or cash equivalent,263674744,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,575.00,07/02/2015,Cash or cash equivalent,263674746,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4837.00,02/27/2015,Cash or cash equivalent,263674748,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,707.00,10/19/2015,Cash or cash equivalent,263674750,Darzalex,,"54767414-MMY-3003: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,12200.00,08/21/2015,Cash or cash equivalent,263674752,Darzalex,,An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,219.15,01/08/2015,Cash or cash equivalent,263674754,PANCREAZE,,A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,750.00,11/30/2015,Cash or cash equivalent,263674756,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,775.00,03/27/2015,Cash or cash equivalent,263674758,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,950.00,10/30/2015,Cash or cash equivalent,263674760,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1223.00,10/05/2015,Cash or cash equivalent,263674762,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1506.00,04/09/2015,Cash or cash equivalent,263674764,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,821.00,12/31/2015,Cash or cash equivalent,263674766,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2643.00,08/20/2015,Cash or cash equivalent,263674768,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2765.00,01/26/2015,Cash or cash equivalent,263674770,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,708.00,10/23/2015,Cash or cash equivalent,263674772,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,775.00,03/27/2015,Cash or cash equivalent,263674774,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2765.00,01/26/2015,Cash or cash equivalent,263674776,Xarelto,,"A  Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo For Reducing the Risk of Death , Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7500.00,12/28/2015,Cash or cash equivalent,263674778,Xarelto,,"R092670-SCH-3006R092670-SCH-3006: A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open",,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,500.00,03/12/2015,Cash or cash equivalent,263671646,Simponi,,"A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFa Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis",,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,52.70,02/04/2015,Cash or cash equivalent,263671648,Aragon,Zytiga,"A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC).",,
Covered Recipient Physician,,,34606,WILLIAM,HENRY,CORYELL,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1481.57,08/04/2015,In-kind items and services,263670958,,,"ESKETINTRD3005, 3001, 3002, 3003, 3004 Investigator Meeting for all 5 ESKETAMINE Protocols in Atlanta, GA on 8/3/2015 to 8/3/2015  Description Only Totality ID 211509  for Professional and Pass Thru fees for approx. $166,639.57 and Full Totality ID #214328 for HCP Value Exchange for $231,222.00 / ICD 798403 SERVICE AGREEMENT with Dallas Fanfares",,
Covered Recipient Physician,,,34606,WILLIAM,HENRY,CORYELL,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,97.12,08/04/2015,Cash or cash equivalent,263670960,,,"ESKETINTRD3005, 3001, 3002, 3003, 3004 Investigator Meeting for all 5 ESKETAMINE Protocols in Atlanta, GA on 8/3/2015 to 8/3/2015  Description Only Totality ID 211509  for Professional and Pass Thru fees for approx. $166,639.57 and Full Totality ID #214328 for HCP Value Exchange for $231,222.00 / ICD 798403 SERVICE AGREEMENT with Dallas Fanfares",,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,50301,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6000.00,12/01/2015,Cash or cash equivalent,263686908,Xarelto,,Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk,,
Covered Recipient Physician,,,125678,MICHAEL,S,BROOKS,202 10TH STREET SE,,CEDAR RAPIDS,52403-2404,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,30.00,01/20/2015,In-kind items and services,263669958,SIRUKUMAB,,"Vaccine Response Substudy of: A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1320.00,08/10/2015,Cash or cash equivalent,263702066,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1460.00,06/01/2015,Cash or cash equivalent,263702070,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2340.00,12/31/2015,Cash or cash equivalent,263702074,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3340.00,10/30/2015,Cash or cash equivalent,263702078,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1100.00,03/02/2015,Cash or cash equivalent,263702082,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,800.00,07/02/2015,Cash or cash equivalent,263702086,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,940.00,04/17/2015,Cash or cash equivalent,263702090,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,800.00,01/09/2015,Cash or cash equivalent,263702094,,,Outcomes Registry of Better Quality of Care In the Treatment (ORBIT) Atrial Fibrillation Registry.,,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2185.00,12/04/2015,Cash or cash equivalent,263699502,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,187.00,04/02/2015,Cash or cash equivalent,263699504,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,374.00,06/01/2015,Cash or cash equivalent,263699508,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,707.00,08/13/2015,Cash or cash equivalent,263699510,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4260.00,06/17/2015,Cash or cash equivalent,263695096,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,87.00,08/10/2015,Cash or cash equivalent,263695098,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2981.00,08/10/2015,Cash or cash equivalent,263695102,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,202.00,08/10/2015,Cash or cash equivalent,263695106,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,726.00,08/10/2015,Cash or cash equivalent,263695110,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,200.00,08/18/2015,Cash or cash equivalent,263695114,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1005.00,12/01/2015,Cash or cash equivalent,263695118,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,54023.00,01/07/2015,Cash or cash equivalent,263695082,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,15428.00,01/05/2015,Cash or cash equivalent,263695086,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave Ofc 450,,Des Moines,50314,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,21968.00,07/29/2015,Cash or cash equivalent,263695091,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1850.00,11/06/2015,Cash or cash equivalent,263711572,Imbruvica,,"A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Brutons Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy",,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,707.00,01/30/2015,Cash or cash equivalent,263699484,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,894.00,12/31/2015,Cash or cash equivalent,263699490,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1040.00,04/17/2015,Cash or cash equivalent,263699494,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,1622 E LOMBARD STREET,,DAVENPORT,52803,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1081.00,10/30/2015,Cash or cash equivalent,263699498,Xarelto,,Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II),,
Non-covered Recipient Entity,,,,,,,Grants Accounting Office,B5 Jessup Hall,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,18130.00,07/27/2015,Cash or cash equivalent,263713880,Darzalex,,A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autuologous stem cell transplant,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4500.00,10/02/2015,Cash or cash equivalent,263712786,,,"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4500.00,10/02/2015,Cash or cash equivalent,263712790,,,"An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionSafety and Sustenance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-2)",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,15750.00,07/20/2015,Cash or cash equivalent,263713724,Imbruvica,,An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma,,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,30.00,10/13/2015,In-kind items and services,263707428,SIRUKUMAB,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,8394.00,07/01/2015,Cash or cash equivalent,263707432,SIRUKUMAB,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1736.00,08/17/2015,Cash or cash equivalent,263707436,SIRUKUMAB,,"Vaccine Response Substudy of: A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,19660.00,09/04/2015,Cash or cash equivalent,263707442,SIRUKUMAB,,"Vaccine Response Substudy of: A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1470.00,08/26/2015,Cash or cash equivalent,263707448,SIRUKUMAB,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5600.00,10/13/2015,Cash or cash equivalent,263707452,SIRUKUMAB,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,9494.00,10/19/2015,Cash or cash equivalent,263707456,SIRUKUMAB,,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003Sub-study Protocol in CNTO136ARA3004: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T) Sub-study for Evaluating the Usability of SmartJect Auto",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,517.00,10/19/2015,Cash or cash equivalent,263707460,SIRUKUMAB,,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003Sub-study Protocol in CNTO136ARA3004: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T) Sub-study for Evaluating the Usability of SmartJect Auto",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,441.00,10/19/2015,Cash or cash equivalent,263707464,SIRUKUMAB,,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003Sub-study Protocol in CNTO136ARA3004: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T) Sub-study for Evaluating the Usability of SmartJect Auto",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4617.00,12/28/2015,Cash or cash equivalent,263707468,SIRUKUMAB,,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7286.00,12/14/2015,Cash or cash equivalent,263707472,SIRUKUMAB,,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003Sub-study Protocol in CNTO136ARA3004: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T) Sub-study for Evaluating the Usability of SmartJect Auto",,
Non-covered Recipient Entity,,,,,,,202 10th St SE,,Cedar Rapids,52403,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,730.00,12/14/2015,Cash or cash equivalent,263707476,SIRUKUMAB,,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003Sub-study Protocol in CNTO136ARA3004: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T) Sub-study for Evaluating the Usability of SmartJect Auto",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,150.00,01/02/2015,Cash or cash equivalent,263693354,Remicade,,"Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Relapse in Crohns Disease Patients Undergoing Surgical Resection",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,270.00,01/06/2015,Cash or cash equivalent,263693358,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,179.91,01/09/2015,Cash or cash equivalent,263693362,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2153.00,07/09/2015,Cash or cash equivalent,263693366,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,239.88,06/15/2015,Cash or cash equivalent,263693370,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6501.00,05/26/2015,Cash or cash equivalent,263693372,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct,Ste 8,Clive,50325,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5432.00,10/23/2015,Cash or cash equivalent,263693376,Stelara,,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohns Disease",,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3750.00,01/28/2015,Cash or cash equivalent,247060910,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE STE 205,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,450.00,01/28/2015,Cash or cash equivalent,247060912,,,QUICKFLEX 1258T PAS,,
Covered Recipient Teaching Hospital,2938,Mercy Medical Center-Des Moines,,,,,1111 6TH AVE,,DES MOINES,50314,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,250.00,01/21/2015,Cash or cash equivalent,247060914,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,1200.00,04/15/2015,Cash or cash equivalent,247060916,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,300.00,04/29/2015,Cash or cash equivalent,247060918,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,300.00,07/29/2015,Cash or cash equivalent,247060920,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,1250 E 9TH ST,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,1800.00,07/22/2015,Cash or cash equivalent,247060922,,,SJ4 POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,150.00,11/04/2015,Cash or cash equivalent,247060924,,,QUICKFLEX 1258T PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3500.00,05/06/2015,Cash or cash equivalent,247061010,,,CARDIOMEMS HF SYSTEM POST APPROVAL STUDY,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3745.00,07/29/2015,Cash or cash equivalent,247061012,,,CARDIOMEMS HF SYSTEM POST APPROVAL STUDY,,
Covered Recipient Teaching Hospital,2948,Univ Of Iowa Hosp & Clinic,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2500.00,04/22/2015,Cash or cash equivalent,247059718,,,VPA,,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,587.00,10/19/2015,Cash or cash equivalent,263723224,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,643.00,10/19/2015,Cash or cash equivalent,263723228,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1374.00,08/04/2015,Cash or cash equivalent,263723232,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1215.00,08/04/2015,Cash or cash equivalent,263723236,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1121.00,08/04/2015,Cash or cash equivalent,263723240,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1374.00,10/19/2015,Cash or cash equivalent,263723244,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1215.00,10/19/2015,Cash or cash equivalent,263723248,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1121.00,10/19/2015,Cash or cash equivalent,263723252,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,587.00,10/19/2015,Cash or cash equivalent,263723256,,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Two-arm, Multicenter Study to Assess the Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and Nephropathy",,
Non-covered Recipient Entity,,,,,,,1701 W Broadway,,Council Bluffs,51501,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4036.00,08/10/2015,Cash or cash equivalent,263723260,,,"A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects with Type 1 Diabetes Mellitus",,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,2673.00,01/22/2015,Cash or cash equivalent,278343136,Ranexa,,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization",,GILDA;1312885;1312885-1;420680448;;GS-US-259-0116
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,5880 UNIVERSITY,,WEST DES MOINES,50266,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,200.00,06/11/2015,Cash or cash equivalent,278343143,Ranexa,,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization",,IPP;1519055;1519055-1;420680448;;GS-US-259-0116
Covered Recipient Teaching Hospital,2940,Iowa Methodist Medical Center,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2990.50,02/04/2015,Cash or cash equivalent,247062188,,,ADVANCE CRT REGISTRY,,
Covered Recipient Teaching Hospital,2940,Iowa Methodist Medical Center,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2283.00,04/29/2015,Cash or cash equivalent,247062190,,,ADVANCE CRT REGISTRY,,
Non-covered Recipient Entity,,,,,,,1301 PENNSYLVANIA AVE STE 411,,DES MOINES,50316,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,150.00,05/13/2015,Cash or cash equivalent,247062192,,,OPTIMUM - LEAD REGISTRY,,
Covered Recipient Teaching Hospital,2940,Iowa Methodist Medical Center,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,4933.50,08/12/2015,Cash or cash equivalent,247062194,,,ADVANCE CRT REGISTRY,,
Covered Recipient Teaching Hospital,2940,Iowa Methodist Medical Center,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,9223.00,11/18/2015,Cash or cash equivalent,247062196,,,ADVANCE CRT REGISTRY,,
Covered Recipient Teaching Hospital,2946,Genesis Medical Center,,,,,1227 E RUSHOLME ST,,DAVENPORT,52803,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,5000.00,09/24/2015,Cash or cash equivalent,247062558,,,CARDIOMEMS HF SYSTEM POST APPROVAL STUDY,,
Covered Recipient Teaching Hospital,2946,Genesis Medical Center,,,,,1227 E RUSHOLME ST,,DAVENPORT,52803,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2050.00,11/11/2015,Cash or cash equivalent,247062560,,,CARDIOMEMS HF SYSTEM POST APPROVAL STUDY,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,200.00,08/05/2015,Cash or cash equivalent,247059226,,,QUADRIPOLAR PACING PAS,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,200.00,11/04/2015,Cash or cash equivalent,247059228,,,QUADRIPOLAR PACING PAS,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,250.00,04/29/2015,Cash or cash equivalent,247059230,,,QUADRIPOLAR PACING PAS,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3000.00,10/01/2015,Cash or cash equivalent,247059232,,,QUADRIPOLAR PACING PAS,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVE NE,,CEDAR RAPIDS,52402,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,200.00,02/04/2015,Cash or cash equivalent,247059234,,,QUADRIPOLAR PACING PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,5990.00,02/18/2015,Cash or cash equivalent,247058734,,,SCORE,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,6050.00,04/29/2015,Cash or cash equivalent,247058736,,,SCORE,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,7120.00,08/26/2015,Cash or cash equivalent,247058738,,,SCORE,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3660.00,11/04/2015,Cash or cash equivalent,247058740,,,SCORE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,3577.39,01/22/2015,Cash or cash equivalent,278346232,Letairis,,"ABS-LT: Ambrisentan in Pulmonary Hypertension: A Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects with Pulmonary Hypertension",,CLINENT;1314906-11964381;1314906-11964381-1;426004813;;GS-US-300-0124
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,14791.25,01/22/2015,Cash or cash equivalent,278346238,Letairis,,"ABS-LT: Ambrisentan in Pulmonary Hypertension: A Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects with Pulmonary Hypertension",,GILDA;1312392;1312392-1;426004813;;GS-US-300-0124
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,13240.28,02/17/2015,Cash or cash equivalent,278346245,Letairis,,"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension",,CLINENT;1344068-12209845;1344068-12209845-1;426004813;;GS-US-300-0140
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,GRANT ACCOUNTING OFFICE,B5 JESSUP HALL,IOWA CITY,52242,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,2352.50,07/09/2015,Cash or cash equivalent,278346251,Letairis,,"ABS-LT: Ambrisentan in Pulmonary Hypertension: A Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects with Pulmonary Hypertension",,GILDA;1564060;1564060-1;426004813;;GS-US-300-0124
Covered Recipient Teaching Hospital,2938,Mercy Medical Center-Des Moines,,,,,1111 6TH AVE,,DES MOINES,50314,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,3000.00,06/17/2015,Cash or cash equivalent,247063510,,,ADVANCE ASO,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2500.00,02/11/2015,Cash or cash equivalent,247063264,,,OPTISURE PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2130.00,04/15/2015,Cash or cash equivalent,247063266,,,OPTISURE PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2110.00,08/05/2015,Cash or cash equivalent,247063268,,,OPTISURE PAS,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,"St. Jude Medical, Inc.",100000000310,"St. Jude Medical, Inc.",MN,2780.00,11/18/2015,Cash or cash equivalent,247063270,,,OPTISURE PAS,,
Non-covered Recipient Entity,,,,,,,200 Medicine Administration,,Iowa City,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,48.00,06/08/2015,In-kind items and services,263721694,Darzalex,,A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autuologous stem cell transplant,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,644.00,01/15/2015,Cash or cash equivalent,263719610,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4600.00,01/15/2015,Cash or cash equivalent,263719614,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2310.75,08/06/2015,Cash or cash equivalent,263719618,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3259.25,09/11/2015,Cash or cash equivalent,263719622,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,3306.25,10/30/2015,Cash or cash equivalent,263719626,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4050.00,12/24/2015,Cash or cash equivalent,263719630,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1993.75,12/31/2015,Cash or cash equivalent,263719634,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4600.00,01/15/2015,Cash or cash equivalent,263719638,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4885.75,04/24/2015,Cash or cash equivalent,263719642,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5649.25,02/27/2015,Cash or cash equivalent,263719648,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6672.50,02/06/2015,Cash or cash equivalent,263719652,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4600.00,01/15/2015,Cash or cash equivalent,263719658,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,5649.25,02/27/2015,Cash or cash equivalent,263719662,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6672.50,02/06/2015,Cash or cash equivalent,263719666,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,644.00,01/15/2015,Cash or cash equivalent,263719670,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4600.00,01/15/2015,Cash or cash equivalent,263719674,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,868.00,12/24/2015,Cash or cash equivalent,263719678,Imbruvica,,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,21874.00,12/31/2015,Cash or cash equivalent,263719684,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1410.00,08/28/2015,Cash or cash equivalent,263719688,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1410.00,09/11/2015,Cash or cash equivalent,263719692,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4100.00,06/05/2015,Cash or cash equivalent,263719696,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,18788.00,09/18/2015,Cash or cash equivalent,263719702,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,639.00,09/04/2015,Cash or cash equivalent,263719706,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,740.00,08/14/2015,Cash or cash equivalent,263719710,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,751.00,06/05/2015,Cash or cash equivalent,263719715,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6273.00,03/02/2015,Cash or cash equivalent,263719720,,,"A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,13155.00,03/27/2015,Cash or cash equivalent,263719723,,,"A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,751.00,10/02/2015,Cash or cash equivalent,263719726,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4166.00,07/31/2015,Cash or cash equivalent,263719732,,,"A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,13843.00,07/02/2015,Cash or cash equivalent,263719736,,,"A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2556.00,05/01/2015,Cash or cash equivalent,263719740,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4945.00,11/25/2015,Cash or cash equivalent,263719744,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,6840.00,08/28/2015,Cash or cash equivalent,263719746,,,"ESKETIN-SUI-2001: A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,4100.00,06/05/2015,Cash or cash equivalent,263719750,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,205.20,07/17/2015,Cash or cash equivalent,263719752,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1448.00,11/13/2015,Cash or cash equivalent,263719756,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1448.00,12/14/2015,Cash or cash equivalent,263719760,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,7224.00,11/02/2015,Cash or cash equivalent,263719762,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,16104.00,12/03/2015,Cash or cash equivalent,263719766,,,"A Prospective,  Observational 126-month Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder (MDD) Who Have Responded to Antidepressant Treatment.",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1046.00,07/17/2015,Cash or cash equivalent,263719772,Imbruvica,,Retrospective Analysis of Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Therapies,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1064.00,07/17/2015,Cash or cash equivalent,263719776,Imbruvica,,Retrospective Analysis of Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Therapies,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,77.27,07/17/2015,Cash or cash equivalent,263719782,Imbruvica,,Retrospective Analysis of Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Therapies,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,588.00,07/17/2015,Cash or cash equivalent,263719786,Imbruvica,,Retrospective Analysis of Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Therapies,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,165.00,01/23/2015,Cash or cash equivalent,263719790,Imbruvica,,Copy of (77447) Sikic - CCL2 Blockade as a Therapy in Ovarian Cancers) for Balance of 1861 Purchase Order under new business unit 1270,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,537.00,01/30/2015,Cash or cash equivalent,263719794,Imbruvica,,"OZ1-HV1-102/Mitsuyashu,R/UCLA Care Center",,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,644.00,01/22/2015,Cash or cash equivalent,263719798,Imbruvica,,A Psychometric and Health Economic Evaluation of Metrics for Prescription Opioid Overutilization,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,178.00,10/30/2015,Cash or cash equivalent,263719804,Imbruvica,,COMETI Endocrine Therapy Index Assay -Univ of Mich/Daniel Hayes - Bob McCormack,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,885.00,09/04/2015,Cash or cash equivalent,263719808,Imbruvica,,COMETI Endocrine Therapy Index Assay -Univ of Mich/Daniel Hayes - Bob McCormack,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1615.00,04/24/2015,Cash or cash equivalent,263719812,Imbruvica,,COMETI Endocrine Therapy Index Assay -Univ of Mich/Daniel Hayes - Bob McCormack,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1288.00,11/16/2015,Cash or cash equivalent,263719818,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1360.00,11/13/2015,Cash or cash equivalent,263719822,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,340.00,06/29/2015,Cash or cash equivalent,263719826,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,550.00,11/12/2015,Cash or cash equivalent,263719830,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,775.00,11/12/2015,Cash or cash equivalent,263719834,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,163.00,11/20/2015,Cash or cash equivalent,263719838,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1000.00,11/12/2015,Cash or cash equivalent,263719842,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1000.00,11/12/2015,Cash or cash equivalent,263719846,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1050.00,11/12/2015,Cash or cash equivalent,263719852,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,825.00,11/13/2015,Cash or cash equivalent,263719856,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,170.00,11/13/2015,Cash or cash equivalent,263719860,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2340.00,01/15/2015,Cash or cash equivalent,263719864,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,340.00,06/29/2015,Cash or cash equivalent,263719868,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,340.00,11/12/2015,Cash or cash equivalent,263719872,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,350.00,11/13/2015,Cash or cash equivalent,263719876,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,1960.00,06/29/2015,Cash or cash equivalent,263719880,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2261.00,11/13/2015,Cash or cash equivalent,263719884,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,GRANT ACCOUNTING OFFICEB5 JESSUP HALL,,IOWA CITY,52242,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,2890.00,11/06/2015,Cash or cash equivalent,263719888,Yondelis,,A Randomized Controlled Study of YONDELIS (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,,
Non-covered Recipient Entity,,,,,,,JUNE E NYLEN CANCER CENTER,230 NEBRASKA STREET,SIOUX CITY,51101,,,Gilead Sciences Inc,100000000108,Gilead Sciences Inc,CA,6450.00,08/06/2015,Cash or cash equivalent,278378316,Zydelig,,"A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia",,GILDA;1604076;1604076-1;421411233;;GS-US-312-0118
Covered Recipient Physician,,,525937,ANA,,RECOBER MONTILLA,200 HAWKINS DR,NBR  2RCP,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,262.00,10/15/2015,In-kind items and services,263814786,,,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE",https://clinicaltrials.gov/ct2/show/NCT02438826,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Physician,,,1057493,CHARLES,F,LYNCH,200 HAWKINS DR C,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Pathology|Anatomic Pathology,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,4561.05,07/24/2015,Cash or cash equivalent,263815028,TRULICITY,,THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION,,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Physician,,,1057493,CHARLES,F,LYNCH,200 HAWKINS DR C,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Pathology|Anatomic Pathology,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,353.30,04/06/2015,In-kind items and services,263815030,TRULICITY,,THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION,,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Physician,,,125678,MICHAEL,STEVEN,BROOKS,202 10TH ST SE,,CEDAR RAPIDS,52403,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,529.15,11/23/2015,In-kind items and services,263816364,,,"A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02584855,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PKWY,,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,1233.71,11/19/2015,In-kind items and services,263816022,,,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY",https://clinicaltrials.gov/ct2/show/NCT02614183,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,1326.41,01/14/2015,In-kind items and services,263818608,CIALIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY,https://clinicaltrials.gov/ct2/show/NCT01865084,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,27398.00,01/06/2015,Cash or cash equivalent,263818610,CIALIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 TRIAL OF TADALAFIL FOR DUCHENNE MUSCULAR DYSTROPHY,https://clinicaltrials.gov/ct2/show/NCT01865084,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,741.85,11/23/2015,In-kind items and services,263818612,CYRAMZA,,"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN -AFP- FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB",https://clinicaltrials.gov/ct2/show/NCT02435433,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,2781.00,05/11/2015,Cash or cash equivalent,263818614,,,A RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING LY2875358 PLUS ERLOTINIB AND LY2875358 MONOTHERAPY IN MET DIAGNOSTIC POSITIVE NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO ERLOTINIB,https://clinicaltrials.gov/ct2/show/NCT01900652,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,2032.70,03/26/2015,In-kind items and services,263818616,,,ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY,https://clinicaltrials.gov/ct2/show/NCT02008357,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,18.40,12/23/2015,In-kind items and services,263818618,,,A RANDOMIZED PHASE 3 STUDY OF LY2835219 PLUS BEST SUPPORTIVE CARE VERSUS ERLOTINIB PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH STAGE IV NSCLC WITH A DETECTABLE KRAS MUTATION WHO HAVE PROGRESSED AFTER PLATINUM BASED CHEMOTHERAPY,https://clinicaltrials.gov/ct2/show/NCT02152631,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,102300.00,04/15/2015,Cash or cash equivalent,263818620,,,ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY,https://clinicaltrials.gov/ct2/show/NCT02008357,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,65445.30,04/06/2015,Cash or cash equivalent,263824888,,,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED 24-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02349295,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,4492.10,02/19/2015,In-kind items and services,263824890,,,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED 24-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02349295,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,509.80,10/17/2015,In-kind items and services,263824892,,,"A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02584855,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,6.01,03/10/2015,In-kind items and services,263824894,,,A MULTICENTER RANDOMIZED DOUBLE-BLIND ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,https://clinicaltrials.gov/ct2/show/NCT01870284,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE STE 285,,CEDAR RAPIDS,52403,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,200.00,02/16/2015,Cash or cash equivalent,263820376,,,A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF TABALUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA,https://clinicaltrials.gov/ct2/show/NCT01602224,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,43.80,01/23/2015,In-kind items and services,263822722,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,https://clinicaltrials.gov/ct2/show/NCT01816295,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,18069.00,01/06/2015,Cash or cash equivalent,263822724,AXIRON,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL STUDY WITH AN OPEN LABEL EXTENSION TO ASSESS THE IMPACT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE SEX DRIVE AND ENERGY IN HYPOGONADAL MEN,https://clinicaltrials.gov/ct2/show/NCT01816295,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,15869.00,01/20/2015,Cash or cash equivalent,263822726,HUMALOG,,AN INDIVIDUALIZED TREATMENT APPROACH FOR OLDER PATIENTS - A RANDOMIZED CONTROLLED STUDY IN TYPE 2 DIABETES MELLITUS -IMPERIUM,https://clinicaltrials.gov/ct2/show/NCT02072096,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,278.40,03/26/2015,In-kind items and services,263822728,HUMALOG,,AN INDIVIDUALIZED TREATMENT APPROACH FOR OLDER PATIENTS - A RANDOMIZED CONTROLLED STUDY IN TYPE 2 DIABETES MELLITUS -IMPERIUM,https://clinicaltrials.gov/ct2/show/NCT02072096,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,6000.00,08/31/2015,Cash or cash equivalent,263822730,HUMULIN,,"SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL",https://clinicaltrials.gov/ct2/show/NCT02561078,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,1139.00,09/09/2015,In-kind items and services,263822732,HUMULIN,,"SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL",https://clinicaltrials.gov/ct2/show/NCT02561078,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,3525.00,06/02/2015,Cash or cash equivalent,263822734,,,A COMPARISON OF LY2605541 ONCE DAILY AT A FIXED TIME WITH LY2605541 VARIABLE TIME OF DOSING IN PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS - AN OPEN LABEL RANDOMIZED CROSSOVER STUDY,https://clinicaltrials.gov/ct2/show/NCT01792284,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,26956.07,01/05/2015,Cash or cash equivalent,263822736,,,A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY2409021 COMPARED TO SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS,https://clinicaltrials.gov/ct2/show/NCT02111096,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,50997.00,01/06/2015,Cash or cash equivalent,263822738,,,COMPARISON OF THE OXYNTOMODULIN ANALOG LY2944876 TO ONCE WEEKLY EXENATIDE AND TO PLACEBO IN PATIENTS WITH TYPE 2 DIABETES,https://clinicaltrials.gov/ct2/show/NCT02119819,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,1785.11,01/23/2015,In-kind items and services,263822740,,,COMPARISON OF THE OXYNTOMODULIN ANALOG LY2944876 TO ONCE WEEKLY EXENATIDE AND TO PLACEBO IN PATIENTS WITH TYPE 2 DIABETES,https://clinicaltrials.gov/ct2/show/NCT02119819,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1111 6TH AVENUE STE 450,,DES MOINES,50314,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,932.65,01/23/2015,In-kind items and services,263822742,,,A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY2409021 COMPARED TO SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS,https://clinicaltrials.gov/ct2/show/NCT02111096,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,5526.95,01/14/2015,In-kind items and services,263822702,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,https://clinicaltrials.gov/ct2/show/NCT01646177,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,201180.50,02/25/2015,Cash or cash equivalent,263822704,,,A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD,https://clinicaltrials.gov/ct2/show/NCT01646177,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,1990.00,01/15/2015,In-kind items and services,263824318,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,https://clinicaltrials.gov/ct2/show/NCT01687998,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,37204.00,04/06/2015,Cash or cash equivalent,263824320,,,ASSESSMENT OF CLINICAL EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION WITH EVACETRAPIB IN PATIENTS AT A HIGH RISK FOR VASCULAR OUTCOMES,https://clinicaltrials.gov/ct2/show/NCT01687998,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVE,,DES MOINES,50314,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,4982.20,01/08/2015,Cash or cash equivalent,263435146,ENTRESTO,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO ENALAPRIL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVE,,DES MOINES,50314,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,15677.25,06/03/2015,Cash or cash equivalent,263435150,ENTRESTO,,AN OPEN LABEL MULTICENTER STUDY TO PROVIDE LCZ696 TO PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION FOLLOWING IN PARADIGM HF,,
Non-covered Recipient Entity,,,,,,,225 E BURLINGTON ST,,IOWA CITY,52240,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,4778.31,01/06/2015,Cash or cash equivalent,263435156,UTIBRON,,A MULTI CENTRE RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF QVA149 COMPARED TO QAB IN PATIENTS WITH COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DRIVE CC10,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,840.00,01/01/2015,In-kind items and services,263435168,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Non-covered Recipient Entity,,,,,,,11196 I PFP,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2000.13,02/25/2015,Cash or cash equivalent,263435178,ZYKADIA,,A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2850.00,05/01/2015,Cash or cash equivalent,263435194,TASIGNA,,PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR FOUR AND A HALF FOR 1 VERSUS 2 YEARS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,5400.00,02/25/2015,Cash or cash equivalent,263435206,XOLAIR,,LONG TERM NATURAL HISTORY OF PATIENTS WITH SEVERE OR DIFFICULT TO TREAT ASTHMA FROM THE TENOR OBSERVATIONAL STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,6000.00,09/02/2015,Cash or cash equivalent,263435210,ENTRESTO,,A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO VALSARTAN ON MORBIDITY AND MORTALITY IN HEART FAILURE PATIENTS NYHA CLASS II TO IV WITH PRESERVED EJECTION FRACTION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,8700.00,03/04/2015,Cash or cash equivalent,263435214,XOLAIR,,LONG TERM NATURAL HISTORY OF PATIENTS WITH SEVERE OR DIFFICULT TO TREAT ASTHMA FROM THE TENOR OBSERVATIONAL STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,14711.25,09/22/2015,Cash or cash equivalent,263435234,TASIGNA,,A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,38891.00,08/26/2015,Cash or cash equivalent,263435240,FARYDAK,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,41319.59,01/23/2015,Cash or cash equivalent,263435244,TOBI PODHALER,,A 24 WEEK OPEN LABEL PARALLEL GROUP INTERVENTIONAL PHASE IV STUDY COMPARING TOBRAMYCIN INHALATION POWDER TIP ADMINISTERED ONCE DAILY CONTINUOUSLY VERSUS TIP ADMINISTERED BID IN 28 DAY ON AND OR 28 DAY OFF CYCLES FOR THE TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,85600.08,02/20/2015,Cash or cash equivalent,263435253,GILENYA,,A 3 YEAR MULTI CENTER STUDY TO EVALUATE OPTICAL COHERENCE TOMOGRAPHY AS AN OUTCOME MEASURE IN PATIENTS WITH MULTIPLE SCLEROSIS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,312605.18,01/27/2015,Cash or cash equivalent,263435260,TASIGNA,,A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP,,
Covered Recipient Physician,,,12930,BRUCE,,HUGHES,1111 6TH AVE,,DES MOINES,50314-2610,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,520.00,05/21/2015,In-kind items and services,263468404,GILENYA,,RESEARCH RELATED PUBLICATION SUPPORT,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010-5400,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,840.00,01/01/2015,In-kind items and services,263450010,ILARIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010-5400,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,3385.80,03/18/2015,Cash or cash equivalent,263450016,ILARIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265-0433,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2380.59,02/23/2015,Cash or cash equivalent,263450020,GILENYA,,LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265-0433,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,77645.39,01/01/2015,In-kind items and services,263450024,GILENYA,,A 12 MONTH RANDOMIZED RATER AND DOSE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FINGOLIMOD TWENTY FIVE HUNDREDTH OF A MG AND HALF OF A MG ADMINISTERED ORALLY ONCE DAILY WITH GLATIRAMER ACETATE 20 MG ADMINISTERED SUBCUTANEOUSLY ONCE DAILY IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314-2610,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2595.00,03/31/2015,In-kind items and services,263450028,GILENYA,,A TWELVE MONTH PROSPECTIVE RANDOMIZED ACTIVE CONTROLLED OPEN LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314-2610,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,57490.87,01/13/2015,In-kind items and services,263450034,GILENYA,,A TWELVE MONTH PROSPECTIVE RANDOMIZED ACTIVE CONTROLLED OPEN LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702-5014,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,21134.72,01/01/2015,In-kind items and services,263450039,ILARIS,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP,,
Non-covered Recipient Entity,,,,,,,1600 DIAMOND ST,,ONAWA,51040-1548,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,840.00,01/01/2015,In-kind items and services,263450044,EXJADE,,A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,,COUNCIL BLUFFS,51503-4643,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2550.00,01/23/2015,Cash or cash equivalent,263450054,SEEBRI,,A 12 WEEK MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NVA237 IN STABLE COPD PATIENTS,,
Non-covered Recipient Entity,,,,,,,1130 S SCOTT BLVD,,IOWA CITY,52240-2907,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,552.00,01/01/2015,In-kind items and services,263450062,TOBI PODHALER,,A 24 WEEK OPEN LABEL PARALLEL GROUP INTERVENTIONAL PHASE IV STUDY COMPARING TOBRAMYCIN INHALATION POWDER TIP ADMINISTERED ONCE DAILY CONTINUOUSLY VERSUS TIP ADMINISTERED BID IN 28 DAY ON AND OR 28 DAY OFF CYCLES FOR THE TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,100570.00,01/01/2015,In-kind items and services,263450078,FARYDAK,,EPIGENETIC MODIFICATION OF CHEMOSENSITIVITY AND APOPTOSIS IN METASTATIC MELANOMATREATMENT OF A RESISTANT DISEASE USING DECITABINE TEMOZOLOMIDE AND AND PANOBINOSTAT,,
Non-covered Recipient Entity,,,,,,,105 JESSUP HALL,,IOWA CITY,52242-1316,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1468.00,08/01/2015,In-kind items and services,263450082,UTIBRON,,A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,,CEDAR RAPIDS,52401-2112,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2086.00,07/24/2015,Cash or cash equivalent,263450086,COSENTYX,,A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER STUDY OF SECUKINUMAB TO DEMONSTRATE THE EFFICACY AT 16 WEEKS AND TO ASSESS THE LONG TERM SAFETY TOLERABILITY AND EFFICACY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,2385.00,03/24/2015,Cash or cash equivalent,260906074,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,5233.50,04/02/2015,Cash or cash equivalent,260906078,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Eli Lilly and Company,100000000066,"Lilly USA, LLC",IN,450.00,12/22/2015,Cash or cash equivalent,263818622,,,THE GENETICS AND NEUROENDOCRINOLOGY OF SHORT STATURE INTERNATIONAL STUDY -GENESIS,https://clinicaltrials.gov/ct2/show/NCT01088412,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1827.00,09/08/2015,Cash or cash equivalent,260906082,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,1089.00,11/24/2015,Cash or cash equivalent,260906086,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,427.50,04/20/2015,Cash or cash equivalent,243607582,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,6457.50,03/16/2015,Cash or cash equivalent,243607586,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,225.00,02/17/2015,Cash or cash equivalent,243607588,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1687.50,01/20/2015,Cash or cash equivalent,243607590,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,390.00,01/26/2015,Cash or cash equivalent,294227602,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,5306.00,01/30/2015,Cash or cash equivalent,294227604,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4000.00,02/17/2015,Cash or cash equivalent,243603558,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,11431.08,03/16/2015,Cash or cash equivalent,243603568,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4831.48,04/20/2015,Cash or cash equivalent,243603572,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3677.16,06/01/2015,Cash or cash equivalent,243603588,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3543.46,06/15/2015,Cash or cash equivalent,243603592,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,9851.28,07/20/2015,Cash or cash equivalent,243603594,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3733.23,08/17/2015,Cash or cash equivalent,243603598,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,168.00,02/17/2015,Cash or cash equivalent,294227618,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,2040.00,02/24/2015,Cash or cash equivalent,294227620,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,1506.00,03/05/2015,Cash or cash equivalent,294227632,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,846.00,03/09/2015,Cash or cash equivalent,294227634,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4552.62,09/21/2015,Cash or cash equivalent,243603602,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,805.02,10/19/2015,Cash or cash equivalent,243603604,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1768.16,11/16/2015,Cash or cash equivalent,243603608,,,PLATINUM DIVERSITY: OUTCOMES WITH THE PREMIER STENT IN WOMEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,237.50,12/23/2015,Cash or cash equivalent,243603626,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA (PAS2),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,13888.75,10/05/2015,Cash or cash equivalent,243603646,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA (PAS2),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,423.00,04/24/2015,Cash or cash equivalent,294227644,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,1365.00,05/19/2015,Cash or cash equivalent,294227652,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,12800.00,06/08/2015,Cash or cash equivalent,294227660,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,3325.00,06/08/2015,Cash or cash equivalent,294227662,,,YA-OSS-0003,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,800.00,06/08/2015,Cash or cash equivalent,294227664,,,YA-SHO-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,1400.00,12/15/2015,Cash or cash equivalent,294227678,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,8775.00,12/20/2015,Cash or cash equivalent,294227682,,,YA-OSS-0003,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,13082.50,12/22/2015,Cash or cash equivalent,294227684,,,C-AA-14-003,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,19600.00,12/20/2015,Cash or cash equivalent,294227686,,,OTX-PLUS-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,6800.00,12/20/2015,Cash or cash equivalent,294227688,,,YA-SHO-0001,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,2000.00,12/13/2015,Cash or cash equivalent,294227690,,,C-AA-14-003,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,DENTSPLY IH AB,100000010687,DENTSPLY IH AB,PA,10650.00,12/22/2015,Cash or cash equivalent,294227706,,,D-2012-036,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4696.25,05/04/2015,Cash or cash equivalent,243603824,,,BRONCHIAL THERMOPLASTY IN SEVERE PERSISTENT ASTHMA (PAS2),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,67.50,12/07/2015,Cash or cash equivalent,243607568,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1282.50,10/21/2015,Cash or cash equivalent,243607570,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,10/19/2015,Cash or cash equivalent,243607574,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,540.00,07/20/2015,Cash or cash equivalent,243607576,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,STE 195,WEST DES MOINES,50266-8234,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,675.00,06/15/2015,Cash or cash equivalent,243607580,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,400.00,02/25/2015,Cash or cash equivalent,243631966,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4320.00,12/18/2015,In-kind items and services,243628448,,,JET REGISTRY,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4320.00,12/18/2015,In-kind items and services,243628450,,,JET REGISTRY,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3375.00,09/25/2015,In-kind items and services,243628452,,,JET REGISTRY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4209.02,12/07/2015,Cash or cash equivalent,243626318,,,UNDERSTANDING OUTCOMES WITH THE EMBLEM S-ICD IN PRIMARY PREV,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,5000.00,12/07/2015,Cash or cash equivalent,243626322,,,UNDERSTANDING OUTCOMES WITH THE EMBLEM S-ICD IN PRIMARY PREV,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1000.00,12/07/2015,Cash or cash equivalent,243626324,,,UNDERSTANDING OUTCOMES WITH THE EMBLEM S-ICD IN PRIMARY PREV,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,260.00,06/05/2015,In-kind items and services,243627490,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,520.00,01/15/2015,In-kind items and services,243627492,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,260.00,02/10/2015,In-kind items and services,243627494,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,520.00,04/10/2015,In-kind items and services,243627496,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,01/30/2015,In-kind items and services,243627498,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,6993.20,01/27/2015,Cash or cash equivalent,243627542,,,Safety and Effectiveness of JetStream (JS),,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,12846.09,07/28/2015,Cash or cash equivalent,243627544,,,Safety and Effectiveness of JetStream (JS),,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,150000.00,12/22/2015,Cash or cash equivalent,243627546,,,JetStream application in instent restenosis of the SFA/Pop,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,5286.00,11/24/2015,Cash or cash equivalent,243632246,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,BOSTON SCIENTIFIC CORPORATION,100000010636,"Atritech, Inc.",MN,200.00,11/04/2015,Cash or cash equivalent,243632248,,,PROSPECTIVE RANDOMIZED EVALUATION OF THE WATCHMAN LAA CLOSUR,,
Non-covered Recipient Entity,,,,,,,8101 BIRCHWOOD COURT SUITE N,,JOHNSTON,50131,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,520.00,10/16/2015,In-kind items and services,243628164,,,LONGEVITY STUDY CLINICAL PROTOCOL,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,11/02/2015,Cash or cash equivalent,243621392,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1065.00,10/21/2015,Cash or cash equivalent,243621396,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,285.00,10/19/2015,Cash or cash equivalent,243621398,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,266.00,09/08/2015,Cash or cash equivalent,243621402,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,557.00,08/03/2015,Cash or cash equivalent,243621404,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,705.00,06/15/2015,Cash or cash equivalent,243621410,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1912.00,06/15/2015,Cash or cash equivalent,243621412,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,855.00,04/20/2015,Cash or cash equivalent,243621414,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,266.00,03/02/2015,Cash or cash equivalent,243621418,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3805.00,02/18/2015,Cash or cash equivalent,243621422,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,01/20/2015,Cash or cash equivalent,243621428,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,500.00,03/16/2015,Cash or cash equivalent,243620108,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,540.00,02/17/2015,Cash or cash equivalent,243620204,,,SUPERNOVA,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,390.00,07/06/2015,Cash or cash equivalent,243620208,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,500.00,06/15/2015,Cash or cash equivalent,243620210,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 EAST RUSHOLME,,DAVENPORT,52803,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,390.00,06/15/2015,Cash or cash equivalent,243620214,,,EVOLVE II (SYNERGY IDE),,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,570.00,01/20/2015,Cash or cash equivalent,243621620,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1373.00,12/10/2015,Cash or cash equivalent,243622216,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,01/20/2015,Cash or cash equivalent,243621624,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,2990.00,01/20/2015,Cash or cash equivalent,243621626,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,398.00,11/18/2015,Cash or cash equivalent,243622402,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,221.00,08/03/2015,Cash or cash equivalent,243622408,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1551.00,07/20/2015,Cash or cash equivalent,243622416,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,3000.00,05/18/2015,Cash or cash equivalent,243622418,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,398.00,05/18/2015,Cash or cash equivalent,243622422,,,STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,1146.61,03/16/2015,Cash or cash equivalent,243622434,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,2935,ST. LUKES METHODIST HOSPITAL,,,,,1026 A AVENUE N.E.,,CEDAR RAPIDS,52406,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,175.00,01/20/2015,Cash or cash equivalent,243622440,,,MULTISENSOR CHRONIC EVALUATIONS IN AMBULATORY HEART FAILURE,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,890.00,10/19/2015,Cash or cash equivalent,243621336,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,4175.00,08/03/2015,Cash or cash equivalent,243621340,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,280.00,12/07/2015,Cash or cash equivalent,243621344,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,12/07/2015,Cash or cash equivalent,243621346,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,140.00,04/20/2015,Cash or cash equivalent,243621348,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,876.00,03/16/2015,Cash or cash equivalent,243621352,,,CAP2 - PREVAIL CONTINUED ACCESS REGISTRY,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,250.00,01/20/2015,Cash or cash equivalent,243621354,,,ION US COA,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6TH AVENUE,,DES MOINES,50314,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,645.00,12/07/2015,Cash or cash equivalent,243621358,,,LONGITUDINAL SURVEILLANCE REGISTRY OF 4-SITE,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,390.00,03/13/2015,Cash or cash equivalent,295286048,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,6001 Westown Pkwy,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,32.00,11/19/2015,Cash or cash equivalent,295938806,,,PSR,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,480.63,11/06/2015,Cash or cash equivalent,295939542,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2145.88,04/29/2015,Cash or cash equivalent,295939549,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1072.94,06/05/2015,Cash or cash equivalent,295939554,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,112.00,06/16/2015,Cash or cash equivalent,295939558,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1553.57,08/07/2015,Cash or cash equivalent,295939564,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,184.00,08/11/2015,Cash or cash equivalent,295939568,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1500.00,08/11/2015,Cash or cash equivalent,295939572,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2250.00,08/11/2015,Cash or cash equivalent,295939576,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,65.81,08/26/2015,Cash or cash equivalent,295939580,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,Ste 450,Des Moines,50314,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,961.26,10/12/2015,Cash or cash equivalent,295939586,,,CEP266 ASPIRE Post Market,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,78.00,01/15/2015,Cash or cash equivalent,295939590,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,4856.00,01/20/2015,Cash or cash equivalent,295939596,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,26.00,03/19/2015,Cash or cash equivalent,295939600,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,8023.00,05/06/2015,Cash or cash equivalent,295939604,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,208.00,07/14/2015,Cash or cash equivalent,295939608,,,PPP Fully Integrated,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1828.00,08/11/2015,Cash or cash equivalent,295939614,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,6558.00,10/12/2015,Cash or cash equivalent,295939618,,,PSR,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,20430.75,11/19/2015,Cash or cash equivalent,295939622,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,2115.00,08/11/2015,Cash or cash equivalent,295939624,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,3527.00,11/19/2015,Cash or cash equivalent,295939628,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,3522.00,01/27/2015,Cash or cash equivalent,295939634,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,5250.00,05/12/2015,Cash or cash equivalent,295939636,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,1119.00,05/12/2015,Cash or cash equivalent,295939642,,,PSR,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,500.00,06/16/2015,Cash or cash equivalent,295939646,,,PSR,,
Non-covered Recipient Entity,,,,,,,1802 Calvin CT,Apt 3,Iowa City,52246,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,7970.02,12/17/2015,Cash or cash equivalent,294775768,,,CEP249 Enlite Ped FU,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,20564.07,09/02/2015,Cash or cash equivalent,294774744,,,CEP249 Enlite Ped FU,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,Ste C606,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,5225.00,06/29/2015,Cash or cash equivalent,294775996,,,CEP249 Enlite Ped FU,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,Ste C606,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,18963.28,12/21/2015,In-kind items and services,294775998,,,CEP249 Enlite Ped FU,,
Non-covered Recipient Entity,,,,,,,202 Pco,,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,5225.00,07/15/2015,Cash or cash equivalent,294776002,,,CEP249 Enlite Ped FU,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,9909.07,10/19/2015,Cash or cash equivalent,294774751,,,CEP249 Enlite Ped FU,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Medtronic MiniMed, Inc.",100000010391,"Medtronic MiniMed, Inc.",MN,7048.43,11/06/2015,Cash or cash equivalent,294774756,,,CEP249 Enlite Ped FU,,
Covered Recipient Physician,,,537419,JAMES,,LAMORGESE,4885 Lakewood Dr,,Cedar Rapids,52411,Medical Doctor,Allopathic & Osteopathic Physicians|Neurological Surgery,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,1575.00,10/07/2015,Cash or cash equivalent,295139074,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,375.00,02/05/2015,Cash or cash equivalent,295288232,,,InterStim Cycling,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,752.00,03/23/2015,Cash or cash equivalent,295139306,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2820.00,03/23/2015,Cash or cash equivalent,295139316,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,1504.00,04/16/2015,Cash or cash equivalent,295139330,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,1128.00,05/29/2015,Cash or cash equivalent,295139338,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2068.00,06/25/2015,Cash or cash equivalent,295139348,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,188.00,07/17/2015,Cash or cash equivalent,295139356,,,P03 03 Prestige LP PAS,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10th St SE,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,376.00,08/25/2015,Cash or cash equivalent,295139364,,,P12 03 EVOLVE,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,3330.00,06/05/2015,Cash or cash equivalent,295143474,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,48.75,07/07/2015,Cash or cash equivalent,295143482,,,P04 12 Prestige LP 2,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,3074.00,06/25/2015,Cash or cash equivalent,295288240,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,9706.00,08/20/2015,Cash or cash equivalent,295288247,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,10959.00,11/19/2015,Cash or cash equivalent,295288254,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,445.00,12/16/2015,Cash or cash equivalent,295288260,,,InterStim Cycling,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,165.00,05/29/2015,Cash or cash equivalent,295140974,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,8490.00,01/16/2015,Cash or cash equivalent,295140982,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,315.00,05/29/2015,Cash or cash equivalent,295140994,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,3158.00,06/29/2015,Cash or cash equivalent,295141000,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,636.00,07/01/2015,Cash or cash equivalent,295141011,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,1688.00,07/28/2015,Cash or cash equivalent,295141018,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2250.00,08/20/2015,Cash or cash equivalent,295141027,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,304.00,09/01/2015,Cash or cash equivalent,295141035,,,P03 03 Prestige LP PAS,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,942.50,03/13/2015,Cash or cash equivalent,295937108,,,PSR,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,842.40,04/17/2015,Cash or cash equivalent,295286008,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,390.00,05/18/2015,Cash or cash equivalent,295286014,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,549.90,07/21/2015,Cash or cash equivalent,295286020,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,390.00,07/16/2015,Cash or cash equivalent,295286026,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,1365.00,09/29/2015,Cash or cash equivalent,295286032,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,780.00,02/04/2015,Cash or cash equivalent,295286038,,,InSite OAB,,
Covered Recipient Physician,,,22316,KARL,,KREDER,200 Hawkins Dr,# 3120,Iowa City,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Urology,"Medtronic USA, Inc.",100000010383,"Medtronic USA, Inc.",MN,452.40,02/09/2015,Cash or cash equivalent,295286042,,,InSite OAB,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,353.00,10/05/2015,Cash or cash equivalent,295141046,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2250.00,02/04/2015,Cash or cash equivalent,295141055,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2574.00,02/13/2015,Cash or cash equivalent,295141064,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,4914.00,04/22/2015,Cash or cash equivalent,295141072,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,12076.00,05/07/2015,Cash or cash equivalent,295141080,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2128.00,05/18/2015,Cash or cash equivalent,295141090,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,10110.00,06/01/2015,Cash or cash equivalent,295141098,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,701 10th ST Se,,Cedar Rapids,52403,,,"Medtronic Sofamor Danek USA, Inc.",100000010386,"Medtronic Sofamor Danek USA, Inc.",MN,2739.00,05/29/2015,Cash or cash equivalent,295141104,,,P03 03 Prestige LP PAS,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,7350.00,07/20/2015,Cash or cash equivalent,298484862,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,9080.00,04/16/2015,Cash or cash equivalent,298484930,,,,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,4570.00,06/16/2015,Cash or cash equivalent,298484996,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,2550.00,04/08/2015,Cash or cash equivalent,298485028,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,4000.00,01/08/2015,Cash or cash equivalent,298485040,,,,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,22273.50,01/26/2015,Cash or cash equivalent,295405818,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2988.50,05/29/2015,Cash or cash equivalent,295405824,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/11/2015,Cash or cash equivalent,295405828,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,89424.00,11/03/2015,Cash or cash equivalent,295405832,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/19/2015,Cash or cash equivalent,295405836,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/19/2015,Cash or cash equivalent,295405840,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3082.00,01/20/2015,Cash or cash equivalent,295405844,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,03/26/2015,Cash or cash equivalent,295405854,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2424.00,07/15/2015,Cash or cash equivalent,295405858,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,8932.00,10/19/2015,Cash or cash equivalent,295405862,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2638.00,01/21/2015,Cash or cash equivalent,295405866,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2737.00,05/13/2015,Cash or cash equivalent,295405870,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,23087.00,08/07/2015,Cash or cash equivalent,295405874,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4119.00,11/13/2015,Cash or cash equivalent,295405878,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4713.00,10/15/2015,Cash or cash equivalent,295405882,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1950.00,02/11/2015,Cash or cash equivalent,295405886,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,60.00,05/20/2015,Cash or cash equivalent,295405890,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,75.00,08/04/2015,Cash or cash equivalent,295405893,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,22273.50,01/26/2015,Cash or cash equivalent,295405896,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2988.50,05/29/2015,Cash or cash equivalent,295405900,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/11/2015,Cash or cash equivalent,295405905,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,89424.00,11/03/2015,Cash or cash equivalent,295405910,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/19/2015,Cash or cash equivalent,295405914,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,11/19/2015,Cash or cash equivalent,295405918,,,CoreValve SURTAVI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6099.00,02/17/2015,Cash or cash equivalent,295405930,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,39377.00,08/07/2015,Cash or cash equivalent,295405934,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1448.00,09/03/2015,Cash or cash equivalent,295405938,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,680.00,10/15/2015,Cash or cash equivalent,295405944,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1437.00,11/11/2015,Cash or cash equivalent,295405948,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,12/18/2015,Cash or cash equivalent,295405952,,,WRAP IT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,6610.00,07/21/2015,Cash or cash equivalent,295405958,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,11/24/2015,Cash or cash equivalent,295405962,,,Sure Scan PAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,05/05/2015,Cash or cash equivalent,295405966,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,39540.00,09/17/2015,Cash or cash equivalent,295405971,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,406.00,10/23/2015,Cash or cash equivalent,295405976,,,ICY AVNRT,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,03/11/2015,Cash or cash equivalent,295405996,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1490.00,04/22/2015,Cash or cash equivalent,295406002,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,500.00,06/12/2015,Cash or cash equivalent,295406008,,,INPACT SFA II,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,18082.00,03/03/2015,Cash or cash equivalent,295405608,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,11755.00,03/16/2015,Cash or cash equivalent,295408394,,,Protect CA,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,150.00,03/19/2015,Cash or cash equivalent,295405616,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/10/2015,Cash or cash equivalent,295405620,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2250.00,06/30/2015,Cash or cash equivalent,295405624,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2000.00,07/16/2015,Cash or cash equivalent,295405626,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,07/28/2015,Cash or cash equivalent,295405630,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,744.00,08/12/2015,Cash or cash equivalent,295405634,,,Evera MRI,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4830.00,01/16/2015,Cash or cash equivalent,295405710,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,06/29/2015,Cash or cash equivalent,295405712,,,Resolute US,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,04/30/2015,Cash or cash equivalent,295405714,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,08/13/2015,Cash or cash equivalent,295405718,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,11/25/2015,Cash or cash equivalent,295405722,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,11/25/2015,Cash or cash equivalent,295405726,,,REFINE ICD,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,482.00,01/08/2015,Cash or cash equivalent,295405732,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,482.00,02/04/2015,Cash or cash equivalent,295405736,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,03/10/2015,Cash or cash equivalent,295405742,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3372.00,03/12/2015,Cash or cash equivalent,295405746,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,399.00,04/20/2015,Cash or cash equivalent,295405748,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,250.00,11/06/2015,Cash or cash equivalent,295405752,,,Attain Performa Lead,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3082.00,01/20/2015,Cash or cash equivalent,295405764,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,125.00,03/26/2015,Cash or cash equivalent,295405770,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2424.00,07/15/2015,Cash or cash equivalent,295405774,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,8932.00,10/19/2015,Cash or cash equivalent,295405778,,,CoreValve US Pivotal,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2638.00,01/21/2015,Cash or cash equivalent,295405784,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2737.00,05/13/2015,Cash or cash equivalent,295405788,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,23087.00,08/07/2015,Cash or cash equivalent,295405792,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4119.00,11/13/2015,Cash or cash equivalent,295405796,,,CoreValve CAS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,4713.00,10/15/2015,Cash or cash equivalent,295405802,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1950.00,02/11/2015,Cash or cash equivalent,295405806,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,60.00,05/20/2015,Cash or cash equivalent,295405810,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,5880 University Ave,,West Des Moines,50266,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,75.00,08/04/2015,Cash or cash equivalent,295405814,,,CoreValve EUS,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,3500.00,10/23/2015,Cash or cash equivalent,298486204,,,"A Prospective, Multi-Center, Non-Randomized, Safety and Efficacy Clinical, Study of the LEGION Primary Knee System for Primary Total Knee Replacement in Subjects with Degenerative Knee Disease",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Smith & Nephew, Inc.",100000005456,"Smith & Nephew, Inc.",TN,9922.00,08/13/2015,Cash or cash equivalent,298486890,,,,,
Non-covered Recipient Entity,,,,,,,411 Laurel St Ste 3262,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,6500.00,12/07/2015,Cash or cash equivalent,295961226,JARDIANCE,,EASE 2  52w eff safety  T1DM pat,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,500.00,06/19/2015,Cash or cash equivalent,295392712,,,Resolute US,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,8030.00,02/06/2015,Cash or cash equivalent,295393130,,,ENDURANT,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,2500.00,03/10/2015,Cash or cash equivalent,295393134,,,ENDURANT,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,5950 University Ave,suite 235,West Des Moines,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,1000.00,01/21/2015,Cash or cash equivalent,295923962,,,ILLUMENATE Pivotal,,
Non-covered Recipient Entity,,,,,,,700 E University Ave,,Des Moines,50316,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,3750.00,03/11/2015,Cash or cash equivalent,295924684,,,ILLUMENATE Pivotal,,
Non-covered Recipient Entity,,,,,,,1622 E. Lombard St,,Davenport,52803,,,"Medtronic Vascular, Inc.",100000010384,"Medtronic Vascular, Inc.",MN,455.00,08/19/2015,Cash or cash equivalent,295924772,,,DURABILITY ILIAC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,30.00,12/02/2015,In-kind items and services,297509754,Blincyto,,"A Phase II Study of Blinatumomab and POMP for Patients =65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients =65 years of Age with N",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,43348.70,09/22/2015,Cash or cash equivalent,297509944,IMLYGIC,,Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,360.00,07/14/2015,In-kind items and services,297509948,IMLYGIC,,Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,14468.00,01/02/2015,Cash or cash equivalent,297509952,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,43745.00,03/25/2015,Cash or cash equivalent,297509956,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6800.00,06/01/2015,Cash or cash equivalent,297509960,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2919.00,05/07/2015,In-kind items and services,297509962,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,39.25,09/21/2015,In-kind items and services,297509966,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,992.77,04/10/2015,In-kind items and services,297509968,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,88000.00,12/10/2015,In-kind items and services,297509972,IMLYGIC,,P1b2 TVEC + Yervoy combo melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1629.20,03/25/2015,In-kind items and services,297509974,IMLYGIC,,P3 OPTiM Melanoma,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Amgen Inc.,100000000203,Amgen Inc.,CA,22307.40,01/21/2015,Cash or cash equivalent,297501112,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE,SUITE 240,WEST DES MOINES,50266,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1854.00,01/01/2015,In-kind items and services,297501116,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 231,DES MOINES,50266,,,Amgen Inc.,100000000203,Amgen Inc.,CA,286.54,01/23/2015,In-kind items and services,297501122,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 231,DES MOINES,50266,,,Amgen Inc.,100000000203,Amgen Inc.,CA,132.66,10/15/2015,In-kind items and services,297501126,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266,,,Amgen Inc.,100000000203,Amgen Inc.,CA,21145.05,01/09/2015,In-kind items and services,297501128,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2945,COVENANT MEDICAL CENTER,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2500.00,04/07/2015,Cash or cash equivalent,297507984,Neulasta,,FN Prophylaxis in breast cancer and NHL (Cabs),,
Non-covered Recipient Entity,,,,,,,855 A AVENUE NORTHEAST,MEDICAL OFFICE PLAZA 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,600.00,03/27/2015,In-kind items and services,297492322,Neulasta,,Bone Pain Educational Tool US (VINE study),,
Non-covered Recipient Entity,,,,,,,202 10TH ST S E,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4598.00,03/26/2015,Cash or cash equivalent,297492328,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,855 A AVENUE NORTHEAST,MEDICAL OFFICE PLAZA 4TH FLOOR,CEDAR RAPIDS,52402,,,Amgen Inc.,100000000203,Amgen Inc.,CA,800.00,04/21/2015,In-kind items and services,297492332,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,3633.08,01/22/2015,In-kind items and services,297492337,XGEVA,,P3 Adjuvant Breast Cancer,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1273.13,01/01/2015,In-kind items and services,297483308,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,5083.06,03/26/2015,In-kind items and services,297483310,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,181.92,01/01/2015,In-kind items and services,297483315,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.76,05/26/2015,In-kind items and services,297483318,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,53.06,06/01/2015,In-kind items and services,297483324,Sensipar,,"Cinacalcet Open label, single arm study in pediatric dialysis subjects with SHPT",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4001.52,02/19/2015,In-kind items and services,297483330,Sensipar,,"Pediatric 26week, Time until Transplant",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1821.48,04/27/2015,In-kind items and services,297483334,Sensipar,,"Pediatric 26week, Time until Transplant",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,700.00,05/05/2015,Cash or cash equivalent,297483336,Aranesp,,Peds De novo Q2W Aranesp correction,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,24357.50,01/19/2015,Cash or cash equivalent,297483844,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,927.00,01/01/2015,In-kind items and services,297483850,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,106.96,02/24/2015,In-kind items and services,297483856,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,MCFARLAND CLINIC,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,164.58,10/13/2015,In-kind items and services,297483858,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,633.25,04/13/2015,In-kind items and services,297483861,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40148.00,01/07/2015,In-kind items and services,297483865,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6500.00,03/06/2015,Cash or cash equivalent,297490084,Nplate,,Pediatric Long Term Treatment Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,333.59,01/23/2015,In-kind items and services,297490088,Nplate,,Pediatric Long Term Treatment Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,27.00,01/14/2015,In-kind items and services,297490094,Nplate,,Pediatric Long Term Treatment Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,184.58,05/26/2015,In-kind items and services,297490098,Nplate,,Pediatric Long Term Treatment Study,,
Non-covered Recipient Entity,,,,,,,1000 4TH STREET SOUTHWEST,,MASON CITY,50401,,,Amgen Inc.,100000000203,Amgen Inc.,CA,600.00,02/13/2015,In-kind items and services,297529066,Neulasta,,Bone Pain Educational Tool US (VINE study),,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,34640.17,01/27/2015,In-kind items and services,297515624,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,273.00,02/02/2015,In-kind items and services,297515628,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,49579.77,02/25/2015,Cash or cash equivalent,297528166,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,191.69,01/23/2015,In-kind items and services,297528170,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1073.10,04/27/2015,In-kind items and services,297528174,XGEVA,,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,172.52,10/27/2015,In-kind items and services,297528178,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,118.45,12/28/2015,In-kind items and services,297528182,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1470.00,01/05/2015,In-kind items and services,297528185,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,127157.49,01/05/2015,In-kind items and services,297528190,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,"2055 KIMBALL AVE, STE 101",,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4250.00,03/27/2015,Cash or cash equivalent,297515360,Repatha,,EBBINGHAUS Cognitive Function Sub-Study,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,425.00,08/10/2015,In-kind items and services,297515364,Repatha,,EBBINGHAUS Cognitive Function Sub-Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,282.44,11/23/2015,In-kind items and services,297522417,Nplate,,Pediatric ITP Safety Exposure Database,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,67216.80,11/23/2015,In-kind items and services,297522422,Nplate,,Pediatric ITP Safety Exposure Database,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,40330.08,01/29/2015,In-kind items and services,297522426,Nplate,,Pediatric Long Term Treatment Study,,
Non-covered Recipient Entity,,,,,,,"2055 KIMBALL AVE, STE 101",,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,80201.10,01/14/2015,Cash or cash equivalent,297515368,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2487.25,01/01/2015,In-kind items and services,297515370,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1470.37,01/29/2015,In-kind items and services,297515374,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,408.83,10/05/2015,In-kind items and services,297515376,Repatha,,FOURIER CV Outcome,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,SUITE 101,WATERLOO,50702,,,Amgen Inc.,100000000203,Amgen Inc.,CA,87970.80,01/14/2015,In-kind items and services,297515380,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,88.03,11/19/2015,In-kind items and services,297518350,Repatha,,DESCARTES Effect Durability,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,83156.40,01/30/2015,Cash or cash equivalent,297518370,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,313.40,04/07/2015,Cash or cash equivalent,297518374,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,579.63,01/14/2015,In-kind items and services,297518378,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,552.99,04/02/2015,In-kind items and services,297518382,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2830.00,01/08/2015,In-kind items and services,297518386,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,113336.20,01/09/2015,In-kind items and services,297518390,Repatha,,FOURIER CV Outcome,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,9178.75,02/13/2015,Cash or cash equivalent,297518394,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,209.72,02/19/2015,In-kind items and services,297518399,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,510.40,05/26/2015,In-kind items and services,297518404,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,380.00,05/29/2015,In-kind items and services,297518406,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,36293.40,01/02/2015,In-kind items and services,297518410,Repatha,,OSLER OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,29500.00,02/13/2015,Cash or cash equivalent,297518416,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1074.00,04/23/2015,Cash or cash equivalent,297518418,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,163.35,04/28/2015,In-kind items and services,297518422,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,9.29,08/31/2015,In-kind items and services,297518428,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,770.33,09/02/2015,In-kind items and services,297518432,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,2780.00,05/13/2015,In-kind items and services,297518436,Repatha,,OSLER2 Ph3 OLE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Amgen Inc.,100000000203,Amgen Inc.,CA,31657.80,02/13/2015,In-kind items and services,297518440,Repatha,,OSLER2 Ph3 OLE,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,213000.00,02/19/2015,In-kind items and services,297513780,Kyprolis,,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,6690.00,03/11/2015,Cash or cash equivalent,297515604,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,198.62,01/23/2015,In-kind items and services,297515608,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,427.23,04/27/2015,In-kind items and services,297515610,XGEVA,,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,140.46,10/27/2015,In-kind items and services,297515614,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,108.89,12/28/2015,In-kind items and services,297515620,Prolia,XGEVA,P3  Multiple Myeloma Frontline,,
Non-covered Recipient Entity,,,,,,,PO BOX 3014,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,1671.00,02/02/2015,Cash or cash equivalent,297477932,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE.,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,11.13,01/23/2015,In-kind items and services,297477936,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,,AMES,50010,,,Amgen Inc.,100000000203,Amgen Inc.,CA,745.00,06/12/2015,In-kind items and services,297477940,Aranesp,,Aranesp START CKD,,
Non-covered Recipient Entity,,,,,,,1111 6th Aveste A100 East Tow,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,400.35,04/01/2015,In-kind items and services,295978872,PRADAXA,,Secondary Prevention of Stroke,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,125.66,01/01/2015,In-kind items and services,295969530,PRADAXA,,Secondary Prevention of Stroke,,
Covered Recipient Physician,,,333602,MICHAEL,R.K.,JACOBY,1111 6th Ave Ste A100,,Des Moines,50314,Medical Doctor,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,213.62,01/01/2015,In-kind items and services,295975822,PRADAXA,,Secondary Prevention of Stroke,,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1099.20,05/01/2015,Cash or cash equivalent,295972346,PRADAXA,,GLORIA AF Registry Phase II III  Core,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,143.75,04/01/2015,In-kind items and services,295976768,PRAXBIND,,Bleeding or emerg.surgery procedure,,
Non-covered Recipient Entity,,,,,,,B5 University Of Iowa,,Iowa City,52242,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,24456.00,04/01/2015,Cash or cash equivalent,295977540,PRADAXA,,GLORIA AF Registry Phase II III  Core,,
Non-covered Recipient Entity,,,,,,,411 Laurel St Ste 3262,,Des Moines,50314,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,1505.04,01/23/2015,In-kind items and services,295976116,JARDIANCE,,EASE 2  52w eff safety  T1DM pat,,
Non-covered Recipient Entity,,,,,,,1227 E Rusholme St,,Davenport,52803,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,204.97,06/01/2015,In-kind items and services,295973558,PRADAXA,,RE DUAL PCI,,
Non-covered Recipient Entity,,,,,,,5950 University Ave Ste 321,,West Des Moines,50266,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",100000000234,"Boehringer Ingelheim Pharmaceuticals, Inc.",CT,2498.40,08/01/2015,Cash or cash equivalent,295976958,PRADAXA,,GLORIA AF Registry Phase II III  Core,,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,Amgen Inc.,100000000203,Amgen Inc.,CA,5000.00,02/05/2015,Cash or cash equivalent,297533118,Repatha,,LAPLACE2 Combination Therapy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,01/01/2015,Cash or cash equivalent,295108380,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,15.40,01/02/2015,Cash or cash equivalent,295108384,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,02/01/2015,Cash or cash equivalent,295108388,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,03/01/2015,Cash or cash equivalent,295108392,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 E. 10TH ST. SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,398.22,01/23/2015,In-kind items and services,297532262,XGEVA,,P3 Adjuvant Breast Cancer,,
Non-covered Recipient Entity,,,,,,,202 E. 10TH ST. SOUTHEAST,,CEDAR RAPIDS,52403,,,Amgen Inc.,100000000203,Amgen Inc.,CA,118.79,04/27/2015,In-kind items and services,297532266,XGEVA,,P3 Adjuvant Breast Cancer,,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,Amgen Inc.,100000000203,Amgen Inc.,CA,79.66,06/07/2015,In-kind items and services,297533160,Repatha,,MENDEL2 Monotherapy,,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,Amgen Inc.,100000000203,Amgen Inc.,CA,151.88,06/07/2015,In-kind items and services,297533162,Repatha,,MENDEL2 Monotherapy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,7.31,03/13/2015,Cash or cash equivalent,295108394,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,199.15,03/13/2015,Cash or cash equivalent,295108398,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,35.80,03/13/2015,Cash or cash equivalent,295108403,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,38.91,03/13/2015,Cash or cash equivalent,295108408,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,70.00,03/13/2015,Cash or cash equivalent,295108412,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,43.44,03/13/2015,Cash or cash equivalent,295108416,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,903.70,03/13/2015,Cash or cash equivalent,295108422,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,358.74,03/13/2015,Cash or cash equivalent,295108426,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,60.00,03/27/2015,Cash or cash equivalent,295108430,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,2.60,03/27/2015,Cash or cash equivalent,295108434,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,04/01/2015,Cash or cash equivalent,295108438,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4116.61,04/09/2015,Cash or cash equivalent,295108442,,,"A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,15163.75,04/13/2015,Cash or cash equivalent,295108444,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,05/01/2015,Cash or cash equivalent,295108448,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,06/01/2015,Cash or cash equivalent,295108454,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,125.00,07/01/2015,Cash or cash equivalent,295108458,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,575.00,07/16/2015,Cash or cash equivalent,295108462,,,"A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1113.50,08/14/2015,Cash or cash equivalent,295108466,,,"An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,6070.00,08/14/2015,Cash or cash equivalent,295108470,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,3598.75,10/26/2015,Cash or cash equivalent,295108476,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Incyte Corporation,100000000263,Incyte Corporation,DE,30.00,12/09/2015,Cash or cash equivalent,295108480,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,22.50,05/04/2015,In-kind items and services,297530376,Blincyto,,"A Phase II Study of Blinatumomab and POMP for Patients =65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients =65 years of Age with N",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,213000.00,01/08/2015,In-kind items and services,297530380,Kyprolis,,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Amgen Inc.,100000000203,Amgen Inc.,CA,4205.00,02/23/2015,Cash or cash equivalent,297530384,Neulasta,,FN Prophylaxis in breast cancer and NHL (Cabs),,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,Amgen Inc.,100000000203,Amgen Inc.,CA,43.64,08/30/2015,In-kind items and services,297532754,Repatha,,Consistent and Clinically Equivalent LDL-C Reduction with Q2W and QM in Phase 3,,
Covered Recipient Physician,,,35650,JENNIFER,G,ROBINSON,200 HAWKINS DR,,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,Amgen Inc.,100000000203,Amgen Inc.,CA,15.94,10/12/2015,In-kind items and services,297532868,Repatha,,Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes,,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,STE 285,CEDAR RAPIDS,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,558.00,01/25/2015,Cash or cash equivalent,295124592,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,STE 285,CEDAR RAPIDS,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,9414.00,04/13/2015,Cash or cash equivalent,295124598,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,STE 285,CEDAR RAPIDS,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4108.50,08/11/2015,Cash or cash equivalent,295124602,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,STE 285,CEDAR RAPIDS,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,2542.50,12/21/2015,Cash or cash equivalent,295124605,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,05/21/2015,Cash or cash equivalent,295155776,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,05/21/2015,Cash or cash equivalent,295155782,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,05/21/2015,Cash or cash equivalent,295155790,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,05/21/2015,Cash or cash equivalent,295155800,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,25.30,05/26/2015,Cash or cash equivalent,295155808,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,25.30,05/26/2015,Cash or cash equivalent,295155814,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1500.00,06/01/2015,Cash or cash equivalent,295155822,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5750.00,06/01/2015,Cash or cash equivalent,295155828,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,06/05/2015,Cash or cash equivalent,295155834,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,06/05/2015,Cash or cash equivalent,295155842,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,06/05/2015,Cash or cash equivalent,295155854,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,06/22/2015,Cash or cash equivalent,295155866,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,16.97,06/25/2015,Cash or cash equivalent,295155872,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,1930.00,07/02/2015,Cash or cash equivalent,295155876,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,17.90,07/14/2015,Cash or cash equivalent,295155884,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,15.40,07/14/2015,Cash or cash equivalent,295155893,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.95,07/14/2015,Cash or cash equivalent,295155904,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.95,07/14/2015,Cash or cash equivalent,295155914,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,10.80,08/21/2015,Cash or cash equivalent,295155926,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,5350.00,09/22/2015,Cash or cash equivalent,295155934,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,22.94,01/23/2015,Cash or cash equivalent,295155750,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,8.95,01/30/2015,Cash or cash equivalent,295155756,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,3.00,05/13/2015,Cash or cash equivalent,295155762,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Incyte Corporation,100000000263,Incyte Corporation,DE,42.84,05/13/2015,Cash or cash equivalent,295155768,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403,,,Incyte Corporation,100000000263,Incyte Corporation,DE,30.00,02/16/2015,Cash or cash equivalent,295175506,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,4000.00,03/09/2015,Cash or cash equivalent,295144749,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,3805.92,04/20/2015,Cash or cash equivalent,295144757,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,126.50,04/27/2015,Cash or cash equivalent,295144764,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.35,04/27/2015,Cash or cash equivalent,295144774,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.35,04/27/2015,Cash or cash equivalent,295144784,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144792,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144800,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144808,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144816,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144826,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.35,04/27/2015,Cash or cash equivalent,295144834,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144842,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,29.75,04/27/2015,Cash or cash equivalent,295144850,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,37.95,05/13/2015,Cash or cash equivalent,295144858,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,28.56,05/13/2015,Cash or cash equivalent,295144864,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,3.00,05/13/2015,Cash or cash equivalent,295144874,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,42.84,05/13/2015,Cash or cash equivalent,295144881,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,37.95,05/19/2015,Cash or cash equivalent,295144890,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,3805.92,05/20/2015,Cash or cash equivalent,295144900,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,63.25,06/05/2015,Cash or cash equivalent,295144911,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.35,06/05/2015,Cash or cash equivalent,295144919,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,49.35,06/05/2015,Cash or cash equivalent,295144930,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,38.85,09/09/2015,Cash or cash equivalent,295144938,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,26.85,09/09/2015,Cash or cash equivalent,295144947,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,45.88,09/09/2015,Cash or cash equivalent,295144954,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,22.94,09/09/2015,Cash or cash equivalent,295144964,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,26.85,09/09/2015,Cash or cash equivalent,295144972,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,680.00,09/28/2015,Cash or cash equivalent,295144980,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,,DES MOINES,50309,,,Incyte Corporation,100000000263,Incyte Corporation,DE,6741.36,10/12/2015,Cash or cash equivalent,295144988,,,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,Incyte Corporation,100000000263,Incyte Corporation,DE,750.00,12/21/2015,Cash or cash equivalent,295186174,,,"PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES",,"The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and support for medical writing services."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.59,06/03/2015,In-kind items and services,280809706,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,4511.20,09/29/2015,Cash or cash equivalent,280812482,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1000.00,11/12/2015,Cash or cash equivalent,280815090,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,580.91,04/09/2015,Cash or cash equivalent,280809774,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3509.95,01/07/2015,Cash or cash equivalent,280813748,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,347.80,09/30/2015,Cash or cash equivalent,280815182,Victoza,,NN9211-4083,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,873.60,09/28/2015,Cash or cash equivalent,280815612,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1799.10,02/23/2015,Cash or cash equivalent,280810722,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,11171.70,07/28/2015,Cash or cash equivalent,280812576,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3038.40,04/24/2015,Cash or cash equivalent,280814170,Tresiba,,NN1250-3998,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,875.00,02/16/2015,Cash or cash equivalent,280809942,Novoeight,,NN7008-3568,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7725.60,06/02/2015,Cash or cash equivalent,280812114,Tresiba,,NN1250-3998,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,150.00,04/09/2015,Cash or cash equivalent,302234432,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7090.00,02/12/2015,Cash or cash equivalent,280810030,Ryzodeg 70/30,,NN5401-3816,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2781.25,06/12/2015,Cash or cash equivalent,280810038,Ryzodeg 70/30,,NN5401-3816,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,103.60,02/16/2015,Cash or cash equivalent,280810040,Ryzodeg 70/30,,NN5401-3816,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,8830.40,02/26/2015,Cash or cash equivalent,280813518,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7741.80,11/24/2015,Cash or cash equivalent,280814286,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1500.00,05/28/2015,Cash or cash equivalent,280810972,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,37.59,02/11/2015,Cash or cash equivalent,280813574,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7149.60,07/28/2015,Cash or cash equivalent,280814390,Tresiba,,NN1250-3998,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,206.25,10/27/2015,Cash or cash equivalent,280810192,Ryzodeg 70/30,,NN5401-3816,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,11992.50,10/22/2015,Cash or cash equivalent,280814584,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,12/30/2015,Cash or cash equivalent,302236880,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,37.91,01/16/2015,Cash or cash equivalent,280828202,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,41.45,01/12/2015,Cash or cash equivalent,280824830,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,42.50,01/08/2015,Cash or cash equivalent,280825164,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,42.50,01/08/2015,Cash or cash equivalent,280825166,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,71.10,01/21/2015,Cash or cash equivalent,280828248,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,35.55,01/21/2015,Cash or cash equivalent,280828250,Victoza,,NN9211-4083,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,70.26,01/22/2015,Cash or cash equivalent,280827240,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,500.00,06/08/2015,In-kind items and services,280823310,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,188.69,01/16/2015,Cash or cash equivalent,280826578,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,87.38,01/07/2015,Cash or cash equivalent,280825264,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,36.65,01/20/2015,Cash or cash equivalent,280826610,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,34.91,01/22/2015,Cash or cash equivalent,280826638,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.86,01/12/2015,Cash or cash equivalent,280825666,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.86,01/12/2015,Cash or cash equivalent,280825668,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.86,01/12/2015,Cash or cash equivalent,280825670,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,31.75,01/29/2015,Cash or cash equivalent,280828378,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,126.98,01/29/2015,Cash or cash equivalent,280828380,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,01/06/2015,Cash or cash equivalent,280825696,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,130.14,01/07/2015,Cash or cash equivalent,280825724,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,126.35,01/09/2015,Cash or cash equivalent,280825752,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,73.96,01/19/2015,Cash or cash equivalent,280827756,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,36.98,01/19/2015,Cash or cash equivalent,280827758,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,79.76,01/13/2015,Cash or cash equivalent,280825448,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,39.88,01/13/2015,Cash or cash equivalent,280825450,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,177.66,01/06/2015,Cash or cash equivalent,280826152,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,177.67,01/06/2015,Cash or cash equivalent,280826154,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,44.41,01/06/2015,Cash or cash equivalent,280826158,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,18263.20,02/27/2015,Cash or cash equivalent,280816368,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,34767.60,11/12/2015,Cash or cash equivalent,280816370,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,56.57,01/29/2015,In-kind items and services,280816720,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,126.86,01/26/2015,In-kind items and services,280818816,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20052.00,02/27/2015,Cash or cash equivalent,280816022,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21744.80,11/13/2015,Cash or cash equivalent,280816024,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2572.00,03/10/2015,Cash or cash equivalent,280816032,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,01/02/2015,Cash or cash equivalent,280822560,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,858.20,03/06/2015,In-kind items and services,280816812,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,477.58,03/18/2015,In-kind items and services,280817256,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,11.40,01/06/2015,In-kind items and services,280819814,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,253.72,02/03/2015,In-kind items and services,280821808,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,147.50,02/18/2015,In-kind items and services,280821810,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,27.50,03/03/2015,In-kind items and services,280817792,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1809.69,01/29/2015,In-kind items and services,280819902,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,4394.00,10/15/2015,Cash or cash equivalent,280815746,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,75.00,10/15/2015,Cash or cash equivalent,280815748,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,209.82,01/13/2015,In-kind items and services,280819018,Victoza,,NN9211-4083,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,13766.40,06/08/2015,Cash or cash equivalent,280815818,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2514.07,02/17/2015,In-kind items and services,280821532,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,825.70,05/05/2015,In-kind items and services,280822386,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1212.60,05/07/2015,In-kind items and services,280822388,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,82.50,03/03/2015,In-kind items and services,280818024,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,500.00,01/22/2015,In-kind items and services,280819646,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2500.00,09/29/2015,Cash or cash equivalent,280816300,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,49.76,01/06/2015,In-kind items and services,280819218,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,13.42,01/07/2015,In-kind items and services,280819220,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,31.26,01/30/2015,Cash or cash equivalent,280829078,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,03/02/2015,Cash or cash equivalent,280830644,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,03/04/2015,Cash or cash equivalent,280833248,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,03/05/2015,Cash or cash equivalent,280832114,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,03/05/2015,Cash or cash equivalent,280832116,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,295.00,07/01/2015,In-kind items and services,280828876,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,03/06/2015,Cash or cash equivalent,280833412,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,03/06/2015,Cash or cash equivalent,280833414,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,31.36,01/30/2015,Cash or cash equivalent,280828966,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,295.00,10/07/2015,In-kind items and services,280832278,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,03/05/2015,Cash or cash equivalent,280833842,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,33.35,01/27/2015,Cash or cash equivalent,280829722,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,62.00,08/21/2015,In-kind items and services,280830904,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3192.70,08/28/2015,In-kind items and services,280830906,Tresiba,,EX1250-4080,,
Covered Recipient Physician,,,550397,CAROLYN,MARIE,HETTRICH,200 HAWKINS DR,,IOWA CITY,52242-1007,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,3500.00,08/24/2015,Cash or cash equivalent,269676592,,,CLIN -  Global Shoulder Reg,,"Investigational device seeking FDA approval to market in the US, Registry is a long term, observational, outcomes study of FDA approved devices"
Covered Recipient Physician,,,550397,CAROLYN,MARIE,HETTRICH,200 HAWKINS DR,,IOWA CITY,52242-1007,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Tornier, Inc.",100000010814,"Tornier, Inc.",MN,21292.00,08/25/2015,Cash or cash equivalent,269676602,,,CLIN -  Global Shoulder Reg,,"Investigational device seeking FDA approval to market in the US, Registry is a long term, observational, outcomes study of FDA approved devices"
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,295.00,09/11/2015,In-kind items and services,280830940,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,07/08/2015,Cash or cash equivalent,280851080,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,11/06/2015,Cash or cash equivalent,280849670,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,07/11/2015,Cash or cash equivalent,280852490,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,11/09/2015,Cash or cash equivalent,280848612,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,05/15/2015,Cash or cash equivalent,280847420,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,07/13/2015,Cash or cash equivalent,280851590,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,05/20/2015,Cash or cash equivalent,280845592,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,05/19/2015,Cash or cash equivalent,280848090,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,05/21/2015,Cash or cash equivalent,280845284,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,11/03/2015,Cash or cash equivalent,280848838,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,05/27/2015,Cash or cash equivalent,280846344,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,05/15/2015,Cash or cash equivalent,280847582,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,160.00,11/05/2015,Cash or cash equivalent,280848874,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,11/02/2015,Cash or cash equivalent,280850038,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,07/07/2015,Cash or cash equivalent,280851990,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,11/04/2015,Cash or cash equivalent,280850062,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,07/15/2015,Cash or cash equivalent,280851382,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,05/11/2015,Cash or cash equivalent,280843746,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,04/16/2015,Cash or cash equivalent,280839982,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,04/27/2015,Cash or cash equivalent,280842414,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,200.00,04/15/2015,Cash or cash equivalent,280841004,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,04/13/2015,Cash or cash equivalent,280840406,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,04/15/2015,Cash or cash equivalent,280840084,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,04/23/2015,Cash or cash equivalent,280842514,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,04/23/2015,Cash or cash equivalent,280842516,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,05/12/2015,Cash or cash equivalent,280844574,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,260.00,05/07/2015,Cash or cash equivalent,280843936,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,05/07/2015,Cash or cash equivalent,280843938,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,04/10/2015,Cash or cash equivalent,280841194,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,05/01/2015,Cash or cash equivalent,280841916,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,04/30/2015,Cash or cash equivalent,280842928,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,04/20/2015,Cash or cash equivalent,280839540,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,04/17/2015,Cash or cash equivalent,280840212,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,90.00,04/24/2015,Cash or cash equivalent,280841602,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,04/28/2015,Cash or cash equivalent,280841622,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,05/07/2015,Cash or cash equivalent,280843366,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,04/30/2015,Cash or cash equivalent,280843048,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,09/29/2015,Cash or cash equivalent,280857200,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,12/10/2015,Cash or cash equivalent,280852828,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,10/09/2015,Cash or cash equivalent,280854516,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,10/13/2015,Cash or cash equivalent,280854536,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,10/08/2015,Cash or cash equivalent,280855542,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,09/24/2015,Cash or cash equivalent,280856938,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,09/30/2015,Cash or cash equivalent,280857916,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,10/15/2015,Cash or cash equivalent,280855600,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,07/02/2015,Cash or cash equivalent,280857686,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,10/05/2015,Cash or cash equivalent,280855622,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,07/06/2015,Cash or cash equivalent,280857014,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,12/14/2015,Cash or cash equivalent,280854348,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,12/21/2015,Cash or cash equivalent,280853398,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,12/15/2015,Cash or cash equivalent,280853440,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,10/12/2015,Cash or cash equivalent,280855442,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,04/06/2015,Cash or cash equivalent,280838658,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,03/13/2015,Cash or cash equivalent,280835242,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,03/13/2015,Cash or cash equivalent,280835252,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,04/09/2015,Cash or cash equivalent,280837998,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,420.00,03/13/2015,Cash or cash equivalent,280835254,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,180.00,03/23/2015,Cash or cash equivalent,280836980,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,03/18/2015,Cash or cash equivalent,280834952,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,03/31/2015,Cash or cash equivalent,280839054,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,03/26/2015,Cash or cash equivalent,280836342,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,160.00,04/06/2015,Cash or cash equivalent,280839114,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,90.00,04/06/2015,Cash or cash equivalent,280839116,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,03/24/2015,Cash or cash equivalent,280836774,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,04/02/2015,Cash or cash equivalent,280839206,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,04/02/2015,Cash or cash equivalent,280839208,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,260.00,03/30/2015,Cash or cash equivalent,280836836,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,03/23/2015,Cash or cash equivalent,280837580,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,08/11/2015,Cash or cash equivalent,280869442,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,08/10/2015,Cash or cash equivalent,280870478,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,12/07/2015,Cash or cash equivalent,280872840,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,09/01/2015,Cash or cash equivalent,280873870,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,08/06/2015,Cash or cash equivalent,280870568,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,08/27/2015,Cash or cash equivalent,280873594,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,12/02/2015,Cash or cash equivalent,280872322,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/09/2015,Cash or cash equivalent,280874020,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,08/03/2015,Cash or cash equivalent,280869956,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,12/08/2015,Cash or cash equivalent,280872038,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,12/03/2015,Cash or cash equivalent,280872698,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,09/03/2015,Cash or cash equivalent,280873422,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,08/05/2015,Cash or cash equivalent,280869736,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,12/01/2015,Cash or cash equivalent,280871508,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,08/13/2015,Cash or cash equivalent,280863728,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,180.00,06/26/2015,Cash or cash equivalent,280867496,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,767.50,11/16/2015,In-kind items and services,280868174,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,06/17/2015,Cash or cash equivalent,280864160,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,07/23/2015,Cash or cash equivalent,280868206,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,07/21/2015,Cash or cash equivalent,280866534,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,740.00,06/16/2015,Cash or cash equivalent,280864590,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,07/20/2015,Cash or cash equivalent,280867334,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,160.00,02/03/2015,Cash or cash equivalent,280875184,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,02/03/2015,Cash or cash equivalent,280875186,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,10/30/2015,Cash or cash equivalent,280880576,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,220.00,09/08/2015,Cash or cash equivalent,280874942,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,11/23/2015,Cash or cash equivalent,280877000,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,10/29/2015,Cash or cash equivalent,280880776,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/04/2015,Cash or cash equivalent,280875662,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,50.00,02/03/2015,Cash or cash equivalent,280876338,Victoza,,NN9211-4083,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,08/26/2015,Cash or cash equivalent,280874636,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,295.00,12/08/2015,In-kind items and services,280878588,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,10/21/2015,Cash or cash equivalent,280881480,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,12/31/2015,Cash or cash equivalent,280875736,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/02/2015,Cash or cash equivalent,280876440,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1697.60,12/21/2015,In-kind items and services,280877166,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,100.00,11/12/2015,Cash or cash equivalent,280859872,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,11/16/2015,Cash or cash equivalent,280859546,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,140.00,08/18/2015,Cash or cash equivalent,280862390,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,11/17/2015,Cash or cash equivalent,280858630,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,90.00,02/10/2015,Cash or cash equivalent,280860376,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,02/10/2015,Cash or cash equivalent,280860378,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,11/19/2015,Cash or cash equivalent,280858766,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,02/09/2015,Cash or cash equivalent,280861534,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/11/2015,Cash or cash equivalent,280860518,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,02/11/2015,Cash or cash equivalent,280860526,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,08/21/2015,Cash or cash equivalent,280862658,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,02/07/2015,Cash or cash equivalent,280860924,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/07/2015,Cash or cash equivalent,280860926,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,597.60,01/06/2015,Cash or cash equivalent,280920650,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,9252.00,08/25/2015,Cash or cash equivalent,280913644,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1584.00,12/22/2015,Cash or cash equivalent,280912862,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,10957.50,08/25/2015,Cash or cash equivalent,280923020,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,9264.60,08/25/2015,Cash or cash equivalent,280926946,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,873.75,07/14/2015,In-kind items and services,280912200,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,300.00,12/08/2015,Cash or cash equivalent,280913853,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,8191.80,04/23/2015,Cash or cash equivalent,280923054,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,398.40,02/05/2015,Cash or cash equivalent,280920926,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,16643.70,02/02/2015,Cash or cash equivalent,280921750,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,300.00,08/25/2015,Cash or cash equivalent,280921036,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1818.90,12/22/2015,Cash or cash equivalent,280925204,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2799.41,04/23/2015,Cash or cash equivalent,280925354,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,07/15/2015,In-kind items and services,280912368,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,88.50,07/22/2015,In-kind items and services,280912372,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,07/29/2015,In-kind items and services,280912376,Tresiba,,NN1250-3998,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,812.80,11/24/2015,Cash or cash equivalent,280921942,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20614.50,07/02/2015,Cash or cash equivalent,280924426,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,9938.70,06/11/2015,Cash or cash equivalent,280915224,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,9135.90,09/22/2015,Cash or cash equivalent,280924536,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7398.90,10/20/2015,Cash or cash equivalent,280926706,Tresiba,,NN1250-3998,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2026.86,11/24/2015,Cash or cash equivalent,280895164,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,10/01/2015,In-kind items and services,280897878,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,202.50,03/31/2015,In-kind items and services,280903216,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1000.00,12/14/2015,Cash or cash equivalent,280909576,Victoza,,NN2211-4059,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,10/05/2015,In-kind items and services,280897900,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,11/25/2015,In-kind items and services,280898682,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,115.82,11/30/2015,In-kind items and services,280898686,Tresiba,,NN1250-3995,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,4585.10,08/25/2015,Cash or cash equivalent,280895360,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1217.15,09/01/2015,In-kind items and services,280897316,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,877.65,09/23/2015,In-kind items and services,280897320,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,28.45,09/30/2015,In-kind items and services,280897324,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,34.95,09/02/2015,In-kind items and services,280897328,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,09/03/2015,In-kind items and services,280897332,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1062.00,08/27/2015,Cash or cash equivalent,280896422,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,902.20,10/27/2015,In-kind items and services,280901068,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,12/01/2015,In-kind items and services,280905248,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,08/05/2015,In-kind items and services,280897494,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,41.72,08/10/2015,In-kind items and services,280897500,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,08/12/2015,In-kind items and services,280897504,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,08/18/2015,In-kind items and services,280897508,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,08/28/2015,In-kind items and services,280897510,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,92.30,08/17/2015,In-kind items and services,280897514,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,08/04/2015,In-kind items and services,280897518,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,08/18/2015,In-kind items and services,280897522,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,12/04/2015,In-kind items and services,280905510,Tresiba,,NN1250-3995,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,916.00,10/29/2015,Cash or cash equivalent,280895698,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,06/09/2015,In-kind items and services,280909420,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,06/11/2015,In-kind items and services,280909424,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,194.95,06/09/2015,In-kind items and services,280909428,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,958.65,06/12/2015,In-kind items and services,280909430,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,28.45,06/02/2015,In-kind items and services,280909434,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,88.50,06/01/2015,In-kind items and services,280909438,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,08/27/2015,In-kind items and services,280897712,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,57.91,11/04/2015,In-kind items and services,280898484,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,6566.00,09/25/2015,Cash or cash equivalent,280939036,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7452.00,12/22/2015,Cash or cash equivalent,280929205,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,106.20,07/28/2015,Cash or cash equivalent,280932822,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,916.00,08/25/2015,Cash or cash equivalent,280933886,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1213.25,01/28/2015,In-kind items and services,280941340,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1578.60,11/24/2015,Cash or cash equivalent,280930013,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,18450.00,07/07/2015,Cash or cash equivalent,280927750,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,19172.70,06/02/2015,Cash or cash equivalent,280929348,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,11034.00,07/28/2015,Cash or cash equivalent,280939522,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1500.00,07/09/2015,Cash or cash equivalent,280933142,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,806.40,05/01/2015,Cash or cash equivalent,280940698,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,25386.30,02/18/2015,Cash or cash equivalent,280934324,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,8524.80,09/24/2015,Cash or cash equivalent,280928858,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,10298.00,12/22/2015,Cash or cash equivalent,280930400,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3485.60,06/04/2015,Cash or cash equivalent,280939960,Victoza,,NN2211-3659,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1625.60,07/23/2015,Cash or cash equivalent,280934496,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,47603.20,07/02/2015,Cash or cash equivalent,280937408,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1397.20,11/19/2015,Cash or cash equivalent,280930500,Victoza,,NN2211-4059,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3000.00,04/24/2015,Cash or cash equivalent,280937472,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,3809.70,11/24/2015,Cash or cash equivalent,280940048,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,09/15/2015,Cash or cash equivalent,280883616,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,280.00,02/17/2015,Cash or cash equivalent,280888830,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,90.00,02/17/2015,Cash or cash equivalent,280888834,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,10/26/2015,Cash or cash equivalent,280882516,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,02/24/2015,Cash or cash equivalent,280888312,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,02/23/2015,Cash or cash equivalent,280889518,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,06/02/2015,Cash or cash equivalent,280890974,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,120.00,02/23/2015,Cash or cash equivalent,280889524,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,50.00,02/23/2015,Cash or cash equivalent,280889526,Victoza,,NN9211-4083,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,06/03/2015,Cash or cash equivalent,280892436,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/19/2015,Cash or cash equivalent,280888444,Victoza,,NN9211-3919,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,150.00,02/18/2015,Cash or cash equivalent,280890406,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,02/20/2015,Cash or cash equivalent,280889718,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/11/2015,Cash or cash equivalent,280884004,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVEDIVISION OF ENDOCRINOLOGYDE,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.00,02/16/2015,Cash or cash equivalent,280889782,Victoza,,NN9211-3919,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/17/2015,Cash or cash equivalent,280883486,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,09/10/2015,Cash or cash equivalent,280886082,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,08/19/2015,Cash or cash equivalent,280983642,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,03/25/2015,Cash or cash equivalent,280977256,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,112.75,01/19/2015,Cash or cash equivalent,280975964,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,05/20/2015,Cash or cash equivalent,280979960,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,03/03/2015,Cash or cash equivalent,280976020,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,08/26/2015,Cash or cash equivalent,280985110,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,05/28/2015,Cash or cash equivalent,280981366,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,06/29/2015,Cash or cash equivalent,280980826,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/22/2015,Cash or cash equivalent,280983324,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,03/20/2015,Cash or cash equivalent,280976290,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1331.33,04/17/2015,In-kind items and services,280974540,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/29/2015,Cash or cash equivalent,280983538,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/23/2015,Cash or cash equivalent,280984270,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,06/02/2015,Cash or cash equivalent,280982348,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,03/05/2015,Cash or cash equivalent,280976492,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,80.00,02/25/2015,Cash or cash equivalent,280967424,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,02/27/2015,Cash or cash equivalent,280966688,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,10/06/2015,Cash or cash equivalent,280970506,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,10/02/2015,Cash or cash equivalent,280969870,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,10/07/2015,Cash or cash equivalent,280970528,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,10/28/2015,Cash or cash equivalent,280969926,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,11/03/2015,Cash or cash equivalent,280970568,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,02/17/2015,Cash or cash equivalent,280968700,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,721.44,02/11/2015,In-kind items and services,280973174,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,421.38,02/23/2015,In-kind items and services,280973178,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,01/02/2015,Cash or cash equivalent,280973246,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,10/24/2015,Cash or cash equivalent,280969470,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.86,05/06/2015,In-kind items and services,280959218,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,873.75,05/11/2015,In-kind items and services,280959222,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,05/07/2015,In-kind items and services,280959224,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,05/14/2015,In-kind items and services,280959228,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,88.50,05/12/2015,In-kind items and services,280959234,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,95.00,02/11/2015,In-kind items and services,280959998,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,14.70,02/27/2015,In-kind items and services,280960002,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,02/19/2015,Cash or cash equivalent,280969580,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,04/08/2015,In-kind items and services,280960088,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,04/14/2015,In-kind items and services,280960094,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,873.75,04/17/2015,In-kind items and services,280960098,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,88.50,04/16/2015,In-kind items and services,280960102,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,99.15,04/20/2015,In-kind items and services,280960106,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,07/13/2015,Cash or cash equivalent,280968988,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,02/12/2015,Cash or cash equivalent,280971522,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,115.00,03/24/2015,Cash or cash equivalent,280966476,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,202.50,12/31/2015,In-kind items and services,280967352,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,10/27/2015,Cash or cash equivalent,280969686,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Scientific and Medical Affairs,100000005403,Astellas Scientific and Medical Affairs,IL,67888.00,03/12/2015,Cash or cash equivalent,279654824,Myrbetriq,,A Prospective Double Blind Randomized Two Period Crossover Multi Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder OAB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1083.30,02/25/2015,Cash or cash equivalent,280999714,Victoza,,NN2211-3965,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,60.00,09/02/2015,Cash or cash equivalent,280986522,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,3524.29,07/24/2015,Cash or cash equivalent,280999774,Victoza,,NN2211-3965,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,40.00,08/17/2015,Cash or cash equivalent,280986676,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1036.76,10/08/2015,Cash or cash equivalent,280999970,Victoza,,NN2211-3965,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,139111.00,06/18/2015,Cash or cash equivalent,297138604,Myrbetriq,,A Prospective Double Blind Randomized Two Period Crossover Multi Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder OAB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,353.30,04/06/2015,Cash or cash equivalent,281000030,Victoza,,NN2211-3965,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,12375.00,02/18/2015,Cash or cash equivalent,281000078,Norditropin,,HGH-2149 ANSWER Study,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,West Des Moines,50266,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,29870.50,01/15/2015,Cash or cash equivalent,297138626,Xtandi,,A Randomized Double Blind Phase II Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,7000.00,08/03/2015,Cash or cash equivalent,281000206,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,12100.00,02/18/2015,Cash or cash equivalent,281000252,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,12000.00,05/04/2015,Cash or cash equivalent,280998322,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,28750.00,08/03/2015,Cash or cash equivalent,281000340,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1200 PLEASANT ST,,DES MOINES,50309,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,8025.00,10/14/2015,Cash or cash equivalent,280998356,Norditropin,,HGH-2149 ANSWER Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,1850.00,10/14/2015,Cash or cash equivalent,280998372,Norditropin,,HGH-2149 ANSWER Study,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,20.00,09/15/2015,Cash or cash equivalent,280985614,Victoza,,EX2211-3748,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1750.00,07/28/2015,Cash or cash equivalent,280991948,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,7428.00,11/24/2015,Cash or cash equivalent,280992052,Novoeight,,NN7008-3568,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000144,Novo Nordisk Inc,NJ,825.00,05/04/2015,Cash or cash equivalent,280998484,Norditropin,,HGH-2149 ANSWER Study,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,33.05,01/14/2015,In-kind items and services,280943874,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,56.93,01/02/2015,In-kind items and services,280943876,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,56.93,01/06/2015,In-kind items and services,280943880,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,128.71,01/28/2015,In-kind items and services,280943884,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,164.75,03/09/2015,In-kind items and services,280944522,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,396.00,09/24/2015,Cash or cash equivalent,280950576,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,2895.20,07/28/2015,Cash or cash equivalent,280951460,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.11,01/05/2015,In-kind items and services,280943444,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,30.11,01/15/2015,In-kind items and services,280943448,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.97,02/17/2015,In-kind items and services,280942754,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,33.05,02/19/2015,In-kind items and services,280942756,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,877.65,02/11/2015,In-kind items and services,280942762,Tresiba,,NN1250-3995,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1776.80,07/02/2015,Cash or cash equivalent,280950740,Victoza,,NN2211-3659,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,33.05,04/22/2015,In-kind items and services,280956413,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,21.50,04/27/2015,In-kind items and services,280956416,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,33.05,04/28/2015,In-kind items and services,280956418,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,164.75,04/30/2015,In-kind items and services,280956420,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,19.03,03/25/2015,In-kind items and services,280944240,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,98.25,03/23/2015,In-kind items and services,280944934,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,9884.00,11/24/2015,Cash or cash equivalent,280950744,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,164.75,04/29/2015,In-kind items and services,280956424,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,202.50,06/30/2015,In-kind items and services,280946858,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,1200.00,07/28/2015,Cash or cash equivalent,280955612,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,877.65,03/23/2015,In-kind items and services,280945042,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,355.75,03/06/2015,In-kind items and services,280945046,Tresiba,,NN1250-3995,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,16961.40,10/27/2015,Cash or cash equivalent,280951887,Victoza,,EX2211-3748,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,202.50,09/30/2015,In-kind items and services,280947148,Tresiba,,EX1250-4080,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,STE 450,DES MOINES,50314,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,95.00,03/06/2015,In-kind items and services,280943846,Tresiba,,NN1250-3998,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Novo Nordisk Inc,100000000163,Novo Nordisk AS,,8332.00,10/22/2015,Cash or cash equivalent,280952038,Tresiba,,EX1250-4080,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,3400.00,07/31/2015,Cash or cash equivalent,321048998,,,Contiuum CoC IDE,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,6000.00,02/27/2015,Cash or cash equivalent,321045265,,,Arcos Revision Stem,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,193.50,04/03/2015,Cash or cash equivalent,321046854,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,2602.64,04/17/2015,Cash or cash equivalent,321046865,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,39705.18,08/07/2015,Cash or cash equivalent,321046872,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,7729.92,08/21/2015,Cash or cash equivalent,321046881,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,25308.51,09/04/2015,Cash or cash equivalent,321046889,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,2505.89,10/05/2015,Cash or cash equivalent,321046898,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,34499.90,10/09/2015,Cash or cash equivalent,321046905,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,2699.39,12/11/2015,Cash or cash equivalent,321046916,,,BBIO.CR.CT002 MarrowStim PAD Kit for treatment of CLI in subjects with severe PAD IDE Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,1700.00,12/08/2015,Cash or cash equivalent,321048444,,,Continuum COC IDE,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,59.43,07/15/2015,In-kind items and services,324146926,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,3199.50,07/07/2015,Cash or cash equivalent,324146928,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,118.36,07/31/2015,In-kind items and services,324146930,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,2565.00,11/18/2015,Cash or cash equivalent,324146932,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascula",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,183.67,11/30/2015,In-kind items and services,324146934,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascula",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,12/31/2015,In-kind items and services,324146936,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,02/03/2015,In-kind items and services,324146938,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,02/03/2015,In-kind items and services,324146940,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,11/03/2015,In-kind items and services,324146942,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,11/03/2015,In-kind items and services,324146944,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,08/05/2015,In-kind items and services,324146946,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,114.08,08/05/2015,In-kind items and services,324146948,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,43.87,08/05/2015,In-kind items and services,324146950,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,73.12,11/03/2015,In-kind items and services,324146952,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,73.12,08/05/2015,In-kind items and services,324146954,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,87.74,08/05/2015,In-kind items and services,324146956,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,87.74,08/05/2015,In-kind items and services,324146958,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,101.39,08/05/2015,In-kind items and services,324146960,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,175.48,11/03/2015,In-kind items and services,324146962,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,10.54,04/02/2015,In-kind items and services,324146964,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,120.00,08/12/2015,Cash or cash equivalent,324146966,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,1989.90,08/14/2015,Cash or cash equivalent,324146968,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,52.40,08/10/2015,In-kind items and services,324146970,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,1981.00,08/10/2015,In-kind items and services,324146972,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,99.75,08/10/2015,In-kind items and services,324146974,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,120.00,09/09/2015,Cash or cash equivalent,324146976,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,836.10,09/21/2015,Cash or cash equivalent,324146978,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,472.00,09/30/2015,In-kind items and services,324146980,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,09/30/2015,In-kind items and services,324146982,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,11728.80,01/22/2015,Cash or cash equivalent,324146984,,,"CARMELINA- A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,89.58,01/31/2015,In-kind items and services,324146986,,,"CARMELINA- A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,150.00,02/23/2015,In-kind items and services,324146902,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,1426.32,03/02/2015,In-kind items and services,324146904,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,427.80,03/02/2015,In-kind items and services,324146906,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,43.87,03/11/2015,In-kind items and services,324146908,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,73.12,03/11/2015,In-kind items and services,324146910,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,87.74,03/16/2015,In-kind items and services,324146912,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,01/01/2015,In-kind items and services,324146914,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,7839.00,04/22/2015,Cash or cash equivalent,324146916,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,81.00,04/30/2015,Cash or cash equivalent,324146918,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,75.00,06/12/2015,In-kind items and services,324146920,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,75.00,06/16/2015,In-kind items and services,324146922,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,06/30/2015,In-kind items and services,324146924,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,7188.75,10/14/2015,Cash or cash equivalent,317686938,,,BPV 14 007 A Prospective Multi Center Clinical Study of the Bard COVERATM Arterivenous AV Stent Graft in the Treatment of Stenosis at the Graft Vein Anastomosis of AV Graft Circuits AVeVA,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,2575.00,09/04/2015,Cash or cash equivalent,317688108,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,100.00,01/09/2015,Cash or cash equivalent,321058544,,,Vanguard Total Knee,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,400.00,09/18/2015,Cash or cash equivalent,321057234,,,Regenerex Tibial Tray Multi-Center Data Collection,,
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,800.00,09/04/2015,Cash or cash equivalent,317688190,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,5000.00,07/07/2015,Cash or cash equivalent,317686544,,,Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions Balloon Angioplasty versus Primary Stenting A Prospective Multi Center Randomized Study,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,400.00,11/23/2015,Cash or cash equivalent,317688804,,,LEVANT 2,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,450.00,09/04/2015,Cash or cash equivalent,317688240,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,5900.00,02/27/2015,Cash or cash equivalent,317686124,,,BPV 12 001 A Prospective Multi Center Non Randomized Single Arm Study of the Bard Balloon Expandable Covered Stent in the Treatment of Iliac Artery Occlusive Disease BOLSTER,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,1875.00,11/17/2015,Cash or cash equivalent,317687130,,,BPV 14 007 A Prospective Multi Center Clinical Study of the Bard COVERATM Arterivenous AV Stent Graft in the Treatment of Stenosis at the Graft Vein Anastomosis of AV Graft Circuits AVeVA,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,250.00,09/04/2015,Cash or cash equivalent,317688290,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,2500.00,02/27/2015,Cash or cash equivalent,317686148,,,BPV 12 001 A Prospective Multi Center Non Randomized Single Arm Study of the Bard Balloon Expandable Covered Stent in the Treatment of Iliac Artery Occlusive Disease BOLSTER,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Physician,,,67755,ROY,,ABRAHAM,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,420.00,09/04/2015,Cash or cash equivalent,321056234,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Covered Recipient Physician,,,67755,ROY,,ABRAHAM,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,1050.00,09/18/2015,Cash or cash equivalent,321056294,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Covered Recipient Teaching Hospital,2942,MERCY MEDICAL CENTER,,,,,701 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,10000.00,03/13/2015,Cash or cash equivalent,321056313,,,ORTHO.GHK3 Vanguard Long Term 7-10 year follow-up,,
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,50.00,09/04/2015,Cash or cash equivalent,317688360,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Physician,,,914881,ERIC,,SCOTT,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,50.00,09/04/2015,Cash or cash equivalent,317688378,,,Lutonix BTK Trial,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,4000.00,09/21/2015,Cash or cash equivalent,317686722,,,BPV 14 007 A Prospective Multi Center Clinical Study of the Bard COVERATM Arterivenous AV Stent Graft in the Treatment of Stenosis at the Graft Vein Anastomosis of AV Graft Circuits AVeVA,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,2500.00,09/21/2015,Cash or cash equivalent,317686726,,,BPV 13 003 A Prospective Multi Centered Study to Assess the Complication Rates of Oncology Patients Accessed with Peripheral Intravenous Lines Versus Implantable Ports For Chemotherapy Administration VEINS FOR LIFE,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,300.00,01/30/2015,Cash or cash equivalent,321055134,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,100.00,03/06/2015,Cash or cash equivalent,321055146,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,500.00,03/13/2015,Cash or cash equivalent,321055152,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,100.00,04/17/2015,Cash or cash equivalent,321055160,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,300.00,05/15/2015,Cash or cash equivalent,321055168,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,200.00,07/24/2015,Cash or cash equivalent,321055176,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,100.00,10/23/2015,Cash or cash equivalent,321055184,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,300.00,12/11/2015,Cash or cash equivalent,321055191,,,ORTHO.CR.ROWG2 Regenerex Tibial Tray Multi-Center Data Collection,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,1650.00,08/13/2015,Cash or cash equivalent,317687864,,,LEVANT 2 CONTINUED ACCESS,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,1622 E Lombard St,,Davenport,52803,,,"C. R. Bard, Inc. & Subsidiaries",100000005481,"Bard Peripheral Vascular, Inc.",AZ,5771.25,12/21/2015,Cash or cash equivalent,317687322,,,BPV 14 006 A Prospective Multi Center Single Arm Study Real World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter in Arteries of the Superficial Femoral Artery and Popliteal Artery SAFEDCB,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,192.50,09/18/2015,Cash or cash equivalent,321055506,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,315.00,01/30/2015,Cash or cash equivalent,321055514,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,700.00,03/06/2015,Cash or cash equivalent,321055527,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,1075.00,03/13/2015,Cash or cash equivalent,321055536,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,260.00,04/17/2015,Cash or cash equivalent,321055544,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,317.50,06/05/2015,Cash or cash equivalent,321055552,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,STE 500,COUNCIL BLUFFS,51503,,,"Zimmer Biomet Holdings, Inc.",100000000103,"Zimmer Biomet Holdings, Inc.",IN,192.50,10/23/2015,Cash or cash equivalent,321055560,,,ORTHO.CR.US30 Oxford Cementless Partial Knee IDE Study,,
Covered Recipient Physician,,,155519,DENNIS,M,FRY,5950 UNIVERSITY AVE,STE 231,WEST DES MOINES,50266,Medical Doctor,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,"C. R. Bard, Inc. & Subsidiaries",100000005491,"Lutonix, Inc.",MN,200.00,08/13/2015,Cash or cash equivalent,317688034,,,LEVANT 2,,"This transfer of value represents a payment for services provided in a research study that is paid for by C. R. Bard, Inc. or a subsidiary of C. R. Bard, Inc."
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,01/01/2015,In-kind items and services,324173358,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,1130.40,04/27/2015,Cash or cash equivalent,324173360,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,81.00,04/30/2015,Cash or cash equivalent,324173362,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,06/30/2015,In-kind items and services,324173364,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,2478.60,06/23/2015,Cash or cash equivalent,324173366,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,255.68,06/30/2015,In-kind items and services,324173368,,,"CARMELINA A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,67.59,11/11/2015,In-kind items and services,324173370,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,12/31/2015,In-kind items and services,324173372,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,11/03/2015,In-kind items and services,324173374,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,02/03/2015,In-kind items and services,324173376,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,29.25,02/03/2015,In-kind items and services,324173378,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,43.87,11/03/2015,In-kind items and services,324173380,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,08/05/2015,In-kind items and services,324173382,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,08/05/2015,In-kind items and services,324173384,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,67.59,08/05/2015,In-kind items and services,324173386,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,08/05/2015,In-kind items and services,324173388,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,11/03/2015,In-kind items and services,324173390,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,08/05/2015,In-kind items and services,324173392,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,58.49,08/05/2015,In-kind items and services,324173394,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,713.16,08/24/2015,In-kind items and services,324173396,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,1130.40,09/21/2015,Cash or cash equivalent,324173398,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,472.00,09/30/2015,In-kind items and services,324173400,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,STE 101,WATERLOO,50702,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010618,Boehringer Ingelheim B.V.,,268.07,09/30/2015,In-kind items and services,324173402,,,"CARMELINA - A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000005541,Boehringer Ingelheim International GmbH,,59.00,06/19/2015,In-kind items and services,324146988,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000005541,Boehringer Ingelheim International GmbH,,889.00,06/19/2015,In-kind items and services,324146990,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000005541,Boehringer Ingelheim International GmbH,,2250.00,06/19/2015,In-kind items and services,324146992,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010438,Boehringer Ingelheim France S.A.S.,,42.16,10/31/2015,In-kind items and services,317910964,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010438,Boehringer Ingelheim France S.A.S.,,42.16,11/30/2015,In-kind items and services,317910969,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010438,Boehringer Ingelheim France S.A.S.,,42.16,08/31/2015,In-kind items and services,317910974,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010438,Boehringer Ingelheim France S.A.S.,,42.16,09/30/2015,In-kind items and services,317910978,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010438,Boehringer Ingelheim France S.A.S.,,42.16,12/30/2015,In-kind items and services,317910984,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,3.46,05/19/2015,In-kind items and services,324161656,,,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate, 110 mg or 150 mg, oral b.i.d., versus acetylsalicylic acid, 100 mg oral q.d., in patients with Embolic Stroke of Undetermined Source, RESPECT ESUS",,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,3.46,05/19/2015,In-kind items and services,324161658,,,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate, 110 mg or 150 mg, oral b.i.d., versus acetylsalicylic acid, 100 mg oral q.d., in patients with Embolic Stroke of Undetermined Source, RESPECT ESUS",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,142.75,04/27/2015,In-kind items and services,324171350,,,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.RE-VERSE AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,1.00,07/28/2015,In-kind items and services,324171352,,,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.RE-VERSE AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,74.81,10/06/2015,In-kind items and services,324147036,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,74.81,10/06/2015,In-kind items and services,324147038,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,149.63,10/26/2015,In-kind items and services,324147040,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,149.63,10/26/2015,In-kind items and services,324147042,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,149.63,10/26/2015,In-kind items and services,324147044,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,172.86,10/26/2015,In-kind items and services,324147046,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,40.00,07/25/2015,In-kind items and services,324147048,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,325.00,07/25/2015,In-kind items and services,324147050,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,349.00,07/25/2015,In-kind items and services,324147052,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,349.00,07/25/2015,In-kind items and services,324147054,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,349.00,07/25/2015,In-kind items and services,324147056,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,549.00,07/25/2015,In-kind items and services,324147058,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,549.00,07/25/2015,In-kind items and services,324147060,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,549.00,07/25/2015,In-kind items and services,324147062,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147064,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147066,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147068,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147070,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147072,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147074,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147076,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.85,07/25/2015,In-kind items and services,324147078,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,7.50,12/15/2015,In-kind items and services,324147080,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,45.00,10/08/2015,In-kind items and services,324147082,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,45.00,11/02/2015,In-kind items and services,324147084,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,210.00,10/08/2015,In-kind items and services,324147086,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,280.00,10/08/2015,In-kind items and services,324147088,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,280.00,11/02/2015,In-kind items and services,324147090,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,294.00,11/20/2015,In-kind items and services,324147092,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,294.00,12/15/2015,In-kind items and services,324147094,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,336.00,11/25/2015,In-kind items and services,324147096,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,650.00,11/20/2015,In-kind items and services,324147098,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,650.00,12/15/2015,In-kind items and services,324147100,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,1098.00,11/20/2015,In-kind items and services,324147102,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,1098.00,12/15/2015,In-kind items and services,324147104,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,698.00,11/20/2015,In-kind items and services,324147106,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,698.00,12/15/2015,In-kind items and services,324147108,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,70.00,11/20/2015,In-kind items and services,324147110,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,149.63,11/23/2015,In-kind items and services,324147112,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus - EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,15.00,11/20/2015,In-kind items and services,324147114,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,525.00,11/02/2015,In-kind items and services,324147116,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,22.50,08/20/2015,In-kind items and services,324147118,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,140.00,11/02/2015,In-kind items and services,324147120,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,30.00,11/02/2015,In-kind items and services,324147122,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,22.50,12/15/2015,In-kind items and services,324147124,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,175.00,10/08/2015,In-kind items and services,324147126,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,140.00,12/15/2015,In-kind items and services,324147128,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,37.50,10/08/2015,In-kind items and services,324147130,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,29.93,07/30/2015,In-kind items and services,324146994,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,29.93,07/30/2015,In-kind items and services,324146996,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,14.96,08/04/2015,In-kind items and services,324146998,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,25.19,08/04/2015,In-kind items and services,324147000,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,29.93,08/04/2015,In-kind items and services,324147002,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,44.89,08/04/2015,In-kind items and services,324147004,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,37.75,09/29/2015,In-kind items and services,324147006,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,58.34,09/29/2015,In-kind items and services,324147008,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,66.03,09/29/2015,In-kind items and services,324147010,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,28.12,09/29/2015,In-kind items and services,324147012,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,25.19,12/17/2015,In-kind items and services,324147014,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,37.75,09/29/2015,In-kind items and services,324147016,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,71.56,09/29/2015,In-kind items and services,324147018,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,88.87,09/29/2015,In-kind items and services,324147022,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,41.19,09/29/2015,In-kind items and services,324147024,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,125.94,12/17/2015,In-kind items and services,324147026,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,197.01,12/17/2015,In-kind items and services,324147028,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,197.01,12/17/2015,In-kind items and services,324147030,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,4.28,09/29/2015,In-kind items and services,324147032,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus -EASE-2",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000061372,Boehringer Ingelheim Limited,,74.81,10/06/2015,In-kind items and services,324147034,,,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 diabetes mellitus EASE-2",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Cepheid,100000010934,Cepheid,CA,13162.50,05/13/2015,Cash or cash equivalent,273881758,,,None,,
Covered Recipient Physician,,,318789,RENE,,RECINOS,250 S CRESCENT DR,,MASON CITY,50401-2926,Medical Doctor,Allopathic & Osteopathic Physicians|Plastic Surgery,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,140.00,09/08/2015,Cash or cash equivalent,321694926,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Covidien LP,100000000083,Covidien LP,MA,5000.00,08/26/2015,Cash or cash equivalent,281313104,,,Comorbidity resolution Analysis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive 1353 Jcp,,Iowa City,52242,,,Covidien LP,100000000083,Covidien LP,MA,6000.00,09/11/2015,Cash or cash equivalent,281313108,,,Comorbidity resolution Analysis,,
Non-covered Recipient Entity,,,,,,,Clinical Research,"1215 Duff Ave, P.O. Box 3014",Ames,50010,,,Cordis Corporation,100000005411,Cordis Corporation,CA,3840.00,04/01/2015,Cash or cash equivalent,283367292,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187242,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187244,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187246,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187248,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187250,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187252,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187254,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187256,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187258,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,1415 Woodland Ave,Ste 218,Des Moines,50309,,,Cordis Corporation,100000005411,Cordis Corporation,CA,600.00,06/11/2015,Cash or cash equivalent,254187900,,,INSPIRATION,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187260,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187262,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187264,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187266,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187268,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187270,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187272,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187274,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187276,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187278,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187280,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187282,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187284,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187286,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187288,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187290,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322356196,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,322356205,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/17/2015,Cash or cash equivalent,322356254,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187032,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187034,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187036,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187038,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187040,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187042,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187044,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187046,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187048,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187050,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187052,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187054,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187056,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187058,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187060,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187062,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187064,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187066,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187068,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,03/18/2015,Cash or cash equivalent,322360288,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,254187070,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322355434,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322355442,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4500.00,12/09/2015,Cash or cash equivalent,322356914,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,51845.74,03/09/2015,Cash or cash equivalent,283363860,,,OPEN STUDY,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363866,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363872,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363876,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363880,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363886,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363890,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363892,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363896,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363900,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363902,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363908,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363914,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363918,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363924,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363928,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363934,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363938,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363940,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363946,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,B5 Jessup Hall,Iowa City,62242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",CA,144.96,10/29/2015,Cash or cash equivalent,324186744,,,DUET,,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,B5 Jessup Hall,Iowa City,62242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",CA,53664.30,12/10/2015,Cash or cash equivalent,324186746,,,DUET,,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,B5 Jessup Hall,Iowa City,62242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",CA,4977.00,02/12/2015,Cash or cash equivalent,324186748,,,DUET,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363950,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363954,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363960,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363964,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363968,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363972,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363978,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,100.00,01/19/2015,Cash or cash equivalent,283363980,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,52.70,02/04/2015,Cash or cash equivalent,283363984,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,03/12/2015,Cash or cash equivalent,283363990,,,SAPPHIRE WW,,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,B5 Jessup Hall,Iowa City,62242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",CA,684.90,07/15/2015,Cash or cash equivalent,324186750,,,DUET,,
Non-covered Recipient Entity,,,,,,,Grant Accounting Office,B5 Jessup Hall,Iowa City,62242,,,"Retrophin, Inc.",100000061305,"Retrophin, Inc.",CA,765.44,09/23/2015,Cash or cash equivalent,324186752,,,DUET,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,500.00,03/24/2015,Cash or cash equivalent,283363996,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,2000.00,03/24/2015,Cash or cash equivalent,283364000,,,SAPPHIRE WW,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,300.00,05/14/2015,Cash or cash equivalent,283364006,,,OPEN STUDY,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4047.06,05/22/2015,Cash or cash equivalent,283364010,,,OPEN STUDY,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,1475.00,05/22/2015,Cash or cash equivalent,283364012,,,OPEN STUDY,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4047.06,07/16/2015,Cash or cash equivalent,283364016,,,OPEN STUDY,,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,Cordis Corporation,100000005411,Cordis Corporation,CA,29034.52,10/28/2015,Cash or cash equivalent,283364022,,,OPEN STUDY,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,175.00,04/06/2015,Cash or cash equivalent,321700782,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,175.00,04/06/2015,Cash or cash equivalent,321700790,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,100.00,06/08/2015,Cash or cash equivalent,321700798,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,175.00,06/08/2015,Cash or cash equivalent,321700804,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,140.00,07/09/2015,Cash or cash equivalent,321700812,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,140.00,10/07/2015,Cash or cash equivalent,321700820,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,100.00,12/04/2015,Cash or cash equivalent,321700826,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Non-covered Recipient Entity,,,,,,,250 S CRESCENT DR,,MASON CITY,50401-2926,,,"Sientra, Inc.",100000010581,"Sientra, Inc.",CA,175.00,12/04/2015,Cash or cash equivalent,321700834,,,SIENTRA SPONSORED SILIMED GEL-FILLED MAMMARY IMPLANT CLINICAL STUDY PROTOCOL CORE CLINICAL INVESTIGATION,,
Covered Recipient Teaching Hospital,2948,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,2000.00,08/12/2015,Cash or cash equivalent,301840050,,,A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease,,
Covered Recipient Teaching Hospital,2948,Univ of Iowa Hosp & Clinic,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,6250.00,07/31/2015,Cash or cash equivalent,301840058,,,A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1600.20,09/30/2015,Cash or cash equivalent,295698096,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1000.00,09/30/2015,Cash or cash equivalent,295698098,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,675.00,09/30/2015,Cash or cash equivalent,295698100,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,2025.00,09/30/2015,Cash or cash equivalent,295698102,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,669.00,01/02/2015,Cash or cash equivalent,295698104,Proleukin,,12PLK01 - A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Non-covered Recipient Entity,,,,,,,Office of Research,"1415 Woodland Ave, Ste 218",Des Moines,50309,,,Cordis Corporation,100000005411,Cordis Corporation,CA,4800.00,11/13/2015,Cash or cash equivalent,283365642,,,INSPIRATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1940.80,01/02/2015,Cash or cash equivalent,295698106,Proleukin,,12PLK01 - A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,4106.70,01/28/2015,Cash or cash equivalent,295698108,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1000.00,01/02/2015,Cash or cash equivalent,295698110,Proleukin,,12PLK01 - A Multi-Center study of High Dose Aldesleukin Interleukin-2 plus Vemurafenib Therapy in Patients with BRAF V600 Mutation Positive Metastatic Melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1350.00,03/25/2015,Cash or cash equivalent,295698112,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,776.25,07/29/2015,Cash or cash equivalent,295698114,Proleukin,,10PLK13 - PROCLAIM Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,2025.00,04/08/2015,Cash or cash equivalent,295698116,Proleukin,,10PLK13 - PROCLAIM Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,4927.50,10/29/2015,Cash or cash equivalent,295698118,Proleukin,,10PLK13 - PROCLAIM Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Prometheus Laboratories Inc.,100000010425,Prometheus Laboratories Inc.,CA,1000.00,08/26/2015,Cash or cash equivalent,295698120,Proleukin,,"12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin Interleukin-2 and Ipilimumab Yervoy in Patients with Metastatic Melanoma",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Roche Diagnostics Operations, Inc.",100000005442,"Roche Diagnostics Operations, Inc.",IN,13545.00,07/31/2015,Cash or cash equivalent,265609485,,,CIM RD002263 TnT Gen 5,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Roche Diagnostics Operations, Inc.",100000005442,"Roche Diagnostics Operations, Inc.",IN,35.00,09/28/2015,Cash or cash equivalent,265609489,,,CIM RD002263 TnT Gen 5,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322367826,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,296.88,09/23/2015,Cash or cash equivalent,322366596,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIACML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Roche Diagnostics Operations, Inc.",100000005442,"Roche Diagnostics Operations, Inc.",IN,40.16,04/01/2015,In-kind items and services,265609648,,,RD002263,,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010824,Boehringer Ingelheim RCV GmbH & Co KG,,34.30,11/30/2015,In-kind items and services,324161660,,,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate ,110 mg or 150 mg, oral b.i.d., versus acetylsalicylic acid ,100 mg oral q.d., in patients with Embolic Stroke of Undetermined Source -RESPECT ESUS",,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Boehringer Ingelheim Pharma GmbH & Co.KG,100000010823,Boehringer Ingelheim Pharma GmbH & Co.KG,,282.40,08/25/2015,In-kind items and services,324183112,,,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care BSC versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.",,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Roche Diagnostics Operations, Inc.",100000005442,"Roche Diagnostics Operations, Inc.",IN,108298.06,02/27/2015,In-kind items and services,265609190,,,RD002263,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,07/22/2015,Cash or cash equivalent,322366200,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,555.00,07/20/2015,Cash or cash equivalent,322419484,,,A Phase 3 Randomized DoubleBlind PlaceboControlled 26Week Multicenter Study With a 78Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Mo,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/07/2015,Cash or cash equivalent,322404702,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,322418644,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,PO BOX 3014,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3500.00,07/15/2015,Cash or cash equivalent,322410434,,,A Study Of PF05280586 RituximabPfizer Or MabThera RituximabEU For The FirstLine Treatment Of Patients With CD20Positive Low Tumor Burden Follicular Lymphoma REFLECTIONS B32806,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,830.54,11/04/2015,Cash or cash equivalent,322412694,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,09/02/2015,Cash or cash equivalent,322419200,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3252.00,09/30/2015,In-kind items and services,322417128,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,322411402,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,06/18/2015,Cash or cash equivalent,322401740,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,06/18/2015,Cash or cash equivalent,322389362,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,11/11/2015,Cash or cash equivalent,322400655,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,582.50,06/18/2015,Cash or cash equivalent,322401748,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE STE 100,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,11678.51,08/03/2015,Cash or cash equivalent,322397400,,,A Phase 3 Randomized Doubleblind Study Assessing The Efficacy And Safety Of Pf06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Metho,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,11/11/2015,Cash or cash equivalent,322401136,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,582.50,07/23/2015,Cash or cash equivalent,322394422,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,322394696,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322425404,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,11/11/2015,Cash or cash equivalent,322427844,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,05/21/2015,Cash or cash equivalent,322431072,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th Street STE 200,,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,70.00,12/30/2015,In-kind items and services,322436704,,,A Multicenter Openlabel Extension Study To Assess Longterm Safety Of Pf00547659 In Subjects With Crohns Disease Opera Ii,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,09/02/2015,Cash or cash equivalent,322423634,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,09/30/2015,In-kind items and services,322428140,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,322434792,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,08/19/2015,Cash or cash equivalent,322431480,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,07/22/2015,Cash or cash equivalent,322426250,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,07/27/2015,In-kind items and services,322435190,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,322437484,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1352.33,03/06/2015,Cash or cash equivalent,322373170,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322379184,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,582.50,06/18/2015,Cash or cash equivalent,322376792,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,322383850,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322383856,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1725.00,02/11/2015,Cash or cash equivalent,322373592,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,322381677,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,4601 WEST 109TH STREET,,SIOUX CITY,66211,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,08/01/2015,In-kind items and services,322379644,TORISEL,,A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS TEMSR REGIMENS IN SUBJECTS WITH RELAPSED REFRACTORY MANTLE CELL LYMPHOMA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,322368758,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,07/23/2015,Cash or cash equivalent,322487651,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,06/18/2015,Cash or cash equivalent,322474825,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,322477098,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322481601,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/14/2015,Cash or cash equivalent,322488226,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/14/2015,Cash or cash equivalent,322471320,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,06/03/2015,Cash or cash equivalent,322455966,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322459454,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,322459470,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322462884,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,03/18/2015,Cash or cash equivalent,322469686,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,10/14/2015,Cash or cash equivalent,322470818,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,938.60,03/06/2015,Cash or cash equivalent,322459930,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322466582,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322460135,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,23494.50,01/26/2015,In-kind items and services,322465588,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,Study Drug
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,38.75,10/21/2015,Cash or cash equivalent,322490988,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,19.50,10/14/2015,Cash or cash equivalent,322491216,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,581.88,12/02/2015,Cash or cash equivalent,322504130,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,322496898,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322496902,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,07/01/2015,Cash or cash equivalent,322498034,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,03/18/2015,Cash or cash equivalent,322500570,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,639.97,12/09/2015,Cash or cash equivalent,322499520,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322453748,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,08/19/2015,Cash or cash equivalent,322448362,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,05/06/2015,Cash or cash equivalent,322450600,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,03/30/2015,In-kind items and services,322454802,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/14/2015,Cash or cash equivalent,322439890,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,322439056,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/21/2015,Cash or cash equivalent,322451170,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,06/24/2015,Cash or cash equivalent,322442260,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/19/2015,Cash or cash equivalent,322451340,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,206.00,09/25/2015,In-kind items and services,322444698,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322453556,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,11/04/2015,Cash or cash equivalent,322442529,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322562534,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322547940,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322562542,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,09/02/2015,Cash or cash equivalent,322549154,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 W BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3912.50,12/03/2015,Cash or cash equivalent,322562714,,,A Phase 3 Randomized DoubleBlind PlaceboControlled 26Week Multicenter Study With a 78Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Mo,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,06/18/2015,Cash or cash equivalent,322549323,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3500.00,09/23/2015,Cash or cash equivalent,322550430,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,502.25,11/11/2015,Cash or cash equivalent,322549462,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,830.54,11/04/2015,Cash or cash equivalent,322546546,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322532938,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,01/14/2015,In-kind items and services,322531896,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,63.12,10/14/2015,Cash or cash equivalent,322543554,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,322533387,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,387.50,12/02/2015,Cash or cash equivalent,322533396,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3150.00,11/04/2015,Cash or cash equivalent,322542581,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,08/12/2015,Cash or cash equivalent,322529032,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/18/2015,Cash or cash equivalent,322531406,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/14/2015,Cash or cash equivalent,322533586,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,Suite 201,201 Ridge Street,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4971.26,03/30/2015,In-kind items and services,322539354,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322578293,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,02/25/2015,Cash or cash equivalent,322572510,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,387.50,12/02/2015,Cash or cash equivalent,322579780,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,05/21/2015,Cash or cash equivalent,322582172,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,06/30/2015,In-kind items and services,322567186,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322569640,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7.16,02/10/2015,Cash or cash equivalent,322571904,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,296.88,09/23/2015,Cash or cash equivalent,322580176,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIACML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322567748,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,07/22/2015,Cash or cash equivalent,322513755,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322526066,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322521420,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/14/2015,Cash or cash equivalent,322525096,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/14/2015,Cash or cash equivalent,322526370,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322509326,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,322525302,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1136.20,03/06/2015,Cash or cash equivalent,322525323,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 341,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.00,12/01/2015,In-kind items and services,322514360,,,A Phase 3 Randomized Double Blind Placebo And Active Controlled Multicenter Parallel Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/12/2015,Cash or cash equivalent,322519494,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,17262.60,08/03/2015,Cash or cash equivalent,322525514,,,,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,752.79,07/01/2015,In-kind items and services,322509764,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,01/07/2015,Cash or cash equivalent,322514720,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322626864,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,12/02/2015,Cash or cash equivalent,322626870,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street,SE,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,8484.00,04/23/2015,Cash or cash equivalent,322623676,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322616496,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,44730.00,08/24/2015,In-kind items and services,322617318,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3150.00,01/21/2015,Cash or cash equivalent,322619880,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322619914,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,322624691,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,12/02/2015,Cash or cash equivalent,322618320,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,913.90,12/02/2015,Cash or cash equivalent,322618328,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/09/2015,Cash or cash equivalent,322624697,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,322613262,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,01/07/2015,Cash or cash equivalent,322602710,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/14/2015,Cash or cash equivalent,322604872,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,11/04/2015,Cash or cash equivalent,322609676,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322606350,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/07/2015,Cash or cash equivalent,322629216,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,07/01/2015,Cash or cash equivalent,322638866,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE STE 100,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3350.00,08/24/2015,Cash or cash equivalent,322640324,,,A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY COMPARING THE EFFICACY SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06410293 AND ADALIMUMAB IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXATE,,
Non-covered Recipient Entity,,,,,,,5950 University Avenue,,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,664.00,12/30/2015,In-kind items and services,322630874,,,A Phase 3 Randomized Double Blind Placebo And Active Controlled Multicenter Parallel Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,322635700,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,06/11/2015,Cash or cash equivalent,322640502,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.00,10/01/2015,In-kind items and services,322631752,,,A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/16/2015,Cash or cash equivalent,322635708,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,08/12/2015,Cash or cash equivalent,322638972,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,149.50,03/06/2015,Cash or cash equivalent,322640426,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322631132,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,69.37,10/14/2015,Cash or cash equivalent,322638438,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/14/2015,Cash or cash equivalent,322629598,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,322629604,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,644.00,01/15/2015,Cash or cash equivalent,322629608,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,JAMES PAGE LOVELL,5950 UNIVERSITY AVE,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,102.25,07/22/2015,In-kind items and services,322630564,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/09/2015,Cash or cash equivalent,322636956,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/16/2015,Cash or cash equivalent,322636962,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,04/17/2015,In-kind items and services,322636966,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,59.80,10/14/2015,Cash or cash equivalent,322628268,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/25/2015,Cash or cash equivalent,322640234,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,10/21/2015,Cash or cash equivalent,322587086,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,08/19/2015,Cash or cash equivalent,322587204,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,439.38,10/21/2015,Cash or cash equivalent,322593840,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/21/2015,Cash or cash equivalent,322600150,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,07/23/2015,Cash or cash equivalent,322588347,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,07/08/2015,Cash or cash equivalent,322597490,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,582.50,06/18/2015,Cash or cash equivalent,322597542,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,06/18/2015,Cash or cash equivalent,322597548,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322666718,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,08/12/2015,Cash or cash equivalent,322671436,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1850.00,09/16/2015,Cash or cash equivalent,322678048,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,322673316,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,03/19/2015,Cash or cash equivalent,322675636,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/16/2015,Cash or cash equivalent,322675032,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1246.88,06/18/2015,Cash or cash equivalent,322668820,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,322677652,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,322672144,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,07/23/2015,Cash or cash equivalent,322675212,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1365.63,07/29/2015,Cash or cash equivalent,322663358,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,10/21/2015,Cash or cash equivalent,322654392,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3506.10,03/06/2015,Cash or cash equivalent,322663154,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,913.90,12/02/2015,Cash or cash equivalent,322681032,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,06/11/2015,Cash or cash equivalent,322685260,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,03/18/2015,Cash or cash equivalent,322679618,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,08/26/2015,Cash or cash equivalent,322682296,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,06/11/2015,Cash or cash equivalent,322645255,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/07/2015,Cash or cash equivalent,322649302,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.81,10/14/2015,Cash or cash equivalent,322650144,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,322649308,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,11/04/2015,Cash or cash equivalent,322646230,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322640778,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,52.00,03/06/2015,Cash or cash equivalent,322650646,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.81,10/14/2015,Cash or cash equivalent,322645116,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,830.54,12/16/2015,Cash or cash equivalent,322722812,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.65,10/14/2015,Cash or cash equivalent,322722855,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,322729208,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,05/21/2015,Cash or cash equivalent,322728464,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,07/08/2015,Cash or cash equivalent,322729257,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1235.05,10/21/2015,Cash or cash equivalent,322718872,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3500.00,09/11/2015,Cash or cash equivalent,322718159,,,A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study Of The Longterm Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/02/2015,Cash or cash equivalent,322730406,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1235.05,11/11/2015,Cash or cash equivalent,322719136,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,07/01/2015,Cash or cash equivalent,322729616,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,07/01/2015,Cash or cash equivalent,322725018,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,08/12/2015,Cash or cash equivalent,322723518,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,12/02/2015,Cash or cash equivalent,322713746,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322708106,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322713907,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322714852,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,10.00,03/31/2015,In-kind items and services,322714039,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,1015 Duff Avenue,,AMES,50010,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,622.17,07/20/2015,In-kind items and services,322716510,,,OA SAFETY STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,04/22/2015,Cash or cash equivalent,322715856,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2076.30,07/20/2015,Cash or cash equivalent,322705202,,,,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,07/01/2015,Cash or cash equivalent,322714216,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,322715138,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,06/30/2015,In-kind items and services,322715158,,,RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZINMK8835PF04971729 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,322736830,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,06/11/2015,Cash or cash equivalent,322735428,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,439.38,03/12/2015,Cash or cash equivalent,322732222,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1495.00,01/29/2015,Cash or cash equivalent,322738870,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,08/19/2015,Cash or cash equivalent,322742414,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,08/19/2015,Cash or cash equivalent,322742420,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,800.00,01/21/2015,Cash or cash equivalent,322693382,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,322694210,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,07/01/2015,Cash or cash equivalent,322698352,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322696902,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4500.00,01/09/2015,Cash or cash equivalent,322694662,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835 AND PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,322692320,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5.00,10/21/2015,Cash or cash equivalent,322782633,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,06/03/2015,Cash or cash equivalent,322771599,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/07/2015,Cash or cash equivalent,322776608,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/18/2015,Cash or cash equivalent,322773380,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/18/2015,Cash or cash equivalent,322782892,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,830.54,11/04/2015,Cash or cash equivalent,322782896,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,04/22/2015,Cash or cash equivalent,322780730,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/14/2015,Cash or cash equivalent,322782338,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,322781700,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,03/06/2015,Cash or cash equivalent,322782521,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322762370,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,03/12/2015,Cash or cash equivalent,322761076,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1250.00,11/04/2015,Cash or cash equivalent,322769446,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.62,10/14/2015,Cash or cash equivalent,322761283,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,02/04/2015,Cash or cash equivalent,322795296,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4594.81,10/21/2015,Cash or cash equivalent,322791222,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,08/12/2015,Cash or cash equivalent,322793784,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,322787360,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/12/2015,Cash or cash equivalent,322790040,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,08/19/2015,Cash or cash equivalent,322784404,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,12/16/2015,Cash or cash equivalent,322789354,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322789376,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322794244,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,03/18/2015,Cash or cash equivalent,322785358,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th Street STE 200,,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,70.00,12/30/2015,In-kind items and services,322784684,,,A Multicenter Openlabel Extension Study To Assess Longterm Safety Of Pf00547659 In Subjects With Crohns Disease Opera Ii,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,322785430,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,322785436,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2945,COVENANT MEDICAL CENTER,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,630.00,09/30/2015,In-kind items and services,322748134,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,06/03/2015,Cash or cash equivalent,322755762,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,11/04/2015,Cash or cash equivalent,322746652,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/07/2015,Cash or cash equivalent,322747412,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,322747422,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,322748300,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,12/02/2015,Cash or cash equivalent,322745282,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5.00,10/21/2015,Cash or cash equivalent,322745328,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,07/08/2015,Cash or cash equivalent,322752618,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,03/25/2015,Cash or cash equivalent,322756958,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.16,10/21/2015,Cash or cash equivalent,322755380,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,10/07/2015,Cash or cash equivalent,322755445,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,1701 West Broadway,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,490.00,03/31/2015,In-kind items and services,322752054,,,RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZINMK8835PF04971729 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,322753830,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322748858,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/16/2015,Cash or cash equivalent,322752208,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,322827271,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322823876,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/14/2015,Cash or cash equivalent,322828863,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/21/2015,Cash or cash equivalent,322828874,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,322837518,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,03/12/2015,Cash or cash equivalent,322811104,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1235.05,12/09/2015,Cash or cash equivalent,322820312,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/19/2015,Cash or cash equivalent,322817122,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322818010,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322818050,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,08/12/2015,Cash or cash equivalent,322822198,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,10/14/2015,Cash or cash equivalent,322822370,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,4601 WEST 109TH STREET,,SIOUX CITY,66211,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.00,07/01/2015,In-kind items and services,322809930,,,A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF04236921 IN SUBJECTS WITH CROHNS DISEASE WHO ARE ANTITNF INADEQUATE RESPONDERS ANDANTE,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,162.50,05/14/2015,Cash or cash equivalent,322811630,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2945,COVENANT MEDICAL CENTER,,,,,3421 W 9TH ST,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,630.00,06/30/2015,In-kind items and services,322819171,,,RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZINMK8835PF04971729 IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3750.00,09/16/2015,Cash or cash equivalent,322813469,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/21/2015,Cash or cash equivalent,322844299,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,23168.75,05/08/2015,Cash or cash equivalent,322855556,,,Phase 1b randomized doubleblind placebo controlled dose escalating study to evaluate the safety tolerability pH pharmacodynamics and pharmacologic activity of multiple ascending dose levels of PF06252616 administered to ambul Duchenne Muscula,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,322853464,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,322855998,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3770.00,03/06/2015,Cash or cash equivalent,322801138,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,10/21/2015,Cash or cash equivalent,322802052,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,322807996,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1084.00,03/31/2015,In-kind items and services,322799770,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,06/03/2015,Cash or cash equivalent,322806490,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/19/2015,Cash or cash equivalent,322798264,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322806566,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,133.45,09/25/2015,In-kind items and services,322803252,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,07/23/2015,Cash or cash equivalent,322806770,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,10/07/2015,Cash or cash equivalent,322796796,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.62,10/14/2015,Cash or cash equivalent,322797690,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,202 10th Street,SE,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3059.00,04/23/2015,Cash or cash equivalent,322800182,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,04/22/2015,Cash or cash equivalent,322896046,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,11/11/2015,Cash or cash equivalent,322899294,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322900388,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/16/2015,Cash or cash equivalent,322897222,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,08/12/2015,Cash or cash equivalent,322908918,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,86.87,10/14/2015,Cash or cash equivalent,322908092,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,220 West Ridgeway,Suite 106,WATERLOO,50701,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2900.00,01/29/2015,Cash or cash equivalent,322893700,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,10/21/2015,Cash or cash equivalent,322889600,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,06/11/2015,Cash or cash equivalent,322891863,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,07/01/2015,Cash or cash equivalent,322882262,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,500.00,10/07/2015,Cash or cash equivalent,322884496,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,49.40,10/14/2015,Cash or cash equivalent,322888828,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322891295,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,588.00,05/06/2015,Cash or cash equivalent,322883936,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,322915122,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,07/01/2015,Cash or cash equivalent,322919102,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322912376,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,322915786,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,07/22/2015,Cash or cash equivalent,322863866,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,11/04/2015,Cash or cash equivalent,322868112,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,322868190,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,914.42,12/09/2015,Cash or cash equivalent,322866328,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,09/16/2015,Cash or cash equivalent,322864214,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,07/23/2015,Cash or cash equivalent,322861190,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,63.12,10/14/2015,Cash or cash equivalent,322872942,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.16,11/11/2015,Cash or cash equivalent,322868720,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/21/2015,Cash or cash equivalent,322869716,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/16/2015,Cash or cash equivalent,322859246,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,03/12/2015,Cash or cash equivalent,322866804,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,322861518,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26838.00,05/01/2015,In-kind items and services,322861552,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,322874354,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,06/30/2015,In-kind items and services,322951102,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1599.33,03/06/2015,Cash or cash equivalent,322960506,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,07/01/2015,Cash or cash equivalent,322963194,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,04/22/2015,Cash or cash equivalent,322959782,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1800.00,08/26/2015,Cash or cash equivalent,322953286,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.81,10/14/2015,Cash or cash equivalent,322955152,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,08/19/2015,Cash or cash equivalent,322955242,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.00,11/01/2015,In-kind items and services,322963624,,,A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,322938196,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,322946812,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,322948640,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/14/2015,Cash or cash equivalent,322937694,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,322938538,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,01/15/2015,Cash or cash equivalent,322943748,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,12/02/2015,Cash or cash equivalent,322949762,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,08/12/2015,Cash or cash equivalent,322937730,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1378 NW 124th Street STE 200,,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,70.00,12/30/2015,In-kind items and services,322939534,,,A Multicenter Openlabel Extension Study To Assess Longterm Safety Of Pf00547659 In Subjects With Crohns Disease Opera Ii,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,102.25,08/14/2015,In-kind items and services,322938750,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322964576,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,387.50,12/02/2015,Cash or cash equivalent,322964586,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,322964596,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 PLEASANT STREET,,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4500.00,12/23/2015,In-kind items and services,322975768,TYGACIL,,LEADER program,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,322977534,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,59.80,10/14/2015,Cash or cash equivalent,322967269,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/16/2015,Cash or cash equivalent,322969047,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,322971576,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,322973305,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,318.00,09/25/2015,In-kind items and services,322970856,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,06/03/2015,Cash or cash equivalent,322976074,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,12/16/2015,Cash or cash equivalent,322966716,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5.00,10/21/2015,Cash or cash equivalent,322966740,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,322975418,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,322972916,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,322967770,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,201 Ridge Street,,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2258.37,07/27/2015,In-kind items and services,322933156,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1395.31,06/18/2015,Cash or cash equivalent,322924658,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,322935986,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26838.00,11/02/2015,In-kind items and services,322934390,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1136.20,03/06/2015,Cash or cash equivalent,322925868,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3252.00,09/30/2015,In-kind items and services,322930178,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,300.06,03/25/2015,Cash or cash equivalent,322926036,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,PO BOX 3014,AMES,50010,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3000.00,03/02/2015,Cash or cash equivalent,322928582,,,A Phase 3 Randomized DoubleBlind PlaceboControlled 26Week Multicenter Study With a 78Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Mo,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,322934665,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3750.00,09/23/2015,Cash or cash equivalent,322929582,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/19/2015,Cash or cash equivalent,323017162,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1246.88,06/18/2015,Cash or cash equivalent,323004514,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,913.90,11/19/2015,Cash or cash equivalent,323009792,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,06/24/2015,Cash or cash equivalent,323003890,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,06/03/2015,Cash or cash equivalent,323010726,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,323011718,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7101.80,03/27/2015,In-kind items and services,323004998,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.16,12/09/2015,Cash or cash equivalent,323005900,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,04/29/2015,Cash or cash equivalent,323004236,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,322994756,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1084.00,03/31/2015,In-kind items and services,322999314,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,322997718,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/14/2015,Cash or cash equivalent,322996328,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,07/08/2015,Cash or cash equivalent,322999520,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,913.90,12/02/2015,Cash or cash equivalent,322991912,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,718.75,01/21/2015,Cash or cash equivalent,322993552,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,06/03/2015,Cash or cash equivalent,322996540,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,09/16/2015,Cash or cash equivalent,322996627,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323029436,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,07/23/2015,Cash or cash equivalent,323026085,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,323029504,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,740.00,12/16/2015,Cash or cash equivalent,323029510,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street,SE,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2638.00,07/27/2015,Cash or cash equivalent,323029650,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,12/02/2015,Cash or cash equivalent,323021348,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,11/11/2015,Cash or cash equivalent,323029860,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,201 Ridge Street,,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4516.74,07/08/2015,In-kind items and services,323027358,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323022364,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,830.54,11/04/2015,Cash or cash equivalent,323020882,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1100.00,12/09/2015,Cash or cash equivalent,323022663,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,04/22/2015,Cash or cash equivalent,322979915,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,11/18/2015,Cash or cash equivalent,322979955,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,06/24/2015,Cash or cash equivalent,322989436,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,08/12/2015,Cash or cash equivalent,322985242,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,691.60,12/16/2015,Cash or cash equivalent,322982788,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,322990444,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2983.88,07/17/2015,Cash or cash equivalent,322989784,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,150.00,11/04/2015,Cash or cash equivalent,322981368,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,322989972,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,639.97,12/09/2015,Cash or cash equivalent,322989980,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,11/04/2015,Cash or cash equivalent,323068110,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2840.71,10/14/2015,Cash or cash equivalent,323065140,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,05/21/2015,Cash or cash equivalent,323064499,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,08/19/2015,Cash or cash equivalent,323065288,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,05/21/2015,Cash or cash equivalent,323069491,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323059488,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1246.88,06/18/2015,Cash or cash equivalent,323069744,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,71.17,10/14/2015,Cash or cash equivalent,323045634,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,11/18/2015,Cash or cash equivalent,323045832,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,11/18/2015,Cash or cash equivalent,323045838,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,12/16/2015,Cash or cash equivalent,323045076,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,10/07/2015,Cash or cash equivalent,323049986,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/21/2015,Cash or cash equivalent,323045200,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,323045208,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323044660,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323051234,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/16/2015,Cash or cash equivalent,323051242,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,581.88,12/02/2015,Cash or cash equivalent,323051248,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,05/21/2015,Cash or cash equivalent,323084289,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,06/11/2015,Cash or cash equivalent,323080622,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,323072194,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/18/2015,Cash or cash equivalent,323082408,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,12/16/2015,Cash or cash equivalent,323075668,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/07/2015,Cash or cash equivalent,323076542,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,12/02/2015,Cash or cash equivalent,323032146,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,46989.00,04/28/2015,In-kind items and services,323034642,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA CML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,03/18/2015,Cash or cash equivalent,323038972,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,439.38,12/02/2015,Cash or cash equivalent,323041900,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323035838,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,12/02/2015,Cash or cash equivalent,323043628,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,10/21/2015,Cash or cash equivalent,323033412,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,323043714,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,09/16/2015,Cash or cash equivalent,323040382,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,84.17,10/14/2015,Cash or cash equivalent,323113582,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1250.00,01/21/2015,Cash or cash equivalent,323115322,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323118830,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/16/2015,Cash or cash equivalent,323122152,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,10.00,03/31/2015,In-kind items and services,323115506,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,01/19/2015,In-kind items and services,323114726,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323116448,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,913.90,12/02/2015,Cash or cash equivalent,323113096,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323123358,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,06/03/2015,Cash or cash equivalent,323125184,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323112444,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,323124473,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,323112602,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,06/03/2015,Cash or cash equivalent,323121152,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3252.00,06/30/2015,In-kind items and services,323104152,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323108628,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,63.12,10/14/2015,Cash or cash equivalent,323099622,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323099636,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,12/16/2015,Cash or cash equivalent,323105766,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323102364,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323102370,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,12/02/2015,Cash or cash equivalent,323102376,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,323102384,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/02/2015,Cash or cash equivalent,323134860,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3500.00,09/16/2015,Cash or cash equivalent,323133398,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323136112,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,11/04/2015,Cash or cash equivalent,323129446,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,323131200,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323131206,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,06/03/2015,Cash or cash equivalent,323134638,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/21/2015,Cash or cash equivalent,323138224,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.00,10/07/2015,Cash or cash equivalent,323130471,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,PO BOX 3014,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,900.00,07/15/2015,Cash or cash equivalent,323131386,,,A Study Of PF05280586 RituximabPfizer Or MabThera RituximabEU For The FirstLine Treatment Of Patients With CD20Positive Low Tumor Burden Follicular Lymphoma REFLECTIONS B32806,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,09/02/2015,Cash or cash equivalent,323086100,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,323086996,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,35784.00,01/22/2015,In-kind items and services,323091396,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,225.00,09/16/2015,Cash or cash equivalent,323090700,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,323086364,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,11/18/2015,Cash or cash equivalent,323095116,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323096976,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,07/08/2015,Cash or cash equivalent,323091958,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,718.75,11/04/2015,Cash or cash equivalent,323094638,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,323181684,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,323176784,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,323172781,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1436.88,06/18/2015,Cash or cash equivalent,323167374,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.31,10/21/2015,Cash or cash equivalent,323169602,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,323171057,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,300 Locust Street,Suite 350,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1545.00,03/06/2015,Cash or cash equivalent,323174458,INLYTA,,MaRCC Registry  Metastatic advanced Renal Cell Cancer Registry,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1420.36,06/25/2015,In-kind items and services,323154622,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,03/18/2015,Cash or cash equivalent,323163254,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,69.37,10/14/2015,Cash or cash equivalent,323161558,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,06/03/2015,Cash or cash equivalent,323162439,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1335.94,02/25/2015,Cash or cash equivalent,323165072,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323155320,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,11/04/2015,Cash or cash equivalent,323160454,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/25/2015,Cash or cash equivalent,323158870,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1246.88,06/18/2015,Cash or cash equivalent,323184232,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,10/21/2015,Cash or cash equivalent,323192074,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/21/2015,Cash or cash equivalent,323192080,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,10/21/2015,Cash or cash equivalent,323189924,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,323194428,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,914.42,11/11/2015,Cash or cash equivalent,323185016,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323191024,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/07/2015,Cash or cash equivalent,323191869,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,323188510,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,03/18/2015,Cash or cash equivalent,323140270,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,323142020,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,45.62,10/14/2015,Cash or cash equivalent,323144670,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,323141272,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5000.00,08/26/2015,Cash or cash equivalent,323149918,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,639.97,12/09/2015,Cash or cash equivalent,323146542,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323149138,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,12/02/2015,Cash or cash equivalent,323143216,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323145162,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,06/03/2015,Cash or cash equivalent,323144353,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,07/22/2015,Cash or cash equivalent,323149422,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,323145252,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,740.00,12/09/2015,Cash or cash equivalent,323236288,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2130.54,06/15/2015,In-kind items and services,323224534,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1235.05,12/09/2015,Cash or cash equivalent,323226311,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/07/2015,Cash or cash equivalent,323233818,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323231324,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,08/19/2015,Cash or cash equivalent,323231385,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,10/07/2015,Cash or cash equivalent,323234810,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,07/23/2015,Cash or cash equivalent,323227482,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323224186,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,11/04/2015,Cash or cash equivalent,323226798,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,06/03/2015,Cash or cash equivalent,323210018,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,323217640,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,323211836,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323213542,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/02/2015,Cash or cash equivalent,323211098,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,150.00,11/04/2015,Cash or cash equivalent,323213748,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/14/2015,Cash or cash equivalent,323213080,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323213086,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,11/04/2015,Cash or cash equivalent,323213238,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,12/16/2015,Cash or cash equivalent,323217382,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/19/2015,Cash or cash equivalent,323250054,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,102.81,10/21/2015,Cash or cash equivalent,323244098,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,914.42,10/21/2015,Cash or cash equivalent,323245826,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,40.31,10/21/2015,Cash or cash equivalent,323239416,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/21/2015,Cash or cash equivalent,323242058,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1365.63,07/29/2015,Cash or cash equivalent,323242070,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/14/2015,Cash or cash equivalent,323242079,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,09/16/2015,Cash or cash equivalent,323244620,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,03/19/2015,Cash or cash equivalent,323238732,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323243065,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,06/04/2015,Cash or cash equivalent,323201214,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,08/12/2015,Cash or cash equivalent,323202172,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323196796,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323208994,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,8313.00,01/21/2015,Cash or cash equivalent,323280574,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,754.06,09/23/2015,Cash or cash equivalent,323278134,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIACML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,12/02/2015,Cash or cash equivalent,323279890,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,225.00,12/16/2015,Cash or cash equivalent,323288311,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,588.00,02/18/2015,Cash or cash equivalent,323286007,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,323280218,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,10/14/2015,Cash or cash equivalent,323277802,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,75.62,10/14/2015,Cash or cash equivalent,323280364,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,07/01/2015,Cash or cash equivalent,323283834,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,03/25/2015,Cash or cash equivalent,323275514,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,05/06/2015,Cash or cash equivalent,323273818,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/17/2015,Cash or cash equivalent,323276482,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,03/25/2015,Cash or cash equivalent,323268140,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,800.00,11/04/2015,Cash or cash equivalent,323264938,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,914.42,12/09/2015,Cash or cash equivalent,323275322,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1235.05,12/09/2015,Cash or cash equivalent,323298265,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,NICOLAS SHAMMAS,1622 E LOMBARD STREET,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,133.45,09/29/2015,In-kind items and services,323293226,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,08/12/2015,Cash or cash equivalent,323297580,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,323304520,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,632.00,07/14/2015,In-kind items and services,323293448,,,A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study Of The Longterm Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,323299466,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,323291819,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323298760,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,07/23/2015,Cash or cash equivalent,323303295,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,38.75,10/21/2015,Cash or cash equivalent,323292992,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323299038,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,12/16/2015,Cash or cash equivalent,323299100,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1128.13,06/18/2015,Cash or cash equivalent,323256800,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323262158,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,647.00,03/25/2015,Cash or cash equivalent,323253820,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,03/19/2015,Cash or cash equivalent,323258310,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,225.00,10/14/2015,Cash or cash equivalent,323258424,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,740.00,12/09/2015,Cash or cash equivalent,323341648,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3252.00,06/30/2015,In-kind items and services,323333437,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,SUITE 201,SIOUX CITY,51101,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5.00,10/21/2015,Cash or cash equivalent,323342665,BOSULIF,,A Phase 3 Randomized Openlabel Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/25/2015,Cash or cash equivalent,323341227,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE STE 100,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7104.71,06/02/2015,Cash or cash equivalent,323338102,,,A Phase 3 Randomized Doubleblind Study Assessing The Efficacy And Safety Of Pf06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Metho,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,150.00,01/21/2015,Cash or cash equivalent,323343878,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,10/21/2015,Cash or cash equivalent,323337428,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,806.00,05/01/2015,Cash or cash equivalent,323334937,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,10/14/2015,Cash or cash equivalent,323328278,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/28/2015,Cash or cash equivalent,323328282,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,225.00,09/23/2015,Cash or cash equivalent,323322368,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323329570,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,06/03/2015,Cash or cash equivalent,323319328,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,5259.00,09/25/2015,In-kind items and services,323320200,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1012.70,11/04/2015,Cash or cash equivalent,323321276,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323322150,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,10/21/2015,Cash or cash equivalent,323355874,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323349806,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323352464,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323353419,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,12/02/2015,Cash or cash equivalent,323349876,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323312040,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,08/12/2015,Cash or cash equivalent,323311262,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,09/02/2015,Cash or cash equivalent,323309556,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323308960,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,07/08/2015,Cash or cash equivalent,323315856,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,11/04/2015,Cash or cash equivalent,323393364,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,323396574,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,09/30/2015,In-kind items and services,323397520,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,568.10,12/16/2015,Cash or cash equivalent,323400148,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,05/21/2015,Cash or cash equivalent,323396800,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,581.88,12/02/2015,Cash or cash equivalent,323398696,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,323397082,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/14/2015,Cash or cash equivalent,323391338,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,20.00,06/30/2015,In-kind items and services,323382796,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/12/2015,Cash or cash equivalent,323385514,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,SUITE 300,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,10/21/2015,Cash or cash equivalent,323378596,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,07/23/2015,Cash or cash equivalent,323385642,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,07/01/2015,Cash or cash equivalent,323384894,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323379640,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323375450,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,04/22/2015,Cash or cash equivalent,323377306,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,07/08/2015,Cash or cash equivalent,323383354,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323379998,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,05/21/2015,Cash or cash equivalent,323381693,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/02/2015,Cash or cash equivalent,323411776,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,639.97,11/11/2015,Cash or cash equivalent,323413414,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,07/22/2015,Cash or cash equivalent,323402190,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/21/2015,Cash or cash equivalent,323413594,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,10/07/2015,Cash or cash equivalent,323413614,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,01/15/2015,Cash or cash equivalent,323411948,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,3150.00,01/21/2015,Cash or cash equivalent,323413626,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,10.00,09/30/2015,In-kind items and services,323406050,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,06/03/2015,Cash or cash equivalent,323410384,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,47.81,10/14/2015,Cash or cash equivalent,323411418,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,724.38,06/18/2015,Cash or cash equivalent,323404020,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,323403346,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,12/02/2015,Cash or cash equivalent,323405792,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,12/02/2015,Cash or cash equivalent,323407526,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,26838.00,08/21/2015,In-kind items and services,323360286,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,Study Drug
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,06/03/2015,Cash or cash equivalent,323370962,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,06/03/2015,Cash or cash equivalent,323370971,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,07/01/2015,Cash or cash equivalent,323367641,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,02/04/2015,Cash or cash equivalent,323370292,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,10/07/2015,Cash or cash equivalent,323373045,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,581.88,12/02/2015,Cash or cash equivalent,323360812,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,130.00,10/07/2015,Cash or cash equivalent,323361694,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,86.87,10/14/2015,Cash or cash equivalent,323361700,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,300 Locust Street,Suite 350,DES MOINES,50309,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1100.00,10/15/2015,Cash or cash equivalent,323446843,INLYTA,,MaRCC Registry  Metastatic advanced Renal Cell Cancer Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,11/04/2015,Cash or cash equivalent,323446106,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,12/09/2015,Cash or cash equivalent,323445372,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323446198,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1514.06,06/18/2015,Cash or cash equivalent,323451430,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/12/2015,Cash or cash equivalent,323450700,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/12/2015,Cash or cash equivalent,323450706,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,12/16/2015,Cash or cash equivalent,323451740,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,07/22/2015,Cash or cash equivalent,323433854,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4500.00,10/07/2015,Cash or cash equivalent,323439114,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,01/21/2015,Cash or cash equivalent,323437450,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,09/02/2015,Cash or cash equivalent,323437721,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,908.44,06/11/2015,Cash or cash equivalent,323434510,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,JAMES POOCK,2055 KIMBALL AVE,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,133.45,08/14/2015,In-kind items and services,323465134,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,06/11/2015,Cash or cash equivalent,323463320,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,JAMES PAGE LOVELL,5950 UNIVERSITY AVE,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,133.45,07/22/2015,In-kind items and services,323466874,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,04/22/2015,Cash or cash equivalent,323459895,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323456812,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,323466318,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,323456062,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323462802,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323415144,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323414504,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,11/18/2015,Cash or cash equivalent,323420022,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1550.00,03/25/2015,Cash or cash equivalent,323426934,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,08/19/2015,Cash or cash equivalent,323414158,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,08/19/2015,Cash or cash equivalent,323414162,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,08/19/2015,Cash or cash equivalent,323500716,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,588.00,02/18/2015,Cash or cash equivalent,323500768,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,323496590,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,06/24/2015,Cash or cash equivalent,323497470,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,11/04/2015,Cash or cash equivalent,323498618,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,06/03/2015,Cash or cash equivalent,323500342,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/14/2015,Cash or cash equivalent,323497882,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,202 10th Street SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7527.90,09/25/2015,In-kind items and services,323500438,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,323502164,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,03/18/2015,Cash or cash equivalent,323506384,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVENUE,BLDG E,WATERLOO,50702,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1100.00,10/07/2015,Cash or cash equivalent,323503146,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,08/12/2015,Cash or cash equivalent,323499760,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,09/02/2015,Cash or cash equivalent,323495602,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.16,12/09/2015,Cash or cash equivalent,323491414,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/07/2015,Cash or cash equivalent,323487288,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,12/02/2015,Cash or cash equivalent,323487361,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323485738,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323486600,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,07/23/2015,Cash or cash equivalent,323518678,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,01/07/2015,Cash or cash equivalent,323520738,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323519876,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,700.00,11/04/2015,Cash or cash equivalent,323517304,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323517427,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,74.06,10/14/2015,Cash or cash equivalent,323510606,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323511442,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,06/03/2015,Cash or cash equivalent,323518554,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,831.25,06/03/2015,Cash or cash equivalent,323478552,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,Suite 201 201 Ridge Street,,COUNCIL BLUFFS,51503,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,7527.90,10/01/2015,In-kind items and services,323470846,CELEBREX,,A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN,,Study Drug
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,10/07/2015,Cash or cash equivalent,323474230,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,249.38,06/03/2015,Cash or cash equivalent,323477752,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,368.13,06/03/2015,Cash or cash equivalent,323474302,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,323468517,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,91.25,10/14/2015,Cash or cash equivalent,323474560,,,Study To Test Whether PF00547659 Is Safe And Improves Disease Symptoms In Patients With Crohns Disease OPERA,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,721.53,07/01/2015,Cash or cash equivalent,323474574,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,482.22,12/09/2015,Cash or cash equivalent,323471236,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.00,12/01/2015,In-kind items and services,323477346,,,A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323476548,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,736.16,12/09/2015,Cash or cash equivalent,323478270,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,SIOUX CITY,51101-1733,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,296.88,09/23/2015,Cash or cash equivalent,323553362,BOSULIF,,AN OPENLABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIACML WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/25/2015,Cash or cash equivalent,323556828,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,623.44,10/14/2015,Cash or cash equivalent,323558566,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,403.75,08/12/2015,Cash or cash equivalent,323562444,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,06/18/2015,Cash or cash equivalent,323563335,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,323554662,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323556336,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,06/11/2015,Cash or cash equivalent,323556342,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1436.88,06/18/2015,Cash or cash equivalent,323551124,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,150.00,01/21/2015,Cash or cash equivalent,323551286,,,AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATORS CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAALL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1076.47,04/30/2015,Cash or cash equivalent,323563680,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323563710,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1741.35,02/05/2015,Cash or cash equivalent,323548086,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,323550748,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,639.97,10/21/2015,Cash or cash equivalent,323539474,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,10/21/2015,Cash or cash equivalent,323550954,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323542154,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,12/02/2015,Cash or cash equivalent,323542160,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1680.00,07/14/2015,In-kind items and services,323550816,,,A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study Of The Longterm Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,730.31,03/25/2015,Cash or cash equivalent,323539802,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323549380,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323540793,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,06/11/2015,Cash or cash equivalent,323540801,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1000.00,06/11/2015,Cash or cash equivalent,323540964,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,4900.00,02/04/2015,Cash or cash equivalent,323550592,RAPAMUNE,,Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,492.19,02/19/2015,Cash or cash equivalent,323578820,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323573588,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,10/21/2015,Cash or cash equivalent,323573614,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,605.15,04/30/2015,Cash or cash equivalent,323572816,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,12/16/2015,Cash or cash equivalent,323567898,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE,PO BOX 3014,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1500.00,07/15/2015,Cash or cash equivalent,323574848,,,A Study Of PF05280586 RituximabPfizer Or MabThera RituximabEU For The FirstLine Treatment Of Patients With CD20Positive Low Tumor Burden Follicular Lymphoma REFLECTIONS B32806,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,19.50,10/14/2015,Cash or cash equivalent,323571408,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,469.06,03/12/2015,Cash or cash equivalent,323568102,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,20.00,09/30/2015,In-kind items and services,323565488,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,290.94,10/14/2015,Cash or cash equivalent,323525882,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1426.43,11/04/2015,Cash or cash equivalent,323527006,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,05/21/2015,Cash or cash equivalent,323533126,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,06/11/2015,Cash or cash equivalent,323534846,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,323526424,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,323528154,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,516.56,05/06/2015,Cash or cash equivalent,323616536,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323613366,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,428.75,02/18/2015,Cash or cash equivalent,323618662,XELJANZ,,Phase 3 Randomized DoubleBlind Study Of The Efficacy And Safety Of 2 Doses Of CP690550 Compared To Methotrexate In MethotrexateNaive Patients With Rheumatoid Arthritis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,12/02/2015,Cash or cash equivalent,323608034,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,914.42,12/09/2015,Cash or cash equivalent,323612918,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,30.00,09/30/2015,In-kind items and services,323607288,,,A Phase 2 Randomized Doubleblind Placebocontrolled Multiple Ascending Dose Study To Evaluate The Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Pf06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,323598020,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,07/01/2015,Cash or cash equivalent,323601542,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323602476,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,12/02/2015,Cash or cash equivalent,323604246,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,19081.25,08/10/2015,Cash or cash equivalent,323597402,,,A Phase 3 Randomized DoubleBlind PlaceboControlled 26Week Multicenter Study With a 78Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Mo,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,03/19/2015,Cash or cash equivalent,323596574,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,DEPARTMENT OF RESEARCH,WEST DES MOINES,50266,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,765.70,11/18/2015,Cash or cash equivalent,323600180,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVENUE,,AMES,50010-3014,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,48.00,09/01/2015,In-kind items and services,323594074,,,Randomized DoubleBlind PlaceboControlled Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin MK8835PF04971729 in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323603040,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,202 10TH STREET SE STE 100,,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,2874.00,08/21/2015,Cash or cash equivalent,323596178,,,A Phase 3 Randomized Doubleblind Study Assessing The Efficacy And Safety Of Pf06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Metho,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323627682,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,860.94,07/22/2015,Cash or cash equivalent,323629408,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,397.81,05/21/2015,Cash or cash equivalent,323633194,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,504.69,12/02/2015,Cash or cash equivalent,323621392,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,387.50,12/02/2015,Cash or cash equivalent,323628256,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,202 10th Street,SE,CEDAR RAPIDS,52403,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,71.00,05/26/2015,Cash or cash equivalent,323624966,CELEBREX,,A Randomized Double Blind Parallelgroup Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen,,
Non-covered Recipient Entity,,,,,,,1701 WEST BROADWAY,,COUNCIL BLUFFS,51501,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,12/02/2015,Cash or cash equivalent,323630224,,,The Evaluation Of PF04950615 RN316 In Reducing The Occurrence Of Major Cardiovascular Events In High Risk SubjectsSPIRE1,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,558.60,04/30/2015,Cash or cash equivalent,323589382,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,475.00,06/18/2015,Cash or cash equivalent,323585978,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1850.00,09/23/2015,Cash or cash equivalent,323579946,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,1500.00,01/27/2015,Cash or cash equivalent,319339314,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Non-covered Recipient Entity,,,,,,,4150 KIMBALL AVE,,WATERLOO,50701,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,500.00,01/27/2015,Cash or cash equivalent,319702840,Avastin,,AVASTIN AS ADJUVANT TREATMENT IN BC PATIENTS,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 8,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,1276.56,06/18/2015,Cash or cash equivalent,323653458,,,A Study To Monitor LongTerm Treatment With PF00547659 OPERA II,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,837.19,10/21/2015,Cash or cash equivalent,323649652,,,Randomized Clinical Trial of RN316 PF04950615 in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsSPIRELDL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000010364,Roche Products Limited,,20052.00,01/12/2015,Cash or cash equivalent,319332324,NonCovered Product,,SUB OPTIMALLY CONTROLLED PTS WITH SCHIZOPHRENIA 3,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,495.79,10/21/2015,Cash or cash equivalent,323653342,,,The Evaluation Of PF04950615 RN316  In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects SPIRE1,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000005726,Hoffmann-La Roche Limited,,1826.40,11/11/2015,Cash or cash equivalent,319495084,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Terumo Medical Corporation,100000000291,Terumo Medical Corporation,NJ,1400.00,04/16/2015,Cash or cash equivalent,283459120,,,OSPREY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Terumo Medical Corporation,100000000291,Terumo Medical Corporation,NJ,697.50,06/03/2015,Cash or cash equivalent,283459122,,,OSPREY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Terumo Medical Corporation,100000000291,Terumo Medical Corporation,NJ,697.50,08/04/2015,Cash or cash equivalent,283459124,,,OSPREY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Terumo Medical Corporation,100000000291,Terumo Medical Corporation,NJ,4908.75,11/02/2015,Cash or cash equivalent,283459126,,,OSPREY,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000005726,Hoffmann-La Roche Limited,,1340.10,11/10/2015,Cash or cash equivalent,319731959,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000005726,Hoffmann-La Roche Limited,,250.00,11/10/2015,Cash or cash equivalent,319731992,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Genentech, Inc.",100000005726,Hoffmann-La Roche Limited,,2500.00,07/01/2015,Cash or cash equivalent,319777034,Zelboraf,,ZELBORAF ROLLOVER STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,320.63,12/02/2015,Cash or cash equivalent,323635717,,,Phase 3 Multi Center Double Blind Randomized Placebo Controlled Parallel Group Evaluation Of The Efficacy Safety And Tolerability Of PF04950615 In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND COURT,SUITE 38,CLIVE,50325,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,732.00,10/07/2015,Cash or cash equivalent,323644526,XELJANZ,,A Randomized DoubleBlind PlaceboControlled Parallel Group MultiCentre Study To Investigate The Safety And Efficacy Of CP690550 For Induction Therapy In Subjects With Moderate To Severe Crohns Disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,433.44,04/22/2015,Cash or cash equivalent,323639368,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVENUE,SUITE 240,WEST DES MOINES,50266-8216,,,Pfizer Inc.,100000000286,Pfizer Inc.,NY,651.70,04/30/2015,Cash or cash equivalent,323642074,,,Randomized Clinical Trial of Bococizumab PF04950615 RN316 in Subjects Who Are Intolerant to Statins SPIRESI,,
Covered Recipient Teaching Hospital,2945,COVENANT MEDICAL CENTER,,,,,3421 W 9th St,,Waterloo,50702,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,9375.00,05/13/2015,Cash or cash equivalent,328636920,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,202 TENTH STREET SE SUITE 285,,CEDAR RAPIDS,52403,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,7875.00,01/21/2015,Cash or cash equivalent,328638796,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,3530 WEST 4TH STREET,,WATERLOO,50701,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,7875.00,01/21/2015,Cash or cash equivalent,328638798,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE PO BOX 3014,,AMES,50016,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,6000.00,02/26/2015,Cash or cash equivalent,328639688,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVENUE PO BOX 3014,,AMES,50016,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,21285.00,01/07/2015,Cash or cash equivalent,328639708,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,3530 W 4th St,,Waterloo,50701,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,70.00,03/18/2015,In-kind items and services,328638468,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,100.00,03/18/2015,In-kind items and services,328640630,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,DBA June E Nylen Cancer Center,Sioux,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,7025.00,05/08/2015,Cash or cash equivalent,328640218,Revlimid,,CC-5013-NHL-008,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,21270.00,01/21/2015,Cash or cash equivalent,328640220,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA STREET,,Sioux City,51101,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,7000.00,05/27/2015,Cash or cash equivalent,328640726,Abraxane,,AX-CL-OTHER-PrECOG-004080,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,150.00,03/12/2015,In-kind items and services,328640320,Revlimid,,Celgene - Connect MM,,
Non-covered Recipient Entity,,,,,,,P O BOX 3014,1215 DUFF AVENUE,AMES,50010,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,2500.00,02/12/2015,Cash or cash equivalent,328640322,Revlimid,,Celgene - Connect MDSAML,,
Non-covered Recipient Entity,,,,,,,202 TENTH STREET SE SUITE 285,,CEDAR RAPIDS,52403,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,4875.00,02/11/2015,Cash or cash equivalent,328641676,Revlimid,,Celgene - Connect CLL,,
Non-covered Recipient Entity,,,,,,,1351 EAST KIMBERLY ROAD SUITE 100,,BETTENDORF,52722,,,Celgene Corporation,100000000343,Celgene Corporation,NJ,2060.00,01/21/2015,Cash or cash equivalent,328641780,Revlimid,,Celgene - Connect MM,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,5830.63,03/27/2015,Cash or cash equivalent,324474812,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7290.00,04/01/2015,Cash or cash equivalent,324474829,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,5830.63,03/27/2015,Cash or cash equivalent,324474854,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,216.95,06/10/2015,Cash or cash equivalent,324474872,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,380.00,09/22/2015,Cash or cash equivalent,324474518,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,430.00,06/01/2015,Cash or cash equivalent,324474576,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,430.00,06/01/2015,Cash or cash equivalent,324474726,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1365.00,06/01/2015,Cash or cash equivalent,324474750,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,15562.00,02/24/2015,Cash or cash equivalent,324474782,Adempas,,Probe Study- Riociguat in CF early signs of efficacy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1400.00,03/27/2015,Cash or cash equivalent,324474786,Adempas,,"BAY63-2521, PDE5i Replace with Riociguat",,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,3500.00,01/29/2015,Cash or cash equivalent,329623103,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,Non Refundable Start-Up
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,500.00,03/10/2015,Cash or cash equivalent,329636959,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081009 V1: Screen Fail Jan 13 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637017,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081001 V3 Mo3 Feb 13 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637019,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081002 V3 Mo3 Feb 12 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637021,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081003 V3 Mo3 Feb 13 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637023,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081004 V3 Mo3 Feb 17 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637025,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081006 V3 Mo3 Feb 10 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,04/02/2015,Cash or cash equivalent,329637027,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081007 V3 Mo3 Feb 17 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,452.50,10/13/2015,Cash or cash equivalent,329636443,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081001 V5 Mo9 Aug 11 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,452.50,10/13/2015,Cash or cash equivalent,329636445,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081002 V5 Mo9 Aug 20 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,452.50,10/13/2015,Cash or cash equivalent,329636447,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081003 V5 Mo9 Aug 10 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,452.50,10/13/2015,Cash or cash equivalent,329636449,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081006 V5 Mo9 Aug 13 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1143.75,04/02/2015,Cash or cash equivalent,329637081,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081010 V2 Feb  5 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,1440.00,04/02/2015,Cash or cash equivalent,329637083,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081010 V1: Visit Jan 16 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,452.50,10/13/2015,Cash or cash equivalent,329636501,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081007 V5 Mo9 Aug 24 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,10/13/2015,Cash or cash equivalent,329636503,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081010 V4 Mo6 Aug  4 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636241,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081001 V4 Mo6 May 11 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636243,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081002 V4 Mo6 May 14 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,500.00,05/08/2015,Cash or cash equivalent,329637155,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081011 V1: Screen Fail Mar 17 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636245,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081004 V4 Mo6 May 11 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636247,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081006 V4 Mo6 May 12 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636249,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081007 V4 Mo6 May 26 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,07/16/2015,Cash or cash equivalent,329636251,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081010 V3 Mo3 May  7 2015
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,546.25,06/09/2015,Cash or cash equivalent,329637223,BELVIQ,,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",,13081003 V4 Mo6 May  5 2013
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1006.00,06/18/2015,Cash or cash equivalent,329669827,HALAVEN,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma",,11081002 Off Treatment Dec 11 2012
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,541.67,01/15/2015,Cash or cash equivalent,331922157,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,416.67,02/09/2015,Cash or cash equivalent,331922163,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,666.67,05/13/2015,Cash or cash equivalent,331922169,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,750.00,08/19/2015,Cash or cash equivalent,331922173,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,500.00,11/19/2015,Cash or cash equivalent,331922179,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,500.00,01/15/2015,Cash or cash equivalent,331922185,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2708.33,01/15/2015,Cash or cash equivalent,331922191,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2083.33,02/09/2015,Cash or cash equivalent,331922199,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,3333.33,05/13/2015,Cash or cash equivalent,331922207,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,3750.00,08/19/2015,Cash or cash equivalent,331922217,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BioMarin Pharmaceutical Inc.,100000010405,BioMarin Pharmaceutical Inc.,CA,2500.00,11/19/2015,Cash or cash equivalent,331922225,KUVAN,,PKU Demographics Outcomes and Safety Registry,,PKUDOS 01
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,IOWA CITY,52242,,,"Sysmex America, Inc.",100000005567,"Sysmex America, Inc.",IL,5625.00,01/05/2015,Cash or cash equivalent,317792774,,,XN-L Clinical Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Sysmex America, Inc.",100000005567,"Sysmex America, Inc.",IL,11439.50,06/16/2015,Cash or cash equivalent,320815248,,,XN-L Clinical Study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET,SUITE 3262,DES MOINES,50314,,,"Dexcom, Inc.",100000010478,"Dexcom, Inc.",CA,47918.00,03/19/2015,Cash or cash equivalent,330948051,,,DIaMonD,,Outcome study
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Eisai Inc.,100000000284,"Eisai Co., Ltd.",,1006.00,06/18/2015,Cash or cash equivalent,329669825,HALAVEN,,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma",,11081001 Off Treatment Arm B Sep 27 2012
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct Ste 8,,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,666.00,06/05/2015,Cash or cash equivalent,299266960,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,3782.50,07/14/2015,Cash or cash equivalent,299276878,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,572.23,01/08/2015,Cash or cash equivalent,299193866,Creon,,P12-792,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct Ste 8,,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,723.50,03/02/2015,Cash or cash equivalent,299222692,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"W. L. Gore & Associates, Inc.",100000010774,"W. L. Gore & Associates, Inc.",DE,7011.45,06/09/2015,Cash or cash equivalent,295837646,,,Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto iliac Aneurysms,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"W. L. Gore & Associates, Inc.",100000010774,"W. L. Gore & Associates, Inc.",DE,901.56,09/09/2015,Cash or cash equivalent,295837648,,,Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto iliac Aneurysms,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"W. L. Gore & Associates, Inc.",100000010774,"W. L. Gore & Associates, Inc.",DE,1303.12,12/08/2015,Cash or cash equivalent,295837650,,,Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto iliac Aneurysms,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,18200.40,01/28/2015,Cash or cash equivalent,325754064,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,13095.65,05/29/2015,Cash or cash equivalent,333206564,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,283.49,04/09/2015,Cash or cash equivalent,333206572,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,500.00,05/29/2015,Cash or cash equivalent,333206580,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,190.00,06/18/2015,Cash or cash equivalent,333206584,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,42800.25,01/12/2015,Cash or cash equivalent,325753978,,,A Phase I Study of MLN6907 in Patients With Metastatic Colorectal,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,3085.40,01/15/2015,In-kind items and services,325752344,ADCETRIS,,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,10525.00,01/27/2015,Cash or cash equivalent,325753585,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,18848.95,02/05/2015,Cash or cash equivalent,333206015,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,3965.30,01/08/2015,Cash or cash equivalent,333206022,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,411 Laurel Street,Suite 3262,Des Moines,50314,,,Halozyme Inc,100000010716,Halozyme Inc,CA,760.00,01/22/2015,Cash or cash equivalent,333206030,Hylenex,,CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII),,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,1003.75,03/18/2015,In-kind items and services,325751354,,,A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,600.00,05/12/2015,Cash or cash equivalent,325751934,,,IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,4881.60,03/25/2015,Cash or cash equivalent,332008573,GARDASIL9,,"A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine Administered to 16- to 26-Year-Old Women",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,17955.00,09/18/2015,Cash or cash equivalent,332008587,KEYTRUDA,,"A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,38418.40,02/18/2015,Cash or cash equivalent,332008601,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,8211.00,04/29/2015,Cash or cash equivalent,332008615,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,40741.80,04/07/2015,Cash or cash equivalent,332008621,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1368.20,01/12/2015,In-kind items and services,332008631,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,189.50,02/09/2015,In-kind items and services,332008639,KEYTRUDA,,"A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5854.99,09/08/2015,Cash or cash equivalent,332021615,DULERA,,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate,Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma Protocol No. P06241 also known as P202",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,12998.90,05/19/2015,Cash or cash equivalent,332005991,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2864.00,10/23/2015,Cash or cash equivalent,332006005,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,9250.00,03/13/2015,Cash or cash equivalent,332006015,KEYTRUDA,,MK-3475 Expanded Access Program,,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2700.00,09/01/2015,Cash or cash equivalent,332021635,RAGWITEK,,"A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambrosia artemisiifolia Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,7669.12,08/18/2015,Cash or cash equivalent,333244458,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,47235.00,08/31/2015,Cash or cash equivalent,333244462,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,80325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,40.80,07/13/2015,Cash or cash equivalent,334216026,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,10.23,04/10/2015,Cash or cash equivalent,334216042,,,MA-209,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,17880.00,10/01/2015,Cash or cash equivalent,325756208,,,A Study of MLN0264 in Patients With Pancreatic Cancer,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,Suite 8,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,375.16,04/16/2015,Cash or cash equivalent,334216086,,,MA-209,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,16519.80,01/28/2015,Cash or cash equivalent,325755682,,,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,655.25,03/04/2015,In-kind items and services,325757500,,,A Study of MLN0264 in Patients With Pancreatic Cancer,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,250.00,02/18/2015,Cash or cash equivalent,333242972,COMETRIQ,,Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone or MDV3100 (COMET-1),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,345.00,01/05/2015,Cash or cash equivalent,333243566,COMETRIQ,,Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,141.31,06/16/2015,In-kind items and services,325757022,,,A Phase I Study of MLN6907 in Patients With Metastatic Colorectal,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101,,,"Millennium Pharmaceuticals, Inc.",100000000080,"Millennium Pharmaceuticals, Inc.",MA,6355.00,02/05/2015,Cash or cash equivalent,325755277,VELCADE,,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct #8,,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,534.00,09/28/2015,Cash or cash equivalent,334215666,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., #8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,55.00,08/07/2015,Cash or cash equivalent,334215674,,,MA-209,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,1400.00,04/29/2015,Cash or cash equivalent,333243702,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,240.00,04/10/2015,Cash or cash equivalent,334215778,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,1100.00,05/28/2015,Cash or cash equivalent,334215788,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct, #8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,376.00,10/06/2015,Cash or cash equivalent,334215803,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,22.50,05/08/2015,Cash or cash equivalent,334215816,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct, #8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,187.58,08/24/2015,Cash or cash equivalent,334215830,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,56.20,04/13/2015,Cash or cash equivalent,334215858,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct, #8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,550.00,09/30/2015,Cash or cash equivalent,334215902,,,MA-209,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,6571.56,01/08/2015,Cash or cash equivalent,333244436,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,6322.94,02/12/2015,Cash or cash equivalent,333244442,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,5120.19,03/10/2015,Cash or cash equivalent,333244446,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,5952.12,04/02/2015,Cash or cash equivalent,333244448,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,3932.31,05/12/2015,Cash or cash equivalent,333244452,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,2384.25,08/13/2015,Cash or cash equivalent,333244456,COMETRIQ,,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR),,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Court #8,,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,11102.50,09/28/2015,Cash or cash equivalent,334215934,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Court #8,,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,81.60,10/13/2015,Cash or cash equivalent,334215940,,,MA-209,,
Non-covered Recipient Entity,,,,,,,2024 Nw 92nd Ct,Suite 8,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,5517.00,05/18/2015,Cash or cash equivalent,334215984,,,MA-209,,
Non-covered Recipient Entity,,,,,,,"2024 Nw 92nd Ct., suite. 8",,Clive,50325,,,Given Imaging Ltd.,100000000349,Given Imaging Ltd.,,187.58,05/08/2015,Cash or cash equivalent,334215990,,,MA-209,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,13396.25,11/23/2015,Cash or cash equivalent,299346152,Humira,Viekira,M14-251,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,11247.50,11/23/2015,Cash or cash equivalent,299346160,Humira,Viekira,M14-251,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,3102.50,12/16/2015,Cash or cash equivalent,299326726,Humira,Viekira,M14-251,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct Ste 8,,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,2772.00,11/30/2015,Cash or cash equivalent,299343758,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,5580.00,11/30/2015,Cash or cash equivalent,299317486,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,2000.00,11/04/2015,Cash or cash equivalent,299317496,Humira,,P11-282,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Ct Ste 8,,Clive,50325,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,636.00,11/18/2015,Cash or cash equivalent,299343770,Humira,,P11-282,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,3460.00,11/18/2015,Cash or cash equivalent,299317502,Humira,,P11-282,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,3102.50,10/26/2015,Cash or cash equivalent,299313032,Humira,Viekira,M14-251,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,12823.75,10/05/2015,Cash or cash equivalent,299313040,Humira,Viekira,M14-251,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 W,,Iowa City,52246,,,"AbbVie, Inc.",100000000204,"AbbVie, Inc.",IL,1750.00,08/19/2015,Cash or cash equivalent,299287976,Humira,Viekira,M14-251,,
Covered Recipient Physician,,,236879,FREDRIC,E,SAGER,1601 NW 114TH ST,SUITE 334,CLIVE,50325-7007,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,50.00,10/07/2015,Cash or cash equivalent,332153995,IMPLANON,,Nexplanon Observational Risk Assessment Study NORA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,625.00,01/15/2015,Cash or cash equivalent,326299470,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1000.00,05/21/2015,Cash or cash equivalent,326299474,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,60.00,06/24/2015,Cash or cash equivalent,326299479,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,502.07,12/31/2015,In-kind items and services,326299484,,,GRIPHON OL HQ - AC-065-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,1041.09,12/31/2015,In-kind items and services,326299488,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,165.00,03/25/2015,In-kind items and services,326299492,OPSUMIT MACITENTAN,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,2814.48,07/30/2015,Cash or cash equivalent,326299496,,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,316.91,07/30/2015,Cash or cash equivalent,326299500,,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,29.18,07/30/2015,Cash or cash equivalent,326299506,,,SERAPHIN OL HQ - AC-055-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000000253,"Actelion Clinical Research, Inc.",NJ,850.00,08/05/2015,Cash or cash equivalent,326299510,,,SERAPHIN OL HQ - AC-055-303,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,250.00,02/06/2015,Cash or cash equivalent,326306152,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3012.00,04/24/2015,Cash or cash equivalent,326306158,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1628.00,07/27/2015,Cash or cash equivalent,326306162,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,165.00,11/12/2015,Cash or cash equivalent,326306166,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,126.00,12/14/2015,Cash or cash equivalent,326306170,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,5000.00,07/10/2015,Cash or cash equivalent,326306175,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,2500.00,07/24/2015,Cash or cash equivalent,326306180,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Non-covered Recipient Entity,,,,,,,1601 NW 114TH ST STE 347,,DES MOINES,50325-7046,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3400.00,11/20/2015,Cash or cash equivalent,326306184,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,172.24,10/06/2015,In-kind items and services,332154941,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,600.00,02/02/2015,Cash or cash equivalent,326305064,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,300 E LOCUST ST,STE 350,DES MOINES,50309,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,72.50,10/29/2015,In-kind items and services,332150102,KEYTRUDA,,A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 Pembrolizumab in Patients with High Risk Resected Melanoma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,460.00,02/26/2015,Cash or cash equivalent,326305070,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1365.00,03/29/2015,Cash or cash equivalent,326305074,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,12792.00,04/24/2015,Cash or cash equivalent,326305078,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1682.00,06/26/2015,Cash or cash equivalent,326305082,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,3516.00,08/03/2015,Cash or cash equivalent,326305086,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1400.00,08/21/2015,Cash or cash equivalent,326305090,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1895.84,11/23/2015,Cash or cash equivalent,326305094,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,600.00,12/14/2015,Cash or cash equivalent,326305098,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,800.00,01/16/2015,Cash or cash equivalent,326305103,OPSUMIT MACITENTAN,TRACLEER BOSENTAN,QUERI EXTENSION - AC-052428 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1200.00,06/12/2015,Cash or cash equivalent,326305110,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1115.00,07/24/2015,Cash or cash equivalent,326305114,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,2000.00,07/24/2015,Cash or cash equivalent,326305118,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,5000.00,07/24/2015,Cash or cash equivalent,326305122,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,515.00,11/20/2015,Cash or cash equivalent,326305128,OPSUMIT MACITENTAN,,OPUS - AC-055-503,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5484.00,10/22/2015,In-kind items and services,332155711,KEYTRUDA,,"A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma",,
Non-covered Recipient Entity,,,,,,,540 E JEFFERSON ST STE 400,,IOWA CITY,52245-2479,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1279.00,02/02/2015,Cash or cash equivalent,326307152,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Non-covered Recipient Entity,,,,,,,540 E JEFFERSON ST STE 400,,IOWA CITY,52245-2479,,,"Actelion Pharmaceuticals US, Inc.",100000010813,"Actelion Pharmaceuticals US, Inc.",CA,1752.00,06/26/2015,Cash or cash equivalent,326307158,OPSUMIT MACITENTAN,,SYMPHONY - AC-055-401 USA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1638.16,10/27/2015,In-kind items and services,332148529,KEYTRUDA,,"Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,591.05,10/06/2015,In-kind items and services,332133333,KEYTRUDA,,"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced  Gastric or Gastroesophageal Junction GEJ Adenocarcinoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,272.00,10/14/2015,In-kind items and services,332133337,KEYTRUDA,,"Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,875.28,07/22/2015,In-kind items and services,332133339,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,8.70,11/25/2015,In-kind items and services,332138888,KEYTRUDA,,"Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group",,
Non-covered Recipient Entity,,,,,,,PO BOX 2959,,IOWA CITY,52244,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1.36,07/30/2015,In-kind items and services,332102891,VICTRELIS,,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,168.00,07/02/2015,In-kind items and services,332103693,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,828.39,02/11/2015,In-kind items and services,332092143,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Non-covered Recipient Entity,,,,,,,225 EAST BURLINGTON,,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,576.12,07/24/2015,In-kind items and services,332120571,RAGWITEK,,"A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambrosia artemisiifolia Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,531.88,04/02/2015,In-kind items and services,332132289,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,Iowa Clinical Research Corporation,225 East Burlington,IOWA CITY,52240,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,638.53,07/20/2015,In-kind items and services,332108927,RAGWITEK,,"A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambrosia artemisiifolia Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,285.80,11/02/2015,In-kind items and services,332105741,KEYTRUDA,,"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced  Gastric or Gastroesophageal Junction GEJ Adenocarcinoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,42.58,01/23/2015,In-kind items and services,332093465,JANUVIA,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,601 HWY 6 W 151,ATTN WARREN SCHMIDT MD,IOWA CITY,52246,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2153.00,08/03/2015,Cash or cash equivalent,332113899,VICTRELIS,,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.",,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West,,IOWA CITY,52246,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,38768.78,03/10/2015,Cash or cash equivalent,332113907,ZERBAXA,,Risk factors and outcomes of multidrug-resistant Gram negative rods among 140 VA Hospitals,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,2831.00,09/03/2015,Cash or cash equivalent,302976524,TECFIDERA,,Dimethyl Fumarate (DMF) Observational Study,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,500.00,10/27/2015,Cash or cash equivalent,302976532,TECFIDERA,,Dimethyl Fumarate (DMF) Observational Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,5290.70,03/17/2015,In-kind items and services,332061881,KEYTRUDA,,"A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma",,
Covered Recipient Physician,,,708876,TIMOTHY,S,STAUDTE,5409 AVENUE O,,FORT MADISON,52627-9601,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,150.00,04/08/2015,Cash or cash equivalent,332049283,IMPLANON,,Nexplanon Observational Risk Assessment Study NORA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,580.70,04/20/2015,In-kind items and services,332086771,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,704.60,09/21/2015,In-kind items and services,332086783,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,61.68,11/06/2015,In-kind items and services,332053398,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1781.82,04/29/2015,In-kind items and services,332053411,KEYTRUDA,,"Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,948.58,04/20/2015,In-kind items and services,332071543,JANUMET,,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin",,
Non-covered Recipient Entity,,,,,,,855 A AVE NE,,CEDAR RAPIDS,52402,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,2012.00,07/30/2015,Cash or cash equivalent,332044057,EMEND for Injection,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting CINV Associated With Moderately Emetogenic Chemotherapy",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,1959.15,03/10/2015,In-kind items and services,332078889,KEYTRUDA,,"A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma",,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,549.00,05/15/2015,Cash or cash equivalent,303033814,TECFIDERA,,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,635.00,01/22/2015,Cash or cash equivalent,303033823,TECFIDERA,,Dimethyl Fumarate (DMF) Observational Study,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,635.00,08/07/2015,Cash or cash equivalent,303033834,TECFIDERA,,Dimethyl Fumarate (DMF) Observational Study,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,291.00,11/24/2015,Cash or cash equivalent,303033842,TECFIDERA,,Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,4523.00,03/04/2015,Cash or cash equivalent,303033850,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,5000.00,06/15/2015,Cash or cash equivalent,303033861,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,2250.00,08/10/2015,Cash or cash equivalent,303033874,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,2250.00,08/11/2015,Cash or cash equivalent,303033886,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,39.00,09/22/2015,Cash or cash equivalent,303033894,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1321.00,08/13/2015,Cash or cash equivalent,303033902,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1016.00,08/13/2015,Cash or cash equivalent,303033910,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,980.00,08/13/2015,Cash or cash equivalent,303033916,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,600.00,03/26/2015,Cash or cash equivalent,303033924,TYSABRI,,TYSABRI Global Observational Program in Safety,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1159.00,10/13/2015,Cash or cash equivalent,303033936,TYSABRI,,Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,2155.00,10/21/2015,Cash or cash equivalent,303033944,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1861.00,10/21/2015,Cash or cash equivalent,303033950,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,101.00,10/21/2015,Cash or cash equivalent,303033959,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,868.00,11/23/2015,Cash or cash equivalent,303033964,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,868.00,11/23/2015,Cash or cash equivalent,303033970,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,483.00,12/01/2015,Cash or cash equivalent,303033978,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,6448.00,12/21/2015,Cash or cash equivalent,303033986,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,3224.00,12/21/2015,Cash or cash equivalent,303033991,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,918.00,12/21/2015,Cash or cash equivalent,303034002,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,259.00,12/21/2015,Cash or cash equivalent,303034010,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,63.00,12/21/2015,Cash or cash equivalent,303034020,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,38.00,12/21/2015,Cash or cash equivalent,303034028,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,3224.00,12/01/2015,Cash or cash equivalent,303034036,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,38.00,12/01/2015,Cash or cash equivalent,303034045,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,966.00,12/21/2015,Cash or cash equivalent,303034052,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,483.00,12/21/2015,Cash or cash equivalent,303034060,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Non-covered Recipient Entity,,,,,,,1111 6th Ave,,Des Moines,50314-2610,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,262.20,12/21/2015,Cash or cash equivalent,303034068,TYSABRI,,Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,500.00,01/23/2015,Cash or cash equivalent,302992432,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,40.00,01/23/2015,Cash or cash equivalent,302992440,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1872.50,01/09/2015,Cash or cash equivalent,302992448,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1104.00,02/16/2015,Cash or cash equivalent,302992460,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,448.00,02/16/2015,Cash or cash equivalent,302992468,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,250.00,06/05/2015,Cash or cash equivalent,302992474,ELOCTATE,,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,1300.00,07/30/2015,Cash or cash equivalent,302992483,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,841.85,07/30/2015,Cash or cash equivalent,302992508,ELOCTATE,,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,4523.00,08/20/2015,Cash or cash equivalent,302992514,PLEGRIDY,,Plegridy Observational Program,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,2153.00,10/08/2015,Cash or cash equivalent,302992522,TYSABRI,,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,260.00,02/23/2015,Cash or cash equivalent,302992530,TYSABRI,,JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4012.75,05/26/2015,Cash or cash equivalent,319454540,GAZYVA,,PH II FL DLBCL SINGLE ARM G CHOP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,310.00,11/03/2015,Cash or cash equivalent,319449689,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6303.00,02/25/2015,Cash or cash equivalent,319455198,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,7139.70,03/24/2015,Cash or cash equivalent,319455220,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2746.00,03/27/2015,Cash or cash equivalent,319455244,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4222.80,07/08/2015,Cash or cash equivalent,319455266,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1098.13,06/09/2015,Cash or cash equivalent,319413078,NonCovered Product,,METMAB PHIII NSCLC,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,870.50,07/10/2015,Cash or cash equivalent,319413887,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,11000.00,02/02/2015,Cash or cash equivalent,319433642,Esbriet,Esbriet,EAP PIPF 031,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,61301.25,11/17/2015,Cash or cash equivalent,319376702,NonCovered Product,,A PHASE III MULTICENTER RANDOMIZED DOUBLE MASKED,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,15146.00,05/13/2015,Cash or cash equivalent,319344043,NonCovered Product,,AM1PRIME PHASE II B,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2955.60,12/16/2015,Cash or cash equivalent,319367314,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1417.00,02/04/2015,Cash or cash equivalent,319335792,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2566.51,12/18/2015,Cash or cash equivalent,319372588,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,9524.24,12/23/2015,Cash or cash equivalent,319377796,NonCovered Product,,ATOPIC DERMATITIS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,30757.76,02/11/2015,Cash or cash equivalent,335016810,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1600.34,01/29/2015,Cash or cash equivalent,319378352,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,2707,MERCY MEDICAL CENTER - NORTH,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1886.65,11/13/2015,Cash or cash equivalent,333595648,Herceptin,,SYSTHERS REGISTRY,,
Covered Recipient Teaching Hospital,2707,MERCY MEDICAL CENTER - NORTH,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,628.88,01/29/2015,Cash or cash equivalent,333595772,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,2707,MERCY MEDICAL CENTER - NORTH,,,,,1000 4TH ST SW,SUITE IOPT,MASON CITY,50401,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3337.90,05/01/2015,Cash or cash equivalent,333595774,Herceptin,,HER2 REGISTRY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1960.00,12/21/2015,Cash or cash equivalent,319374928,Herceptin,Perjeta,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,590.00,11/06/2015,Cash or cash equivalent,319510416,Herceptin,Perjeta,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2500.00,12/11/2015,Cash or cash equivalent,319530708,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,29700.00,01/21/2015,Cash or cash equivalent,319480914,Avastin,,Phase I II Trial Targeting Angiogenesis Using Bevacizumab,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,14850.00,01/22/2015,Cash or cash equivalent,319480933,NonCovered Product,,Using Decitabine for Epigenetic Inhibition,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1250.00,06/26/2015,Cash or cash equivalent,319480950,NonCovered Product,,Using Decitabine for Epigenetic Inhibition,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,14850.00,09/18/2015,Cash or cash equivalent,319493949,NonCovered Product,,Using Decitabine for Epigenetic Inhibition,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3231.25,08/21/2015,Cash or cash equivalent,319511342,Esbriet,Esbriet,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2031.26,12/16/2015,Cash or cash equivalent,319481660,NonCovered Product,,ATOPIC DERMATITIS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,8750.00,10/01/2015,Cash or cash equivalent,319504390,NonCovered Product,,ATOPIC DERMATITIS,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,19440.00,02/19/2015,Cash or cash equivalent,319507804,NonCovered Product,,A PHASE III MULTICENTER RANDOMIZED DOUBLE MASKED,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,24985.00,05/15/2015,Cash or cash equivalent,319507825,NonCovered Product,,A PHASE III MULTICENTER RANDOMIZED DOUBLE MASKED,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,9708.00,06/22/2015,Cash or cash equivalent,319507844,NonCovered Product,,A PHASE III MULTICENTER RANDOMIZED DOUBLE MASKED,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6713.10,09/25/2015,Cash or cash equivalent,319496026,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Non-covered Recipient Entity,,,,,,,309 E CHURCH ST,,MARSHALLTOWN,50158,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,31808.75,08/19/2015,Cash or cash equivalent,319513448,NonCovered Product,,A PHASE III MULTICENTER RANDOMIZED DOUBLE MASKED,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,943.33,11/13/2015,Cash or cash equivalent,319529191,Herceptin,,SYSTHERS REGISTRY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,628.88,11/20/2015,Cash or cash equivalent,319529269,Herceptin,,SYSTHERS REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4567.50,11/02/2015,Cash or cash equivalent,319510151,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,908.50,09/18/2015,Cash or cash equivalent,335016112,KALYDECO,,A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VX661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS HETEROZYGOUS FOR THE F508DELCFTR MUTATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,40546.00,01/01/2015,Cash or cash equivalent,335015516,KALYDECO,,A PHASE 3 ROLLOVER STUDY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS 12 YEARS AND OLDER WITH CYSTIC FIBROSIS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,13628.12,06/01/2015,Cash or cash equivalent,335016198,KALYDECO,,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IVACAFTOR AND VX661 IN COMBINATION WITH IVACAFTOR IN SUBJECTS AGED 12 YEARS AND OLDER WITH CYSTIC FIBROSIS HETEROZYGOUS FOR THE F508DELCFTR MUTATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,4180.20,04/24/2015,Cash or cash equivalent,335014766,,,STUDY OF VX809 ALONE AND IN COMBINATION WITH VX770 IN CYSTIC FIBROSIS CF PATIENTS HOMOZYGOUS OR HETEROZYGOUS FOR THE F508DELCFTR MUTATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,VERTEX PHARMACEUTICALS INCORPORATED,100000000184,VERTEX PHARMACEUTICALS INCORPORATED,MA,4871.42,07/07/2015,Cash or cash equivalent,335016612,KALYDECO,,A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN SUBJECTS WITH CF HOMOZYGOUS FOR THE F508DELCFTR MUTATION,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2364.00,08/25/2015,Cash or cash equivalent,319756592,Esbriet,Esbriet,EAP PIPF 031,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1901.70,04/15/2015,Cash or cash equivalent,319735050,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1080.50,05/26/2015,Cash or cash equivalent,319735074,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3000.00,06/18/2015,Cash or cash equivalent,319735098,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,6394.50,08/13/2015,Cash or cash equivalent,319735107,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4520.00,03/26/2015,Cash or cash equivalent,319712486,Esbriet,Esbriet,EAP PIPF 031,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,850.00,05/21/2015,Cash or cash equivalent,319712505,Esbriet,Esbriet,EAP PIPF 031,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5540.00,02/04/2015,Cash or cash equivalent,319701483,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,208.82,02/04/2015,Cash or cash equivalent,319701498,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1080.50,09/23/2015,Cash or cash equivalent,319720403,Herceptin,Perjeta,TDM1 EXTENSION STUDY IN MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3931.25,01/21/2015,Cash or cash equivalent,319710623,Herceptin,Perjeta,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1911.00,01/26/2015,Cash or cash equivalent,319710643,Herceptin,Perjeta,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1820.00,02/13/2015,Cash or cash equivalent,319710660,Herceptin,Perjeta,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,176.00,02/24/2015,Cash or cash equivalent,319710674,Herceptin,Perjeta,PERTUZUMAB HERCEPTIN IN HER2 MBC 1ST LINE,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,12297.70,11/11/2015,Cash or cash equivalent,319730482,Esbriet,Esbriet,IPF PHASE II STUDY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1531.00,01/05/2015,Cash or cash equivalent,319721532,Esbriet,Esbriet,RECAP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,4312.00,03/16/2015,Cash or cash equivalent,319721562,Esbriet,Esbriet,RECAP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1531.00,04/22/2015,Cash or cash equivalent,319721582,Esbriet,Esbriet,RECAP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3062.00,06/29/2015,Cash or cash equivalent,319721604,Esbriet,Esbriet,RECAP,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,07/10/2015,Cash or cash equivalent,319741776,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,07/10/2015,Cash or cash equivalent,319741792,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,532.00,04/20/2015,Cash or cash equivalent,319715320,Herceptin,Perjeta,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,140.00,07/23/2015,Cash or cash equivalent,319715333,Herceptin,Perjeta,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,2192.63,01/29/2015,Cash or cash equivalent,319642392,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,999.58,05/01/2015,Cash or cash equivalent,319642421,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1438.88,07/09/2015,Cash or cash equivalent,319654314,Herceptin,,SYSTHERS REGISTRY,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5503.00,10/02/2015,Cash or cash equivalent,319674446,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1960.00,10/27/2015,Cash or cash equivalent,319795879,Herceptin,Perjeta,CHEMO TRASTUZUMAB VS CHEMO TRASTUZUMAB PERTUZUMAB,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,28.13,07/09/2015,Cash or cash equivalent,319767108,Herceptin,,SYSTHERS REGISTRY,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1384.00,07/01/2015,Cash or cash equivalent,319776848,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,310.00,08/03/2015,Cash or cash equivalent,319776866,GAZYVA,,GNE PHASE III RTX REF INHL B VS BG,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3500.00,08/27/2015,Cash or cash equivalent,319556935,NonCovered Product,,PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,1257.77,05/01/2015,Cash or cash equivalent,319599852,Herceptin,,HER2 REGISTRY,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,,CLIVE,50325,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,250.00,10/29/2015,Cash or cash equivalent,319590638,NonCovered Product,,OPEN LABEL MAINTENANCE TRIAL GLOBAL,,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,,CLIVE,50325,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,3000.00,10/09/2015,Cash or cash equivalent,319590666,NonCovered Product,,OPEN LABEL MAINTENANCE TRIAL GLOBAL,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,5750.00,05/08/2015,Cash or cash equivalent,319600379,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,1351 KIMBERLY RD,,BETTENDORF,52722,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,966.00,05/08/2015,Cash or cash equivalent,319600392,Herceptin,,RANDOMIZED PHASE III IN 2ND LINE MBC PATIENTS,,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,543.00,12/31/2015,Cash or cash equivalent,248064544,,,Open Hart (ARC16C015),,
Non-covered Recipient Entity,,,,,,,2 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,620.00,12/31/2015,Cash or cash equivalent,248064630,,,Open Hart (ARC16C015),,
Non-covered Recipient Entity,,,,,,,201 Gilmore Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1643.00,11/01/2015,Cash or cash equivalent,248102240,,,Open Hart (ARC16C015),,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1982.00,09/22/2015,Cash or cash equivalent,248097630,,,MS-LAQ-301E,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1875.00,07/31/2015,Cash or cash equivalent,248094972,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2000.00,04/01/2015,Cash or cash equivalent,248092320,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2177.00,06/12/2015,Cash or cash equivalent,248092324,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,1875.00,01/09/2015,Cash or cash equivalent,248091398,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,10750.00,01/09/2015,Cash or cash equivalent,248091402,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,1111 6th Avenue,,Des Moines,50314,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,2731.00,03/19/2015,Cash or cash equivalent,248097424,,,MS-LAQ-301E,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,06/01/2015,Cash or cash equivalent,318649902,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,06/19/2015,Cash or cash equivalent,318683844,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"BioStructures, LLC",100000136421,"BioStructures, LLC",CA,23834.80,10/07/2015,Cash or cash equivalent,335171860,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,04/14/2015,Cash or cash equivalent,318656654,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,04/14/2015,Cash or cash equivalent,318656678,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,04/14/2015,Cash or cash equivalent,318656708,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,06/19/2015,Cash or cash equivalent,318684835,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,06/01/2015,Cash or cash equivalent,318650846,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,06/01/2015,Cash or cash equivalent,318650850,,,,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,937.50,07/31/2015,Cash or cash equivalent,248094968,PROAIR,,ABS-AS-303,,
Non-covered Recipient Entity,,,,,,,B5 Jessup Hall,,Iowa City,52242,,,"Teva Pharmaceuticals USA, Inc.",100000000141,"Teva Pharmaceuticals USA, Inc.",PA,240.00,06/12/2015,Cash or cash equivalent,248092316,PROAIR,,ABS-AS-303,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,01/26/2015,Cash or cash equivalent,318617441,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,01/26/2015,Cash or cash equivalent,318617467,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712354,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712378,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712401,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712421,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712440,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712460,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712488,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712513,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712538,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712561,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318712588,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,260.00,07/17/2015,Cash or cash equivalent,318712656,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,07/17/2015,Cash or cash equivalent,318712679,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,07/17/2015,Cash or cash equivalent,318712692,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,07/17/2015,Cash or cash equivalent,318712720,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,07/17/2015,Cash or cash equivalent,318712742,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,07/17/2015,Cash or cash equivalent,318712760,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,07/17/2015,Cash or cash equivalent,318712788,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,07/17/2015,Cash or cash equivalent,318712823,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,07/17/2015,Cash or cash equivalent,318712847,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,07/17/2015,Cash or cash equivalent,318712874,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,07/17/2015,Cash or cash equivalent,318712899,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,07/17/2015,Cash or cash equivalent,318712922,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713539,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713576,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713608,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713634,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713651,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713667,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713690,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713713,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318713734,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318714916,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318714948,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318714968,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318714998,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,02/19/2015,Cash or cash equivalent,318697870,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,02/19/2015,Cash or cash equivalent,318697897,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,02/19/2015,Cash or cash equivalent,318697923,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715838,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715866,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715890,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715915,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715946,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715957,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318715995,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318716016,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318716038,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318716061,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318716086,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,3750.00,07/29/2015,Cash or cash equivalent,318635845,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,19175.00,07/29/2015,Cash or cash equivalent,318642490,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,19030.00,08/24/2015,Cash or cash equivalent,318642517,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,13300.00,09/30/2015,Cash or cash equivalent,318642534,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,36776.58,10/13/2015,Cash or cash equivalent,318649289,,,SENIOR Eff Elderly T2DM study,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,9155.00,08/24/2015,Cash or cash equivalent,318636114,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,10245.00,09/30/2015,Cash or cash equivalent,318636136,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,300.00,07/29/2015,Cash or cash equivalent,318642844,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,300.00,08/24/2015,Cash or cash equivalent,318642868,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,700.00,09/30/2015,Cash or cash equivalent,318642889,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,2724.00,11/10/2015,Cash or cash equivalent,318649806,,,CAMMS Extension study US CSU,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,40000.00,11/03/2015,Cash or cash equivalent,318646652,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,28634.00,11/03/2015,Cash or cash equivalent,318646672,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,4600.00,07/29/2015,Cash or cash equivalent,318647456,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,3475.00,08/24/2015,Cash or cash equivalent,318647485,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,7205.00,09/30/2015,Cash or cash equivalent,318647512,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,24763.00,10/13/2015,Cash or cash equivalent,318648930,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,41941.83,10/13/2015,Cash or cash equivalent,318649268,,,SENIOR Eff Elderly T2DM study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826623,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826656,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826672,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826702,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826740,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826757,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,09/22/2015,Cash or cash equivalent,318797893,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,1080.00,09/22/2015,Cash or cash equivalent,318797910,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,09/22/2015,Cash or cash equivalent,318797923,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826774,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318826798,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,09/22/2015,Cash or cash equivalent,318797926,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318842936,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318842961,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824572,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824591,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824614,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824634,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824659,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824692,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824715,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824736,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824759,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824783,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,5.00,11/05/2015,Cash or cash equivalent,318824802,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,10/20/2015,Cash or cash equivalent,318834173,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,13660.00,10/21/2015,Cash or cash equivalent,318892649,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,11855.00,11/25/2015,Cash or cash equivalent,318892664,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,5850.00,12/23/2015,Cash or cash equivalent,318892687,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000010771,SANOFI PASTEUR BIOLOGICS LLC,MA,576.32,08/03/2015,In-kind items and services,318836842,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,700.00,10/21/2015,Cash or cash equivalent,318883551,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,300.00,11/25/2015,Cash or cash equivalent,318883588,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,300.00,12/23/2015,Cash or cash equivalent,318883613,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,1215 Duff Avenue,,Ames,50010,,,"ARIAD Pharmaceuticals, Inc.",100000010550,"ARIAD Pharmaceuticals, Inc.",MA,3000.00,12/30/2015,Cash or cash equivalent,335271478,Iclusig,,OMNI,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,2130.00,12/23/2015,Cash or cash equivalent,318905468,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Physician,,,35175,JEFFERY,L,MEIER,200 HAWKINS DR,,IOWA CITY,52242-1009,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,Sanofi Pasteur Inc.,100000010771,SANOFI PASTEUR BIOLOGICS LLC,MA,576.32,03/20/2015,In-kind items and services,318709476,,,H-030-014: Phase III Primary Prevention:H-030-014,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,4830.00,10/21/2015,Cash or cash equivalent,318882006,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,8365.00,11/25/2015,Cash or cash equivalent,318882037,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,5960.00,12/23/2015,Cash or cash equivalent,318882064,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,1575.00,10/21/2015,Cash or cash equivalent,318891169,PRALUENT,,ODYSSEY OUTCOMES,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000076,SANOFI-AVENTIS U.S. LLC,NJ,8275.00,11/25/2015,Cash or cash equivalent,318891195,PRALUENT,,ODYSSEY OUTCOMES,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,180.00,11/24/2015,Cash or cash equivalent,318752444,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,08/27/2015,Cash or cash equivalent,318773341,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,08/27/2015,Cash or cash equivalent,318773360,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,08/27/2015,Cash or cash equivalent,318773384,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,720.00,08/27/2015,Cash or cash equivalent,318773404,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,900.00,08/27/2015,Cash or cash equivalent,318773434,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi Pasteur Inc.,100000000299,Sanofi Pasteur Inc.,PA,260.00,12/15/2015,Cash or cash equivalent,318771204,,,H 030 014  Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1600.00,03/24/2015,Cash or cash equivalent,318437038,,,Eff-SC-Combo Lixi/U100 vs Lixi vs Lantus-on top of metformin,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1180.00,03/24/2015,Cash or cash equivalent,318437042,,,Eff-SC-Combo Lixi/U100 vs Lixi vs Lantus-on top of metformin,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,28281.25,09/08/2015,Cash or cash equivalent,318591938,,,Q2 2015 Gaucher LSD Registry total INV $39406.25,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,11125.00,09/08/2015,Cash or cash equivalent,318591946,,,Q2 2015 Fabry LSD Registry total INV $39406.25,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2446.00,02/03/2015,Cash or cash equivalent,318434820,,,CAMMS Extension study US CSU,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,180.00,01/26/2015,Cash or cash equivalent,318432648,,,Eff-Humalog vs Lispro-T1DM pts,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,3562.50,12/08/2015,Cash or cash equivalent,318842464,,,Q3 2015 Gaucher LSD Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,20468.75,12/08/2015,Cash or cash equivalent,318842468,,,Q32015 Fabry LSD Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,5312.50,06/23/2015,Cash or cash equivalent,318527918,,,Q1 2015 Gaucher LSD Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,58593.75,06/23/2015,Cash or cash equivalent,318527926,,,Q1 2015 Fabry LSD Registry,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12514.00,02/10/2015,Cash or cash equivalent,318435234,,,Eff-SC-Combo Lixi/U100 vs Lixi vs Lantus-on top of metformin,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5993.00,03/17/2015,Cash or cash equivalent,318436432,,,Eff-SC-Efficacy/safety in Elderly - Lyxumia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,3375.00,03/10/2015,Cash or cash equivalent,318450482,,,Q4 2014 Gaucher LSD Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,6968.75,03/10/2015,Cash or cash equivalent,318450492,,,Q4 2014 Fabry LSD Registry,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,600.00,09/29/2015,Cash or cash equivalent,318609450,RENVELA,,An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9.60,03/26/2015,In-kind items and services,318485136,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,62.70,03/26/2015,In-kind items and services,318485154,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,150.50,03/26/2015,In-kind items and services,318485170,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,02/19/2015,In-kind items and services,318476536,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,50.16,01/23/2015,In-kind items and services,318463362,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.30,03/26/2015,In-kind items and services,318482956,,,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,34.45,01/23/2015,In-kind items and services,318463378,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.32,01/23/2015,In-kind items and services,318466608,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.54,02/19/2015,In-kind items and services,318469786,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,107.50,02/19/2015,In-kind items and services,318469795,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,02/19/2015,In-kind items and services,318469802,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,112.86,03/26/2015,In-kind items and services,318476854,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.50,03/26/2015,In-kind items and services,318476862,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,157.28,03/26/2015,In-kind items and services,318476872,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,103.10,03/26/2015,In-kind items and services,318476887,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.32,03/26/2015,In-kind items and services,318476906,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,175.56,01/23/2015,In-kind items and services,318463736,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,172.00,01/23/2015,In-kind items and services,318463748,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,550.48,01/23/2015,In-kind items and services,318463756,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.62,02/19/2015,In-kind items and services,318474092,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,103.10,03/26/2015,In-kind items and services,318476914,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,109.25,02/19/2015,In-kind items and services,318469910,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,63.75,01/23/2015,In-kind items and services,318463912,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,262.20,01/23/2015,In-kind items and services,318463917,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,157.28,02/19/2015,In-kind items and services,318471514,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE/RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.40,02/19/2015,In-kind items and services,318473136,,,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE/RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,0.60,02/19/2015,In-kind items and services,318473146,,,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE/RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.50,02/19/2015,In-kind items and services,318473158,,,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE/RSCH,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.90,02/19/2015,In-kind items and services,318473168,,,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,75.24,02/19/2015,In-kind items and services,318474498,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,86.00,02/19/2015,In-kind items and services,318474505,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,1015 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.54,03/26/2015,In-kind items and services,318481886,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,50.16,01/23/2015,In-kind items and services,318465962,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,43.00,01/23/2015,In-kind items and services,318465978,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,112.86,03/26/2015,In-kind items and services,318479038,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,43.00,03/26/2015,In-kind items and services,318479050,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,03/26/2015,In-kind items and services,318479060,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.55,03/26/2015,In-kind items and services,318479074,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,34.45,03/26/2015,In-kind items and services,318479084,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,113.50,03/26/2015,In-kind items and services,318482357,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,504.00,01/28/2015,Cash or cash equivalent,318441066,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1775.00,03/24/2015,Cash or cash equivalent,318437828,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3400.00,01/12/2015,Cash or cash equivalent,318441116,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,16091.00,05/19/2015,Cash or cash equivalent,318450994,,,Eliglustat ENCORE GZGD02607,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2250.00,04/21/2015,Cash or cash equivalent,318452970,,,Eff-SC-Efficacy/safety in Elderly - Lyxumia,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14193.00,05/19/2015,Cash or cash equivalent,318460270,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,390.00,01/12/2015,Cash or cash equivalent,318441158,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1500.00,05/12/2015,Cash or cash equivalent,318451752,,,Eff-SC-Efficacy/safety in Elderly - Lyxumia,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,800.00,04/14/2015,Cash or cash equivalent,318453634,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2307.00,02/05/2015,Cash or cash equivalent,318437324,,,"Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1508.00,05/19/2015,Cash or cash equivalent,318451958,,,Diabetes Lixisenatide LYXUMIA,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1400.00,03/12/2015,Cash or cash equivalent,318449962,RENVELA,,An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease,,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE STE 101,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5621.00,05/05/2015,Cash or cash equivalent,318452230,,,Eff-SC-Combo LixiLan U100 vs Lixi vs Lantus-on top of metfor,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7390.00,04/21/2015,Cash or cash equivalent,318454134,,,CAMMS Extension study US CSU,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4200.00,05/05/2015,Cash or cash equivalent,318452460,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,59152.00,03/24/2015,Cash or cash equivalent,318437700,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2250.00,05/05/2015,Cash or cash equivalent,318452470,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2125.00,05/05/2015,Cash or cash equivalent,318452480,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2700.00,04/21/2015,Cash or cash equivalent,318454546,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11206.41,06/23/2015,Cash or cash equivalent,318518205,,,SENIOR Eff Elderly T2DM study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3300.00,01/16/2015,Cash or cash equivalent,318512336,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4000.00,02/25/2015,Cash or cash equivalent,318512342,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5000.00,03/18/2015,Cash or cash equivalent,318512344,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,967.50,05/21/2015,Cash or cash equivalent,318525618,,,"Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia",,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1155.00,07/09/2015,Cash or cash equivalent,318532001,RENVELA,,"A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,26589.00,07/07/2015,Cash or cash equivalent,318525956,,,Eff-Humalog vs Lispro-T2DM pts,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9935.00,01/16/2015,Cash or cash equivalent,318505630,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3605.00,01/16/2015,Cash or cash equivalent,318523746,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7600.00,02/25/2015,Cash or cash equivalent,318523760,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,20325.00,02/25/2015,Cash or cash equivalent,318505645,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,20480.00,03/18/2015,Cash or cash equivalent,318505664,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11030.00,03/18/2015,Cash or cash equivalent,318523772,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17117.00,06/09/2015,Cash or cash equivalent,318514098,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1830.00,01/16/2015,Cash or cash equivalent,318506522,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,830.00,02/25/2015,Cash or cash equivalent,318506546,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,600.00,03/18/2015,Cash or cash equivalent,318506561,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4603.12,06/22/2015,In-kind items and services,318678310,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5473.52,06/10/2015,In-kind items and services,318692339,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3480.91,06/23/2015,In-kind items and services,318679260,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8563.93,06/23/2015,In-kind items and services,318679284,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,661.42,06/11/2015,In-kind items and services,318689290,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,83.65,10/27/2015,In-kind items and services,318717763,PRALUENT,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.25,06/12/2015,In-kind items and services,318689466,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1854.25,06/04/2015,In-kind items and services,318692871,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,26.25,06/23/2015,In-kind items and services,318679653,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,386.49,06/29/2015,In-kind items and services,318683146,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,336.00,06/12/2015,In-kind items and services,318690297,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1110.00,06/12/2015,In-kind items and services,318690316,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,107.00,12/28/2015,In-kind items and services,318669745,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.90,06/16/2015,In-kind items and services,318677150,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,115.50,06/16/2015,In-kind items and services,318677175,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.24,06/29/2015,In-kind items and services,318683995,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,245.62,06/29/2015,In-kind items and services,318684027,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,98.40,06/29/2015,In-kind items and services,318684055,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,24.40,06/29/2015,In-kind items and services,318684079,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.64,11/23/2015,In-kind items and services,318709552,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.74,06/16/2015,In-kind items and services,318677207,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,92.50,06/16/2015,In-kind items and services,318677230,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,550.50,06/16/2015,In-kind items and services,318677251,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1024.62,06/17/2015,In-kind items and services,318677562,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,177.70,06/29/2015,In-kind items and services,318684608,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,352.90,06/29/2015,In-kind items and services,318684624,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.45,11/23/2015,In-kind items and services,318670630,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,325.50,10/27/2015,In-kind items and services,318713716,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.00,08/31/2015,In-kind items and services,318622165,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,115.50,04/28/2015,Cash or cash equivalent,318620037,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,154.27,08/05/2015,In-kind items and services,318624915,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.54,02/10/2015,In-kind items and services,318630636,,,"Sixmonth, Randomized, Openlabel, Parallelgroup Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,234.21,04/27/2015,Cash or cash equivalent,318620086,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog? in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,150.40,05/05/2015,Cash or cash equivalent,318620186,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.00,07/16/2015,In-kind items and services,318627877,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,33.97,02/24/2015,In-kind items and services,318630790,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,56.75,09/25/2015,In-kind items and services,318615128,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,271.27,02/05/2015,In-kind items and services,318628006,,,"Sixmonth, Randomized, Openlabel, Parallelgroup Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,122.87,06/16/2015,Cash or cash equivalent,318622868,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,42.60,06/15/2015,Cash or cash equivalent,318622910,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,198.00,06/15/2015,Cash or cash equivalent,318622928,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog? in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,270.22,03/25/2015,In-kind items and services,318631080,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,150.00,09/08/2015,Cash or cash equivalent,318601366,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,36.00,05/08/2015,Cash or cash equivalent,318620542,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog? in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,89.20,05/19/2015,Cash or cash equivalent,318620694,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog? in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,40.06,07/08/2015,In-kind items and services,318645907,,,"OpenLabel Extension Study of EFC12492, R727CL1112, EFC12732 and LTS11717 Studies to Assess the LongTerm Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,31.69,08/12/2015,In-kind items and services,318626101,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,67.80,07/29/2015,In-kind items and services,318623662,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,270.22,02/26/2015,In-kind items and services,318619280,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,315.00,07/08/2015,In-kind items and services,318626452,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.32,07/09/2015,In-kind items and services,318626460,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.10,08/07/2015,In-kind items and services,318646513,,,"OpenLabel Extension Study of EFC12492, R727CL1112, EFC12732 and LTS11717 Studies to Assess the LongTerm Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11254.79,06/15/2015,In-kind items and services,318594711,LANTUS,,Epidemiology of Diabetes Interventions and Complications,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2125.00,09/08/2015,Cash or cash equivalent,318602568,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2480.00,09/08/2015,Cash or cash equivalent,318602585,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,29.10,07/11/2015,In-kind items and services,318626552,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,108.26,06/04/2015,Cash or cash equivalent,318621626,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,39.05,08/18/2015,In-kind items and services,318626720,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1071.00,08/13/2015,Cash or cash equivalent,318644068,,,"OpenLabel Extension Study of EFC12492, R727CL1112, EFC12732 and LTS11717 Studies to Assess the LongTerm Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1200.00,09/22/2015,Cash or cash equivalent,318591336,,,Eff - Lixi vs rapid-acting insulin on top of lantus,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,705.00,09/08/2015,Cash or cash equivalent,318603180,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,427.00,09/08/2015,Cash or cash equivalent,318603202,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1560.00,09/22/2015,Cash or cash equivalent,318591537,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,248.43,01/12/2015,In-kind items and services,318614185,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.00,08/04/2015,In-kind items and services,318624410,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.47,02/27/2015,In-kind items and services,318756278,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,686.86,04/27/2015,In-kind items and services,318734064,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17.34,03/04/2015,In-kind items and services,318756599,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,72.30,03/04/2015,In-kind items and services,318756626,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR #C34-10,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1085.90,07/24/2015,In-kind items and services,318720924,,,QUEST,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.50,11/23/2015,In-kind items and services,318724302,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5210.00,12/08/2015,Cash or cash equivalent,318734474,PRALUENT,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholeste",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,336.01,02/27/2015,In-kind items and services,318757091,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,562.50,03/18/2015,In-kind items and services,318746811,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,145.52,02/27/2015,In-kind items and services,318757107,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,242.57,02/27/2015,In-kind items and services,318757144,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2949,BROADLAWNS MEDICAL CENTER,,,,,1801 HICKMAN ROAD,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2340.00,09/28/2015,Cash or cash equivalent,318728130,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Covered Recipient Teaching Hospital,2949,BROADLAWNS MEDICAL CENTER,,,,,1801 HICKMAN ROAD,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5000.00,08/04/2015,Cash or cash equivalent,318740582,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,141.44,10/27/2015,In-kind items and services,318718514,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,321.82,11/23/2015,In-kind items and services,318725597,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1740.00,10/13/2015,Cash or cash equivalent,318728852,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6200.00,07/21/2015,Cash or cash equivalent,318741067,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5220.00,12/08/2015,Cash or cash equivalent,318735883,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1345.97,03/12/2015,In-kind items and services,318748116,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1108.73,03/12/2015,In-kind items and services,318748648,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2949,BROADLAWNS MEDICAL CENTER,,,,,1801 HICKMAN ROAD,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2880.00,12/08/2015,Cash or cash equivalent,318733810,LANTUS,TOUJEO,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5.60,02/27/2015,In-kind items and services,318756141,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.17,02/27/2015,In-kind items and services,318756161,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,118.31,02/27/2015,In-kind items and services,318756198,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9.16,02/27/2015,In-kind items and services,318756221,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,98.91,02/27/2015,In-kind items and services,318756241,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,68.95,01/28/2015,In-kind items and services,318584730,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,PO BOX 65433,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4926.00,07/28/2015,Cash or cash equivalent,318541659,,,CAMMS Extension study US CSU,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3950.00,06/02/2015,Cash or cash equivalent,318561286,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1500.00,06/02/2015,Cash or cash equivalent,318561305,,,Eff-Humalog vs Lispro-T2DM pts,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37252.85,08/11/2015,Cash or cash equivalent,318575160,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,27518.00,08/04/2015,Cash or cash equivalent,318582172,,,Eff-Humalog vs Lispro-T1DM pts,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,700 EAST UNIVERSITY,,DES MOINES,50316,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,15000.00,04/09/2015,Cash or cash equivalent,318571938,CLOLAR,,"A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lympoblastic Leukemia ALL Testing Clofarabine IND 73789, NSC  606869 in the Very High Risk Stratum",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,23.64,01/28/2015,In-kind items and services,318570356,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,300.00,04/27/2015,Cash or cash equivalent,318567342,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,700.00,06/01/2015,Cash or cash equivalent,318567360,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2200.00,06/29/2015,Cash or cash equivalent,318567382,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 321,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5895.00,06/22/2015,Cash or cash equivalent,318550960,,,Ph II SAR236553 study in hypercholesterolemic pts,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,72.89,01/28/2015,In-kind items and services,318584277,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9850.00,04/27/2015,Cash or cash equivalent,318564275,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5075.00,06/01/2015,Cash or cash equivalent,318564292,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1000.00,06/29/2015,Cash or cash equivalent,318564310,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11450.00,04/27/2015,Cash or cash equivalent,318567858,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,19.70,01/28/2015,In-kind items and services,318570890,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,16405.00,04/27/2015,Cash or cash equivalent,318557474,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17635.00,04/27/2015,Cash or cash equivalent,318557490,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,18450.00,06/29/2015,Cash or cash equivalent,318557510,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9555.00,06/01/2015,Cash or cash equivalent,318567884,,,Odyssey Outcomes,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8340.00,06/29/2015,Cash or cash equivalent,318567914,,,Odyssey Outcomes,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,32085.00,12/15/2015,Cash or cash equivalent,318919253,,,Eff-Humalog vs Lispro-T2DM pts,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,122.71,12/01/2015,In-kind items and services,318913162,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,75.52,12/01/2015,In-kind items and services,318913181,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,292.51,06/25/2015,In-kind items and services,318915130,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,48.00,11/10/2015,In-kind items and services,318915479,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,32.00,11/10/2015,In-kind items and services,318915501,,,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog? in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,36226.59,12/15/2015,Cash or cash equivalent,318919022,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,33989.77,12/15/2015,Cash or cash equivalent,318919036,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.50,12/28/2015,In-kind items and services,318849078,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,897.31,02/23/2015,In-kind items and services,318869178,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,60.67,10/06/2015,In-kind items and services,318836119,,,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.73,02/05/2015,In-kind items and services,318876998,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.93,02/05/2015,In-kind items and services,318877031,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,28.92,02/05/2015,In-kind items and services,318877052,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10.50,02/05/2015,In-kind items and services,318877080,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,2055 KIMBALL AVE,,WATERLOO,50702,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,77.30,02/05/2015,In-kind items and services,318877100,,,"A Randomized, Openlabel, 2arm Parallelgroup, Multicenter, 26week Study Assessing the Safety and Efficacy of H0E901U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on A",,
Non-covered Recipient Entity,,,,,,,1243 8TH ST,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,19.99,02/20/2015,In-kind items and services,318873540,,,A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,,
Non-covered Recipient Entity,,,,,,,1243 8TH ST,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,15.44,02/20/2015,In-kind items and services,318873576,,,A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,,
Non-covered Recipient Entity,,,,,,,1243 8TH ST,,WEST DES MOINES,50265,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,146.85,02/20/2015,In-kind items and services,318873594,,,A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3601.57,02/17/2015,In-kind items and services,318866373,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5709.29,02/17/2015,In-kind items and services,318866386,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8.73,02/19/2015,In-kind items and services,318869940,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6.93,02/19/2015,In-kind items and services,318869968,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,28.92,02/19/2015,In-kind items and services,318869984,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10.50,02/19/2015,In-kind items and services,318870005,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,77.30,02/19/2015,In-kind items and services,318870024,,,Eff Elderly T2DM study - SC,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,351.84,04/27/2015,In-kind items and services,318901528,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,592.87,12/17/2015,Cash or cash equivalent,318837096,,,"Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemi",,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,425.58,12/28/2015,In-kind items and services,318854550,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,52.49,02/23/2015,In-kind items and services,318874381,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,122.71,11/01/2015,In-kind items and services,318825457,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,75.52,11/01/2015,In-kind items and services,318825485,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,149.75,12/28/2015,In-kind items and services,318837626,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Covered Recipient Teaching Hospital,2815,TRINITY BETTENDORF,,,,,4500 UTICA RIDGE ROAD,,BETTENDORF,52722,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,203.24,05/26/2015,In-kind items and services,318902150,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,43.30,02/24/2015,In-kind items and services,318871048,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,555.00,02/24/2015,In-kind items and services,318871068,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,350.27,12/28/2015,In-kind items and services,318855518,PRALUENT,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,234.26,06/25/2015,In-kind items and services,318859836,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11254.79,01/20/2015,In-kind items and services,318827022,LANTUS,,Epidemiology of Diabetes Interventions and Complications,,
Non-covered Recipient Entity,,,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,87.95,12/28/2015,In-kind items and services,318852064,PRALUENT,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1449.00,11/06/2015,Cash or cash equivalent,318835510,,,"Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemi",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,937.96,02/23/2015,In-kind items and services,318868583,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8923.00,08/11/2015,Cash or cash equivalent,318999780,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,1415 WOODLAND AVE STE 218,,DES MOINES,50309,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,58.35,04/27/2015,In-kind items and services,318980677,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,2 GILMORE HALL,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,149.75,04/27/2015,In-kind items and services,318984601,,,Open Label Study of Long Term Safety Evaluation of Alirocumab,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,51.00,05/26/2015,In-kind items and services,318988981,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,178.45,04/27/2015,In-kind items and services,318981984,,,EFC-Randomized-Open-label-2 arm Parallel-group Comparison-T1,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25612.00,11/24/2015,Cash or cash equivalent,318994336,,,Eff-Humalog vs Lispro-T1DM pts,,
Non-covered Recipient Entity,,,,,,,1111 6TH AVE,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,92.40,04/27/2015,In-kind items and services,319004791,LEMTRADA,,Relapsing Forms of MS,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4000.00,06/02/2015,Cash or cash equivalent,318998973,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7500.00,11/24/2015,Cash or cash equivalent,318979506,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6583.00,06/23/2015,Cash or cash equivalent,318998995,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 240,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2500.00,11/24/2015,Cash or cash equivalent,318979672,,,SENIOR Eff Elderly T2DM study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4389.02,05/28/2015,In-kind items and services,318781710,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3196.25,05/28/2015,In-kind items and services,318781744,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,206.80,05/28/2015,In-kind items and services,318781763,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,79.80,03/31/2015,In-kind items and services,318805988,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3920.04,05/14/2015,In-kind items and services,318778627,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3743.90,05/14/2015,In-kind items and services,318778651,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,959.62,04/15/2015,In-kind items and services,318795900,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.68,04/09/2015,In-kind items and services,318799420,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,132.38,04/09/2015,In-kind items and services,318799446,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,53.88,04/07/2015,In-kind items and services,318792760,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,110.90,05/18/2015,In-kind items and services,318786256,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3316.91,04/16/2015,In-kind items and services,318796735,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,351.80,04/09/2015,In-kind items and services,318800006,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,24.37,04/09/2015,In-kind items and services,318800014,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,73.48,04/09/2015,In-kind items and services,318800026,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1004.90,04/09/2015,In-kind items and services,318800049,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,241.63,04/09/2015,In-kind items and services,318800068,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,636.98,04/09/2015,In-kind items and services,318800084,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,50.00,01/09/2015,In-kind items and services,318810556,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4218.25,04/16/2015,In-kind items and services,318796752,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,69.80,01/09/2015,In-kind items and services,318810578,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,333.50,01/09/2015,In-kind items and services,318810593,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2323.75,01/09/2015,In-kind items and services,318810618,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.75,01/09/2015,In-kind items and services,318810636,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.75,01/09/2015,In-kind items and services,318810658,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.75,01/09/2015,In-kind items and services,318810678,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,363.21,05/28/2015,In-kind items and services,318783324,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,206.80,05/20/2015,In-kind items and services,318779802,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1621.04,05/05/2015,In-kind items and services,318790376,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2889.93,01/15/2015,In-kind items and services,318818266,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5112.87,01/15/2015,In-kind items and services,318818286,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,83.14,05/06/2015,In-kind items and services,318787102,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,17.14,05/06/2015,In-kind items and services,318787127,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,37.94,05/06/2015,In-kind items and services,318787148,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,166.39,05/06/2015,In-kind items and services,318787166,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,232.09,05/06/2015,In-kind items and services,318787191,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,98.04,05/06/2015,In-kind items and services,318787220,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,68.55,04/06/2015,In-kind items and services,318807662,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,222.75,04/06/2015,In-kind items and services,318807676,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,14.46,01/12/2015,In-kind items and services,318814816,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.84,01/12/2015,In-kind items and services,318814835,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,132.60,01/12/2015,In-kind items and services,318814866,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,21.74,01/12/2015,In-kind items and services,318814888,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,374.49,01/12/2015,In-kind items and services,318814909,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3345.29,05/04/2015,In-kind items and services,318773460,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4619.55,05/04/2015,In-kind items and services,318773482,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1832.58,04/14/2015,In-kind items and services,318801198,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1751.29,04/14/2015,In-kind items and services,318801218,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4729.38,05/28/2015,In-kind items and services,318780692,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,8233.22,05/28/2015,In-kind items and services,318780712,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,10.01,05/06/2015,In-kind items and services,318773929,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.75,04/06/2015,In-kind items and services,318791785,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3.75,04/06/2015,In-kind items and services,318791802,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,97.00,05/14/2015,In-kind items and services,318777910,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,336.00,05/14/2015,In-kind items and services,318777936,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4069.14,01/05/2015,In-kind items and services,318808970,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2178.28,01/05/2015,In-kind items and services,318808988,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,120.00,12/04/2015,In-kind items and services,319141922,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,555.00,12/04/2015,In-kind items and services,319141942,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2949,BROADLAWNS MEDICAL CENTER,,,,,1801 HICKMAN ROAD,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,168.63,06/23/2015,In-kind items and services,319132859,,,"A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,810.52,11/30/2015,In-kind items and services,319142921,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,23.74,12/15/2015,In-kind items and services,319139204,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,190.74,12/15/2015,In-kind items and services,319139220,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,177.97,12/15/2015,In-kind items and services,319139242,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2342.27,10/29/2015,In-kind items and services,319077478,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2748.87,10/29/2015,In-kind items and services,319077494,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4028.56,09/22/2015,In-kind items and services,319086846,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,5112.87,09/22/2015,In-kind items and services,319086874,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7302.14,09/02/2015,In-kind items and services,319087121,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,9287.78,09/02/2015,In-kind items and services,319087150,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,118.95,10/06/2015,In-kind items and services,319074938,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,445.50,10/06/2015,In-kind items and services,319074956,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,302.19,10/30/2015,In-kind items and services,319078020,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,114.50,10/30/2015,In-kind items and services,319078030,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4836.33,08/27/2015,In-kind items and services,319084184,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,177.97,10/30/2015,In-kind items and services,319078061,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,27.17,10/30/2015,In-kind items and services,319078072,,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to, , Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with, , Type 1 or Type 2 Diabetes and With Hyperch",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,44.99,10/30/2015,In-kind items and services,319078082,,,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to, , Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with, , Type 1 or Type 2 Diabetes and With Hyperch",,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,117.00,11/17/2015,In-kind items and services,319081103,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,117.00,11/17/2015,In-kind items and services,319081128,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,12.84,09/09/2015,In-kind items and services,319084520,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,387.30,10/07/2015,In-kind items and services,319075506,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4985.43,10/08/2015,In-kind items and services,319075618,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1919.25,11/03/2015,In-kind items and services,319078796,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1556.04,11/16/2015,In-kind items and services,319079046,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2515.66,11/16/2015,In-kind items and services,319079073,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,959.62,10/26/2015,In-kind items and services,319082138,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4740.21,09/01/2015,In-kind items and services,319085188,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4367.35,09/01/2015,In-kind items and services,319085213,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,93.00,09/09/2015,In-kind items and services,319085250,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,374.49,09/09/2015,In-kind items and services,319085264,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,57.75,09/09/2015,In-kind items and services,319085276,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,348.94,09/09/2015,In-kind items and services,319085299,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,190.20,09/28/2015,In-kind items and services,319074079,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6690.58,09/28/2015,In-kind items and services,319074178,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1406.94,09/28/2015,In-kind items and services,319074215,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.08,04/27/2015,In-kind items and services,319184754,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3345.29,07/06/2015,In-kind items and services,319029153,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7159.81,07/23/2015,In-kind items and services,319021140,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7647.64,07/23/2015,In-kind items and services,319021156,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,3196.18,07/23/2015,In-kind items and services,319021290,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,97.00,08/06/2015,In-kind items and services,319023534,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,555.00,08/06/2015,In-kind items and services,319023542,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,7.68,07/01/2015,In-kind items and services,319030024,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2178.28,08/03/2015,In-kind items and services,319026974,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2578.10,08/03/2015,In-kind items and services,319026998,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,2450.66,07/30/2015,In-kind items and services,319024066,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1257.83,07/16/2015,In-kind items and services,319019352,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.59,08/07/2015,In-kind items and services,319024254,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.49,08/07/2015,In-kind items and services,319024269,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.05,08/07/2015,In-kind items and services,319024298,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,13.59,07/15/2015,In-kind items and services,319030562,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,29.99,07/15/2015,In-kind items and services,319030586,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,189.49,07/15/2015,In-kind items and services,319030601,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,176.72,07/15/2015,In-kind items and services,319030618,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,176.72,08/07/2015,In-kind items and services,319024311,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,11.25,07/01/2015,In-kind items and services,319030708,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,78.05,07/01/2015,In-kind items and services,319030734,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,72.94,07/01/2015,In-kind items and services,319030756,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,634.32,07/20/2015,In-kind items and services,319019773,,,Eff-Humalog vs Lispro-T1DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,5950 UNIVERSITY AVE STE 195,,WEST DES MOINES,50266,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1257.83,08/13/2015,In-kind items and services,319022246,,,Eff Elderly T2DM study - SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6305.84,07/09/2015,In-kind items and services,319031196,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Non-covered Recipient Entity,,,,,,,411 LAUREL ST STE 3262,,DES MOINES,50314,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,6902.12,07/09/2015,In-kind items and services,319031202,,,Eff-Humalog vs Lispro-T2DM pts using Insulin Glargine-SC,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Varian Medical Systems, Inc.",100000010850,"Varian Medical Systems, Inc.",CA,57865.00,04/06/2015,Cash or cash equivalent,317502090,,,A Portable Real-time HDR Applicator Monitoring System for Intracavitary Brachtherapy,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,4TH FL,CEDAR RAPIDS,52401,,,Stryker Corporation,100000010503,Stryker Corporation,MI,6030.00,05/01/2015,Cash or cash equivalent,333942744,,,Triathlon Cruciate Retaining (CR) Total Knee System Outcomes Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,Iowa City,52242,,,Stryker Corporation,100000010503,Stryker Corporation,MI,4750.00,10/08/2015,Cash or cash equivalent,333946148,,,Matrix And Platinum Sciences (MAPS),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Varian Medical Systems, Inc.",100000010850,"Varian Medical Systems, Inc.",CA,10000.00,09/21/2015,Cash or cash equivalent,317502174,,,A Portable Real-time HDR Applicator Monitoring System for Intracavitary Brachtherapy,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Horizon Pharma plc,100000131389,Horizon Pharma plc,,67349.85,03/24/2015,Cash or cash equivalent,334849634,ACTIMMUNE,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Horizon Pharma plc,100000131389,Horizon Pharma plc,,206882.61,05/11/2015,Cash or cash equivalent,334849638,ACTIMMUNE,,"Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety,",,
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme St,,Davenport,52803,,,The Spectranetics Corporation,100000005380,The Spectranetics Corporation,CO,500.00,02/28/2015,Cash or cash equivalent,294925402,,,EXCITE,,
Non-covered Recipient Entity,,,,,,,600 7TH ST SE,4TH FL,CEDAR RAPIDS,52401,,,Stryker Corporation,100000010503,Stryker Corporation,MI,2720.00,08/06/2015,Cash or cash equivalent,333943510,,,Triathlon Cruciate Retaining (CR) Total Knee System Outcomes Study,,
Covered Recipient Physician,,,1145239,EMILY,ANNE,WAGSTROM,200 HAWKINS DR,DEPARTMENT OF ORTHOPAEDIC SURGERY,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,Orthofix International N.V.,100000005619,Orthofix International N.V.,TX,18.08,11/22/2015,In-kind items and services,335547420,,,R&D - ExFix,,
Covered Recipient Physician,,,1145239,EMILY,ANNE,WAGSTROM,200 HAWKINS DR,DEPARTMENT OF ORTHOPAEDIC SURGERY,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,Orthofix International N.V.,100000005619,Orthofix International N.V.,TX,48.07,11/21/2015,In-kind items and services,335547454,,,R&D - ExFix,,
Covered Recipient Physician,,,1145239,EMILY,ANNE,WAGSTROM,200 HAWKINS DR,DEPARTMENT OF ORTHOPAEDIC SURGERY,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,Orthofix International N.V.,100000005619,Orthofix International N.V.,TX,405.78,11/22/2015,In-kind items and services,335547510,,,R&D - ExFix,,
Covered Recipient Physician,,,1145239,EMILY,ANNE,WAGSTROM,200 HAWKINS DR,DEPARTMENT OF ORTHOPAEDIC SURGERY,IOWA CITY,52242,Medical Doctor,Allopathic & Osteopathic Physicians|Orthopaedic Surgery,Orthofix International N.V.,100000005619,Orthofix International N.V.,TX,201.91,11/21/2015,In-kind items and services,335547544,,,R&D - ExFix,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,76.69,09/01/2015,In-kind items and services,319246610,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,124.61,09/01/2015,In-kind items and services,319246628,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,76.69,08/01/2015,In-kind items and services,319221688,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,124.61,08/01/2015,In-kind items and services,319221706,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,ATN: GRANT ACCTING OFFICE,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,25.08,05/26/2015,In-kind items and services,319196412,,,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727),,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,75.52,10/01/2015,In-kind items and services,319237133,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,122.71,10/01/2015,In-kind items and services,319237154,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,222.38,08/04/2015,In-kind items and services,319223530,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,444.76,08/04/2015,In-kind items and services,319223550,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,16.68,08/04/2015,In-kind items and services,319223571,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,16.68,08/04/2015,In-kind items and services,319224186,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.45,08/04/2015,In-kind items and services,319224203,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,4.45,08/04/2015,In-kind items and services,319224226,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,33.36,08/04/2015,In-kind items and services,319224246,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,22.24,08/04/2015,In-kind items and services,319224268,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,83.39,08/04/2015,In-kind items and services,319224289,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,111.19,08/04/2015,In-kind items and services,319224312,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,1623.37,08/04/2015,In-kind items and services,319224332,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,111.19,08/04/2015,In-kind items and services,319224352,,,Evaluation of Dupilumab in Patients with Persistent Asthma,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1118.99,09/15/2015,Cash or cash equivalent,336418454,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,922.43,09/15/2015,Cash or cash equivalent,336418456,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418458,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1118.99,09/15/2015,Cash or cash equivalent,336418460,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,12/19/2015,Cash or cash equivalent,336418462,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,12/19/2015,Cash or cash equivalent,336418466,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,12/19/2015,Cash or cash equivalent,336418468,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,117.00,12/12/2015,Cash or cash equivalent,336418470,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418474,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418478,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418480,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418482,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418486,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,468.00,12/12/2015,Cash or cash equivalent,336418488,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,117.00,12/12/2015,Cash or cash equivalent,336418492,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,292.50,12/12/2015,Cash or cash equivalent,336418494,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418496,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418499,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418502,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418504,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,864.63,12/12/2015,Cash or cash equivalent,336418508,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,864.63,12/12/2015,Cash or cash equivalent,336418510,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,922.43,12/19/2015,Cash or cash equivalent,336418512,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,12/19/2015,Cash or cash equivalent,336418516,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,12/19/2015,Cash or cash equivalent,336418518,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1118.99,12/19/2015,Cash or cash equivalent,336418520,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,12/19/2015,Cash or cash equivalent,336418524,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,12/19/2015,Cash or cash equivalent,336418526,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,922.43,12/19/2015,Cash or cash equivalent,336418530,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.07,12/19/2015,Cash or cash equivalent,336418532,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,12/19/2015,Cash or cash equivalent,336418536,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,689.36,12/19/2015,Cash or cash equivalent,336418538,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,12/19/2015,Cash or cash equivalent,336418542,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,292.50,12/12/2015,Cash or cash equivalent,336418544,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,819.00,12/12/2015,Cash or cash equivalent,336418548,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,12/19/2015,Cash or cash equivalent,336418550,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,12/19/2015,Cash or cash equivalent,336418554,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,12/19/2015,Cash or cash equivalent,336418556,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,12/19/2015,Cash or cash equivalent,336418558,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,12/19/2015,Cash or cash equivalent,336418562,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,12/19/2015,Cash or cash equivalent,336418564,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,12/19/2015,Cash or cash equivalent,336418568,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,454.19,12/19/2015,Cash or cash equivalent,336418570,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,09/15/2015,Cash or cash equivalent,336418574,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.07,09/15/2015,Cash or cash equivalent,336418576,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,09/15/2015,Cash or cash equivalent,336418578,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,09/15/2015,Cash or cash equivalent,336418580,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,09/15/2015,Cash or cash equivalent,336418584,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1432.08,09/15/2015,Cash or cash equivalent,336418586,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,09/15/2015,Cash or cash equivalent,336418588,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,09/15/2015,Cash or cash equivalent,336418592,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,922.43,09/15/2015,Cash or cash equivalent,336418594,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,09/15/2015,Cash or cash equivalent,336418596,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418600,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,09/15/2015,Cash or cash equivalent,336418602,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418606,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,689.36,09/15/2015,Cash or cash equivalent,336418608,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,200.07,09/15/2015,Cash or cash equivalent,336418612,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418614,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,09/15/2015,Cash or cash equivalent,336418616,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1432.08,09/15/2015,Cash or cash equivalent,336418620,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,140.99,09/15/2015,Cash or cash equivalent,336418622,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418626,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,09/15/2015,Cash or cash equivalent,336418628,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418632,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,09/15/2015,Cash or cash equivalent,336418634,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1432.08,09/15/2015,Cash or cash equivalent,336418637,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,09/15/2015,Cash or cash equivalent,336418640,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,09/15/2015,Cash or cash equivalent,336418642,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,09/15/2015,Cash or cash equivalent,336418646,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418648,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1784.25,09/15/2015,Cash or cash equivalent,336418650,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,922.43,09/15/2015,Cash or cash equivalent,336418440,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,281.50,09/15/2015,Cash or cash equivalent,336418442,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,887.33,09/15/2015,Cash or cash equivalent,336418445,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,689.36,09/15/2015,Cash or cash equivalent,336418448,,,Treatment of Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,251998,KATHLEEN,SUE,JONES,5950 UNIVERSITY AVE,STE 151,WEST DES MOINES,50266-8216,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,999.65,09/15/2015,Cash or cash equivalent,336418450,,,Treatment of Pain Associated With Fibromyalgia,,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,3646.00,05/07/2015,Cash or cash equivalent,336444714,Savaysa,,DU176b-E-U210,,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,750.00,03/10/2015,Cash or cash equivalent,336445880,,,"Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury ASCI",,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1400.00,03/17/2015,Cash or cash equivalent,336445086,,,"Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury ASCI",,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,05/11/2015,Cash or cash equivalent,336434560,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/24/2015,Cash or cash equivalent,336434564,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,08/12/2015,Cash or cash equivalent,336434568,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/24/2015,Cash or cash equivalent,336434570,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,08/12/2015,Cash or cash equivalent,336434574,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,08/12/2015,Cash or cash equivalent,336434576,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,05/11/2015,Cash or cash equivalent,336434580,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,09/16/2015,Cash or cash equivalent,336434586,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/02/2015,Cash or cash equivalent,336434588,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,05/11/2015,Cash or cash equivalent,336434592,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,07/24/2015,Cash or cash equivalent,336434598,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,09/16/2015,Cash or cash equivalent,336434600,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434602,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/24/2015,Cash or cash equivalent,336434604,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/24/2015,Cash or cash equivalent,336434608,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,09/16/2015,Cash or cash equivalent,336434612,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434618,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434622,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,05/11/2015,Cash or cash equivalent,336434624,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,500.00,04/20/2015,Cash or cash equivalent,336434628,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,08/12/2015,Cash or cash equivalent,336434631,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,09/16/2015,Cash or cash equivalent,336434634,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434638,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,07/24/2015,Cash or cash equivalent,336434642,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,437.50,09/16/2015,Cash or cash equivalent,336434646,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,07/22/2015,Cash or cash equivalent,336434650,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/24/2015,Cash or cash equivalent,336434652,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/24/2015,Cash or cash equivalent,336434656,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/22/2015,Cash or cash equivalent,336434662,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,09/16/2015,Cash or cash equivalent,336434666,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,08/12/2015,Cash or cash equivalent,336434668,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/22/2015,Cash or cash equivalent,336434670,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434674,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,07/24/2015,Cash or cash equivalent,336434679,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434684,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,07/24/2015,Cash or cash equivalent,336434688,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,437.50,07/02/2015,Cash or cash equivalent,336434690,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,09/16/2015,Cash or cash equivalent,336434696,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,07/24/2015,Cash or cash equivalent,336434700,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,09/16/2015,Cash or cash equivalent,336434702,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,07/24/2015,Cash or cash equivalent,336434706,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434708,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,09/16/2015,Cash or cash equivalent,336434712,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,05/11/2015,Cash or cash equivalent,336434716,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434720,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,05/11/2015,Cash or cash equivalent,336434724,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,09/16/2015,Cash or cash equivalent,336434728,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,05/11/2015,Cash or cash equivalent,336434732,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434734,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,08/12/2015,Cash or cash equivalent,336434736,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,09/16/2015,Cash or cash equivalent,336434740,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1096.25,05/18/2015,Cash or cash equivalent,336434742,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,08/12/2015,Cash or cash equivalent,336434746,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/02/2015,Cash or cash equivalent,336434750,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,09/16/2015,Cash or cash equivalent,336434754,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,08/12/2015,Cash or cash equivalent,336434758,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,07/24/2015,Cash or cash equivalent,336434760,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1000.00,04/20/2015,Cash or cash equivalent,336434764,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,4000.00,09/16/2015,Cash or cash equivalent,336434772,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,07/24/2015,Cash or cash equivalent,336434776,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434780,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,07/24/2015,Cash or cash equivalent,336434784,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/24/2015,Cash or cash equivalent,336434788,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,09/16/2015,Cash or cash equivalent,336434792,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,05/11/2015,Cash or cash equivalent,336434800,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1096.25,08/12/2015,Cash or cash equivalent,336434802,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,3500.00,04/20/2015,Cash or cash equivalent,336434804,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,09/16/2015,Cash or cash equivalent,336434808,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,07/24/2015,Cash or cash equivalent,336434812,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,09/16/2015,Cash or cash equivalent,336434816,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434819,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,12/15/2015,Cash or cash equivalent,336434824,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434827,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434830,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434834,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434838,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434842,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,12/15/2015,Cash or cash equivalent,336434846,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434850,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434854,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434856,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,12/15/2015,Cash or cash equivalent,336434860,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434862,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,106.25,12/15/2015,Cash or cash equivalent,336434864,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434866,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1096.25,12/15/2015,Cash or cash equivalent,336434870,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434872,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,12/15/2015,Cash or cash equivalent,336434874,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,12/15/2015,Cash or cash equivalent,336434876,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434880,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434882,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434886,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434888,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434892,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434894,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434896,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,968.13,12/15/2015,Cash or cash equivalent,336434899,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,12/15/2015,Cash or cash equivalent,336434904,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434908,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434913,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434918,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434922,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,437.50,12/15/2015,Cash or cash equivalent,336434926,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434928,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434930,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434934,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434938,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434940,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434944,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1096.25,12/15/2015,Cash or cash equivalent,336434948,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434952,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434955,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434960,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,437.50,12/15/2015,Cash or cash equivalent,336434964,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434966,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,708.75,12/15/2015,Cash or cash equivalent,336434974,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,274.38,12/15/2015,Cash or cash equivalent,336434978,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,1368.13,12/15/2015,Cash or cash equivalent,336434982,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Physician,,,304617,KENNETH,LAWRENCE,POLLACK,6001 WESTOWN PARKWAY,,WEST DES MOINES,50266-7702,Medical Doctor,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,758.75,12/15/2015,Cash or cash equivalent,336434986,,,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,3640.50,07/15/2015,Cash or cash equivalent,324482812,PRALUENT (alirocumab) Injection,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",,"The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,590.63,01/12/2015,Cash or cash equivalent,324482608,PRALUENT (alirocumab) Injection,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",,"The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,1250.00,02/18/2015,Cash or cash equivalent,324482638,PRALUENT (alirocumab) Injection,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",,"The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,2673.24,08/17/2015,Cash or cash equivalent,324482852,PRALUENT (alirocumab) Injection,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",,"The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication."
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Photocure Inc,100000010742,Photocure Inc,NJ,1123.49,08/05/2015,Cash or cash equivalent,335495900,,,A STUDY OF BLUE LIGHT FLEXIBLE CYSTOSCOPY WITH CYSVIEW IN THE DETECTION OF BLADDER CANCER IN THE SURVEILLANCE SETTING,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,Photocure Inc,100000010742,Photocure Inc,NJ,113.94,08/05/2015,Cash or cash equivalent,335495904,,,A STUDY OF BLUE LIGHT FLEXIBLE CYSTOSCOPY WITH CYSVIEW IN THE DETECTION OF BLADDER CANCER IN THE SURVEILLANCE SETTING,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,1471.50,03/30/2015,Cash or cash equivalent,324482666,PRALUENT (alirocumab) Injection,,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",,"The purpose of the study is to determine if the study drug (alirocumab)administered every 4 weeks, given by injection under the skin is effective and safe compared with placebo in lowering cholesterol, if used alone or added to the participants' current cholesterol-lowering medication."
Non-covered Recipient Entity,,,,,,,1241 8th St,,Wdm,50265,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,4000.00,05/11/2015,Cash or cash equivalent,324486172,,,A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,,"This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD)."
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,2351.25,08/06/2015,Cash or cash equivalent,336470832,,,"Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury ASCI",,
Non-covered Recipient Entity,,,,,,,The University of Iowa,Attn Grant Accounting Office,Iowa City,52242,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,2026.47,08/27/2015,Cash or cash equivalent,336470648,,,"Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury ASCI",,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,16.35,10/31/2015,Cash or cash equivalent,258841426,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,945.00,03/24/2015,Cash or cash equivalent,258841076,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,AMES,50010-3014,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,1274.40,12/04/2015,Cash or cash equivalent,258840242,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,Po Box 3014,,AMES,50010-3014,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,683.03,12/07/2015,In-kind items and services,270266665,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Covered Recipient Physician,,,126578,JERRY,L,ROZEBOOM,855 A AVE NE,,CEDAR RAPIDS,52402,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,"DySIS Medical, Inc.",100000061329,"DySIS Medical, Inc.",FL,12000.00,11/09/2015,Cash or cash equivalent,337527654,,,IMproved PRactice Outcomes and Value Excellence in Colposcopy,,The study will observe and quantify shifts in colposcopy practice and outcome improvements in U.S. community-based cervical screening colposcopy examinations after the introduction of the DySIS colposcope with Advanced Cervical Scan
Covered Recipient Physician,,,370516,MARGARET,A,SMOLLEN,319 E BLOOMINGTON ST,,IOWA CITY,52245,Medical Doctor,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology,"DySIS Medical, Inc.",100000061329,"DySIS Medical, Inc.",FL,3000.00,11/11/2015,Cash or cash equivalent,337154770,,,IMproved PRactice Outcomes and Value Excellence in Colposcopy,,The study will observe and quantify shifts in colposcopy practice and outcome improvements in U.S. community-based cervical screening colposcopy examinations after the introduction of the DySIS colposcope with Advanced Cervical Scan
Non-covered Recipient Entity,,,,,,,Po Box 3014,,Ames,50010,,,Sunovion Pharmaceuticals Inc.,100000000254,Sunovion Pharmaceuticals Inc.,MA,1890.00,09/08/2015,Cash or cash equivalent,258843408,Aptiom,,Eslicarbazepine Acetate Monotherapy Long Term Study,,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3500.00,03/17/2015,Cash or cash equivalent,307898664,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,6045.30,05/12/2015,Cash or cash equivalent,307898668,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3193.20,05/05/2015,Cash or cash equivalent,307898672,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,8890.00,05/01/2015,Cash or cash equivalent,331304591,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Non-covered Recipient Entity,,,,,,,202 10TH ST SE,,CEDAR RAPIDS,52403-2414,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,14668.00,08/31/2015,Cash or cash equivalent,331305487,Xofigo,,Phase IIb study of radium 223 in breast cancer,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,7780.00,03/04/2015,Cash or cash equivalent,331304681,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Non-covered Recipient Entity,,,,,,,974 73RD ST,STE 23,WINDSOR HEIGHTS,50324-1026,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,3184.00,10/21/2015,Cash or cash equivalent,331305567,Xarelto,,"BAY59-7939, 2.5mg, reduction atherothrombotic events vs. ASA",,
Non-covered Recipient Entity,,,,,,,801 5th St Ste 2211,,Sioux City,51101,,,Theravance Biopharma Inc.,100000010610,Theravance Biopharma Inc.,CA,24.17,04/01/2015,Cash or cash equivalent,337650812,,,Etests,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,4190.00,07/03/2015,Cash or cash equivalent,331304791,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,08/11/2015,Cash or cash equivalent,331305637,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1129.44,05/26/2015,Cash or cash equivalent,331305643,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,261.88,05/26/2015,Cash or cash equivalent,331305649,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,883.00,05/26/2015,Cash or cash equivalent,331305663,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2918.00,08/11/2015,Cash or cash equivalent,331305667,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,01/08/2015,Cash or cash equivalent,331305669,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,449.38,05/26/2015,Cash or cash equivalent,331305679,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,736.00,05/26/2015,Cash or cash equivalent,331305683,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1459.00,05/15/2015,Cash or cash equivalent,331305693,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,IOWA CITY,52242,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,2918.00,05/15/2015,Cash or cash equivalent,331305703,Adempas,,BAY 63-2521 ph II LVD-assoc.-PH,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,4770.00,09/09/2015,Cash or cash equivalent,331305001,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,22223.74,09/10/2015,Cash or cash equivalent,330095661,Prolastin-C,,"A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,1415 WOODLAND AVE.,SUITE 218,DES MOINES,50309,,,Theravance Biopharma Inc.,100000010610,Theravance Biopharma Inc.,CA,7719.00,08/03/2015,Cash or cash equivalent,337649998,,,Non-Integrated_Full_Ph,,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,750.00,05/04/2015,Cash or cash equivalent,331305189,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,230 NEBRASKA ST,,SIOUX CITY,51101-1733,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,6310.10,08/05/2015,Cash or cash equivalent,331305203,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Non-covered Recipient Entity,,,,,,,701 10TH ST SE,,CEDAR RAPIDS,52403-1251,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,4531.40,08/03/2015,Cash or cash equivalent,331305231,Stivarga,,"Bay73-4506, Regorafenib CRC EAP after failure of std therapy",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,2602.15,01/21/2015,Cash or cash equivalent,330094569,Prolastin-C,,"A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a human plasma-derived Alpha1-Proteinase Inhibitor in Subjects with New-Onset Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,1910.00,01/06/2015,Cash or cash equivalent,331304363,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Non-covered Recipient Entity,,,,,,,5880 UNIVERSITY AVE,,WEST DES MOINES,50266-8209,,,Bayer HealthCare LLC,100000005467,Bayer HealthCare Pharmaceuticals Inc.,NJ,4300.00,11/04/2015,Cash or cash equivalent,331305321,Xarelto,,BAY59-7939 prevention of CV events in vascular disease,,
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1474.20,01/14/2015,Cash or cash equivalent,307904944,ADVAIR DISKUS,SERETIDE,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,15.00,09/29/2015,Cash or cash equivalent,307904955,ADVAIR DISKUS,SERETIDE,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,201 RIDGE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,500.00,10/29/2015,Cash or cash equivalent,307904958,ADVAIR DISKUS,SERETIDE,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,57200.00,04/10/2015,In-kind items and services,330093633,Prolastin-C,,"A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a human plasma-derived Alpha1-Proteinase Inhibitor in Subjects with New-Onset Type 1 Diabetes Mellitus",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"Grifols Shared Services North America, Inc.",100000005422,Grifols Therapeutics Inc.,CA,55900.00,04/10/2015,In-kind items and services,330093709,Prolastin-C,,"A Multicenter, Randomized, Partial Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1Proteinase Inhibitor in Subjects With New Onset Type 1 Diabetes Mellitus",,
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,353.30,05/19/2015,Cash or cash equivalent,307911462,,,,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3524.29,08/25/2015,Cash or cash equivalent,307911464,,,,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,743.65,08/06/2015,Cash or cash equivalent,307911490,,,"A phase IIIA, randomized, observer blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals  MMR vaccine  209762   Priorix   compared to Merck   Co., Inc. s MMR vaccine  M M R II , as a first dose, both co administered with Varivax, Havrix and Prevnar 13  subset of children  to healthy children 12 to 15 months of age.",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,182.00,07/13/2015,Cash or cash equivalent,307911492,POTIGA,,"A multicenter, open label, long term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial onset seizures  Extension of Study VRX RET E22 301",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3417.50,06/16/2015,Cash or cash equivalent,307920300,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Acute Coronary Syndrome  ACS  to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,70000.00,02/12/2015,Cash or cash equivalent,307920302,,,,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1341.25,02/23/2015,Cash or cash equivalent,307909080,VERAMYST,,113782,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,9500.00,03/17/2015,Cash or cash equivalent,307909082,,,"A two part, Phase IIa, randomized, placebo controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin  GSK1325756  in symptomatic COPD subjects with mild to moderate airflow limita",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,724.50,03/17/2015,Cash or cash equivalent,307909084,ADVAIR DISKUS,SERETIDE,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1427.40,06/09/2015,Cash or cash equivalent,307909088,,,"A two part, Phase IIa, randomized, placebo controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin  GSK1325756  in symptomatic COPD subjects with mild to moderate airflow limita",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,914.00,07/01/2015,Cash or cash equivalent,307909090,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,380.00,09/22/2015,Cash or cash equivalent,307909092,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2908.25,10/27/2015,Cash or cash equivalent,307909094,ADVAIR DISKUS,SERETIDE,A 26 WEEK SAFETY STUDY OF INHALED FLUTICASONE PROPIONATE  SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS  WITH PERSISTENT ASTHMA,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3524.75,10/04/2015,Cash or cash equivalent,307909098,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,307.50,11/03/2015,Cash or cash equivalent,307909101,VERAMYST,,113782,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3125.00,04/02/2015,Cash or cash equivalent,307930526,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3310.20,06/02/2015,Cash or cash equivalent,307930528,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2469.60,06/23/2015,Cash or cash equivalent,307930530,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3310.20,06/16/2015,Cash or cash equivalent,307930532,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1200.00,07/14/2015,Cash or cash equivalent,307930534,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2165.40,07/21/2015,Cash or cash equivalent,307930536,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2737.80,07/21/2015,Cash or cash equivalent,307930538,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2007.00,07/02/2015,Cash or cash equivalent,307930540,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2658.60,07/28/2015,Cash or cash equivalent,307930542,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1267.00,07/14/2015,Cash or cash equivalent,307930544,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1706.25,07/14/2015,Cash or cash equivalent,307930546,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2165.40,08/25/2015,Cash or cash equivalent,307930548,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2658.60,09/08/2015,Cash or cash equivalent,307930550,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2999.70,10/20/2015,Cash or cash equivalent,307930552,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2082.60,10/13/2015,Cash or cash equivalent,307930554,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2603.70,10/06/2015,Cash or cash equivalent,307930556,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2086.20,11/24/2015,Cash or cash equivalent,307930558,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,775.00,01/20/2015,Cash or cash equivalent,307927720,ARZERRA,,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia  CLL  who have responded to induction therapy",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2526.30,09/08/2015,Cash or cash equivalent,307922194,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2265.30,09/08/2015,Cash or cash equivalent,307922196,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2311.20,09/29/2015,Cash or cash equivalent,307922198,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2488.50,10/13/2015,Cash or cash equivalent,307922200,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2477.70,10/06/2015,Cash or cash equivalent,307922202,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2564.10,10/06/2015,Cash or cash equivalent,307922204,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,8880.62,11/03/2015,Cash or cash equivalent,307922206,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2003.40,11/17/2015,Cash or cash equivalent,307922208,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3033.90,11/03/2015,Cash or cash equivalent,307922210,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2083.50,11/24/2015,Cash or cash equivalent,307922212,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4218.30,12/03/2015,Cash or cash equivalent,307922214,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2314.80,01/06/2015,Cash or cash equivalent,307922126,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2239.20,01/06/2015,Cash or cash equivalent,307922128,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2235.60,01/13/2015,Cash or cash equivalent,307922130,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2235.60,01/20/2015,Cash or cash equivalent,307922132,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3387.60,01/20/2015,Cash or cash equivalent,307922134,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2564.10,01/06/2015,Cash or cash equivalent,307922136,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3250.80,02/03/2015,Cash or cash equivalent,307922138,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2769.30,02/17/2015,Cash or cash equivalent,307922140,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,6670.84,02/01/2015,Cash or cash equivalent,307922142,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2239.20,02/10/2015,Cash or cash equivalent,307922144,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3141.90,03/24/2015,Cash or cash equivalent,307922146,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3286.80,03/17/2015,Cash or cash equivalent,307922148,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2643.30,03/10/2015,Cash or cash equivalent,307922150,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2102.40,04/14/2015,Cash or cash equivalent,307922152,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3383.10,01/27/2015,Cash or cash equivalent,307923968,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2142.00,04/28/2015,Cash or cash equivalent,307923970,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3553.20,04/07/2015,Cash or cash equivalent,307923972,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2712.60,04/02/2015,Cash or cash equivalent,307922154,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2102.40,04/14/2015,Cash or cash equivalent,307922156,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2967.30,05/12/2015,Cash or cash equivalent,307922158,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2699.10,05/26/2015,Cash or cash equivalent,307922160,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2083.50,06/23/2015,Cash or cash equivalent,307922162,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2235.60,06/16/2015,Cash or cash equivalent,307922164,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2009.70,06/09/2015,Cash or cash equivalent,307922166,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,50 EIGHT EIGHTY UNIVERSITY,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,5478.75,06/16/2015,Cash or cash equivalent,307923974,,,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Acute Coronary Syndrome  ACS  to Compare the Incidence of Major Adverse Cardiovascular Events  MACE,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,250.00,11/24/2015,Cash or cash equivalent,307923976,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,208 MAILBOX,,WEST DES MOINES,50266,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3542.40,11/24/2015,Cash or cash equivalent,307923978,,,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo  PM1116197,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2520.42,07/01/2015,Cash or cash equivalent,307922168,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2876.40,07/07/2015,Cash or cash equivalent,307922170,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2405.70,07/14/2015,Cash or cash equivalent,307922172,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,4079.70,07/02/2015,Cash or cash equivalent,307922176,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2314.80,07/28/2015,Cash or cash equivalent,307922178,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2772.00,08/06/2015,Cash or cash equivalent,307922180,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2009.70,08/25/2015,Cash or cash equivalent,307922182,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3900.60,08/11/2015,Cash or cash equivalent,307922184,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,20770.20,09/08/2015,Cash or cash equivalent,307922186,RELENZA,,"A Phase III international, randomized, doubleblind, double dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1 EDMUNDSON PL,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,19598.60,09/15/2015,Cash or cash equivalent,307922188,RELENZA,,"A Phase III international, randomized, doubleblind, double dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2449.80,09/29/2015,Cash or cash equivalent,307922190,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,933 E PIERCE ST,,COUNCIL BLUFFS,51503,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2314.80,09/01/2015,Cash or cash equivalent,307922192,,,"A Phase III, 52 week, randomized, double blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF UMEC VI with the fixed dose dual combinations of FF VI and UMEC VI, all administered once d",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,960.49,04/17/2015,Cash or cash equivalent,307940052,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1132.83,07/01/2015,Cash or cash equivalent,307940058,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1983.91,10/04/2015,Cash or cash equivalent,307940060,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1241 8TH ST,,WEST DES MOINES,50265,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,750.00,11/03/2015,Cash or cash equivalent,307940064,VERAMYST,,HZC113782  A Clinical Outcomes Study to compare the effect of Fluticasone Furoate GW642444 Inhalation Powder with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease  COPD  and a history of or at increased risk for developing cardiovascular disease,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,3350.00,07/20/2015,Cash or cash equivalent,336871840,,,Zenith AAA-LP US IDE Clinical Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,5380.00,10/13/2015,Cash or cash equivalent,336871844,,,Zenith AAA-LP US IDE Clinical Study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET,,DES MOINES,50314,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,2000.00,10/20/2015,Cash or cash equivalent,308339148,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II). This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,11024.70,04/28/2015,Cash or cash equivalent,308336854,,,LIBERTY 360,,"LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD).  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD)."
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,5890.00,01/27/2015,Cash or cash equivalent,336870410,,,Zenith AAA-LP US IDE Clinical Study,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,4986.84,07/23/2015,Cash or cash equivalent,308338584,,,LIBERTY 360,,"LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD).  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD)."
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,498.00,01/27/2015,Cash or cash equivalent,336870412,,,TX2 Post-approval Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,250.00,02/13/2015,Cash or cash equivalent,336870416,,,Zenith AAA-LP US IDE Clinical Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,822.00,04/14/2015,Cash or cash equivalent,336870418,,,TX2 Post-approval Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,16340.00,04/20/2015,Cash or cash equivalent,336870420,,,Zenith AAA-LP US IDE Clinical Study,,
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET,,DES MOINES,50314,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,250.00,11/03/2015,Cash or cash equivalent,308339446,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II). This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET,,DES MOINES,50314,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,550.00,04/28/2015,Cash or cash equivalent,308337164,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II). This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,5670.00,01/27/2015,Cash or cash equivalent,308334214,,,LIBERTY 360,,"LIBERTY 360 Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease PAD.  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease PAD."
Non-covered Recipient Entity,,,,,,,"5880 University Ave, 208",,West Des Moines,50266,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,6050.00,02/24/2015,Cash or cash equivalent,308335228,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions ORBIT II. This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,5000.00,06/16/2015,Cash or cash equivalent,308338008,,,LIBERTY 360,,"LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD).  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD)."
Non-covered Recipient Entity,,,,,,,345 BEAVER KREEK CTR,,NORTH LIBERTY,52317,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,31280.00,06/11/2015,Cash or cash equivalent,307928806,,,,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,345 BEAVER KREEK CTR,,NORTH LIBERTY,52317,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,38850.00,06/11/2015,Cash or cash equivalent,307928808,,,,,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,1622 East Lombard Street,,Davenport,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,1924.90,02/03/2015,Cash or cash equivalent,308334352,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY CLARITY I. CLARITY I is a pilot study to identify the clinically appropriate endpoints of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia CLI."
Non-covered Recipient Entity,,,,,,,411 LAUREL STREET,,DES MOINES,50314,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,550.00,07/21/2015,Cash or cash equivalent,308338116,,,ORBIT II,,"Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360 Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II). This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects."
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,5435.00,07/20/2015,Cash or cash equivalent,336871242,,,Zenith AAA-LP US IDE Clinical Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,386.00,07/20/2015,Cash or cash equivalent,336871244,,,TX2 Post-approval Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,224.00,10/13/2015,Cash or cash equivalent,336871246,,,TX2 Post-approval Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,4925.00,10/13/2015,Cash or cash equivalent,336871250,,,Zenith AAA-LP US IDE Clinical Study,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Cook Research Incorporated,100000005386,Cook Research Incorporated,IN,250.00,10/29/2015,Cash or cash equivalent,336871252,,,TX2 Post-approval Study,,
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,1025.51,04/14/2015,Cash or cash equivalent,308336406,,,CLARITY,,"Complete Lesion Assessment With ffR and IVUS TechnologY (CLARITY I). CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia (CLI)."
Non-covered Recipient Entity,,,,,,,1622 EAST LOMBARD STREET,,DAVENPORT,52803,,,Cardiovascular Systems Inc.,100000000117,Cardiovascular Systems Inc.,MN,9065.82,10/20/2015,Cash or cash equivalent,308339806,,,LIBERTY 360,,"LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD).  The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD)."
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,2000.00,09/01/2015,Cash or cash equivalent,307938422,TANZEUM,EPERZAN,"A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,3000.00,11/17/2015,Cash or cash equivalent,307938424,TANZEUM,EPERZAN,"A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1260.90,11/03/2015,Cash or cash equivalent,307938426,TANZEUM,EPERZAN,"A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,411 LAUREL ST,,DES MOINES,50314,,,"GlaxoSmithKline, LLC.",100000005449,"GlaxoSmithKline, LLC.",NC,1800.00,12/15/2015,Cash or cash equivalent,307938428,TANZEUM,EPERZAN,"A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,4040.00,07/16/2015,Cash or cash equivalent,331373335,,,Not Applicable,,
Non-covered Recipient Entity,,,,,,,411 Laurel St Ste 3262,Ste 3262,Des Moines,50314,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,154790.13,01/30/2015,Cash or cash equivalent,331380965,FARXIGA,,Phase III T1D Initial,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,700 E University Ave,,Des Moines,50316,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,9053.00,09/08/2015,Cash or cash equivalent,331370941,ELIQUIS,,Phase III VTE Prev in Children w ALL,,
Covered Recipient Teaching Hospital,2942,Mercy Medical Center,,,,,701 10th St SE,,Cedar Rapids,52403,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,83984.00,02/05/2015,In-kind items and services,331369265,ERBITUX,,Erbitux Comparing Carboplat Paclitax W WO Concur Cetux BMSSP,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,2350.00,12/09/2015,Cash or cash equivalent,331371057,SPRYCEL,,DASCERN Dasatinib Early Switch,,
Non-covered Recipient Entity,,,,,,,CC101 Gh Attn Inv Drug Ser,200 Hawkins Dr,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,568.71,02/18/2015,In-kind items and services,331376629,NULOJIX,,Phase IIIB CNI to bela Switch Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,21006.73,01/26/2015,Cash or cash equivalent,331371233,OPDIVO,,Phase III RCC Monotherapy vs everolimus ONO 4538 03,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,700 E University Ave,,Des Moines,50316,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,16100.00,06/01/2015,Cash or cash equivalent,331372209,YERVOY,,NIR Advanced melanoma IMAGE,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,42.88,01/16/2015,Cash or cash equivalent,331375479,ELIQUIS,,Phase III AFib ARISTOTLE,,
Non-covered Recipient Entity,,,,,,,230 Nebraska St,,Sioux City,51101,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1424.00,01/07/2015,Cash or cash equivalent,331376209,EMPLICITI,,NIR Phase III PREAMBLE,,
Covered Recipient Teaching Hospital,2707,MERCY MEDICAL CENTER - NORTH,,,,,1000 4th St SW,SUITE IOPT,Mason City,50401,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,5800.00,08/26/2015,Cash or cash equivalent,331369867,SPRYCEL,,GMA NIR SIMPLICITY TREATMENT PATTERNS AND OUTCOMES IN CML PATIENTS WHO ARE INTOLERANT TO IMATINIB,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,700 E University Ave,,Des Moines,50316,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,33600.00,01/29/2015,Cash or cash equivalent,331371547,NULOJIX,,Evaluating Nulojix Belatacept Long Term Safety in Transplant ENLIST,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,2586.80,01/02/2015,Cash or cash equivalent,331369899,EMPLICITI,,ELOQUENT 1 Ph III 1st Line,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,6000.00,03/12/2015,Cash or cash equivalent,331370803,NULOJIX,,Phase IIIB CNI to bela Switch Study,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,21.99,06/24/2015,Cash or cash equivalent,331370807,ELIQUIS,,Phase III VTE Prev in Children w ALL,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,7640.00,03/18/2015,Cash or cash equivalent,333610560,,,Magna Mitral 2006-05,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,1209.82,05/08/2015,Cash or cash equivalent,333611090,,,The PARTNER II Trial: Placement of Aortic Transcatheter Valve Trial 2010-12,,
Non-covered Recipient Entity,,,,,,,5880 University Avenue,,West De Moines,50266,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,12472.40,05/29/2015,Cash or cash equivalent,333613156,,,Magna Mitral 2006-05,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,126009.30,07/06/2015,Cash or cash equivalent,338561398,OPDIVO,,Ph IIb 2L Bladder Registrational,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,3000.00,07/24/2015,Cash or cash equivalent,333611640,,,Magna Mitral 23mm 2008-07,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,2425.00,07/24/2015,Cash or cash equivalent,333611644,,,Magna Mitral 23mm 2008-07,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,45494.67,07/24/2015,Cash or cash equivalent,333611648,,,Magna Mitral 23mm 2008-07,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,250.00,06/10/2015,Cash or cash equivalent,333611264,,,Magna Mitral 2006-05,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,21326.39,07/29/2015,Cash or cash equivalent,333611770,,,The PARTNER II Trial: Placement of Aortic Transcatheter Valve Trial 2010-12,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,23259.00,04/20/2015,Cash or cash equivalent,338560785,,,Phase IB Rituxan combination,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Ave,,Des Moines,50314,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,250.00,02/11/2015,Cash or cash equivalent,333610308,,,Magna Mitral 2006-05,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,1910.00,07/15/2015,Cash or cash equivalent,333611448,,,Magna Mitral 2006-05,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,39640.00,05/28/2015,Cash or cash equivalent,338561132,OPDIVO,,Phase III RCC 1L,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,36043.80,11/11/2015,Cash or cash equivalent,333612466,,,The PARTNER II Trial: Placement of Aortic Transcatheter Valve Trial 2010-12,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,10500.00,10/23/2015,Cash or cash equivalent,333612032,,,The PARTNER II Trial: Placement of Aortic Transcatheter Valve Trial 2010-12,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,4955.54,04/06/2015,Cash or cash equivalent,338562256,YERVOY,,PhIII Prostate 2nd line CRPC Ipi RT vs RT,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,9284.25,02/18/2015,Cash or cash equivalent,333610554,,,The PARTNER II Trial: Placement of Aortic Transcatheter Valve Trial 2010-12,,
Non-covered Recipient Entity,,,,,,,CC101GH Joanna Nohr,200 Hawkins Drive,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,49.69,04/10/2015,In-kind items and services,331382533,OPDIVO,,Ph IIb 2L Bladder Registrational,,
Non-covered Recipient Entity,,,,,,,300 E Locust St Ste 350,suite 350,Des Moines,50309,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,42412.00,08/12/2015,In-kind items and services,331386017,ERBITUX,,Erbitux Comparing Carboplat Paclitax W WO Concur Cetux BMSSP,,
Non-covered Recipient Entity,,,,,,,CC101GH Joanna Nohr,200 Hawkins Drive,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,1228.05,10/15/2015,Cash or cash equivalent,331391173,ELIQUIS,,Phase IV ACS PCI study AUGUSTUS,,
Non-covered Recipient Entity,,,,,,,CC101GH Joanna Nohr,200 Hawkins Drive,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,42.88,01/16/2015,Cash or cash equivalent,331382667,ELIQUIS,,Phase III AFib ARISTOTLE,,
Non-covered Recipient Entity,,,,,,,University Of Iowa,,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,42.88,01/16/2015,Cash or cash equivalent,331390742,ELIQUIS,,Phase III AFib ARISTOTLE,,
Non-covered Recipient Entity,,,,,,,1215 Pleasant St Ste 514,,Des Moines,50309,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,68.97,06/24/2015,Cash or cash equivalent,331385695,ELIQUIS,,Phase III VTE Prev in Children w ALL,,
Non-covered Recipient Entity,,,,,,,CC101GH Joanna Nohr,200 Hawkins Drive,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,3414.69,05/20/2015,Cash or cash equivalent,331389539,NULOJIX,,Phase III Renal Transplant Broad Eligibility Criteria Study,,
Non-covered Recipient Entity,,,,,,,Mary Greeley Medical Ctr Irb,,Ames,50010,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,42.88,01/16/2015,Cash or cash equivalent,331389053,ELIQUIS,,Phase III AFib ARISTOTLE,,
Non-covered Recipient Entity,,,,,,,CC101GH Joanna Nohr,200 Hawkins Drive,Iowa City,52242,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,281.70,02/12/2015,In-kind items and services,331386777,OPDIVO,,Phase III RCC 1L,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,350.00,09/03/2015,Cash or cash equivalent,325623752,Ibrutinib,,PCYC-1123-CA,,"A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide, With and Without Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,158.90,12/23/2015,Cash or cash equivalent,325626132,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,2680.00,06/23/2015,Cash or cash equivalent,325623242,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,317.80,10/21/2015,Cash or cash equivalent,325626348,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,6371.72,10/14/2015,Cash or cash equivalent,325629460,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,3500.00,06/11/2015,Cash or cash equivalent,325621648,Ibrutinib,,PCYC-1123-CA,,"A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide, With and Without Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,14700.00,06/23/2015,Cash or cash equivalent,325621660,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,953.40,09/16/2015,Cash or cash equivalent,325624914,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Pharmacyclics LLC, An AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,596.44,09/16/2015,Cash or cash equivalent,325624950,Ibrutinib,,PCYC-1131-CA,,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1000.00,06/18/2015,Cash or cash equivalent,337647484,Hemophilia - RECOMBINATE,,NCT02210091 - Janice Staber - Iowa City IA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,4375.00,04/14/2015,Cash or cash equivalent,337647486,Hemophilia - RECOMBINATE,,NCT02210091 - Janice Staber - Iowa City IA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1625.00,04/14/2015,Cash or cash equivalent,337647488,Hemophilia - RECOMBINATE,,NCT02210091 - Janice Staber - Iowa City IA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,625.00,04/14/2015,Cash or cash equivalent,337647490,Hemophilia - RECOMBINATE,,NCT02210091 - Janice Staber - Iowa City IA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1415.00,05/27/2015,Cash or cash equivalent,337647492,Hemophilia - RECOMBINATE,,NCT02210091 - Janice Staber - Iowa City IA,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1756.92,06/26/2015,Cash or cash equivalent,337647556,BioTherapeutics - Research & Development,,NCT01508910 - 11 - University of Iowa,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,4440 WEST 95TH STREET,,IOWA CITY,52242,,,Baxter Healthcare,100000011010,Baxter Healthcare,IL,1811.25,03/27/2015,Cash or cash equivalent,337647558,BioTherapeutics - Research & Development,,NCT01508910 - 11 - University of Iowa,,
Non-covered Recipient Entity,,,,,,,4405 Hamilton Blvd,,Sioux City,51104,,,"Ocular Therapeutix, Inc.",100000076361,"Ocular Therapeutix, Inc.",MA,13900.00,12/10/2015,Cash or cash equivalent,337844646,,,"A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Marked, Vehicle Controlled Phase 3 Study Evaluating the Safety and Efficacy of DEXTENZA for the treatment of Ocular Inflammation and Pain after Cataract Surgery",,
Covered Recipient Physician,,,505503,DEBRA,M,PROW,1111 DUFF AVENUE,MCFARLAND CLINIC PC,AMES,50010-3014,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,1480.00,04/24/2015,Cash or cash equivalent,294360452,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,505503,DEBRA,M,PROW,1111 DUFF AVENUE,MCFARLAND CLINIC PC,AMES,50010-3014,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,1295.00,08/13/2015,Cash or cash equivalent,294360458,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,505503,DEBRA,M,PROW,1111 DUFF AVENUE,MCFARLAND CLINIC PC,AMES,50010-3014,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,1295.00,12/10/2015,Cash or cash equivalent,294360462,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,256009,WILLIAM,P,FUSSELMAN,202 10TH STREET SE,,CEDAR RAPIDS,52403-2404,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,295.00,04/24/2015,Cash or cash equivalent,294351806,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,256009,WILLIAM,P,FUSSELMAN,202 10TH STREET SE,,CEDAR RAPIDS,52403-2404,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,295.00,08/13/2015,Cash or cash equivalent,294351810,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,256009,WILLIAM,P,FUSSELMAN,202 10TH STREET SE,,CEDAR RAPIDS,52403-2404,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,295.00,12/10/2015,Cash or cash equivalent,294351814,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Physician,,,344594,ROBERT,WAYNE,WARNER,1 EDMUNDSON PL,SUITE 100,COUNCIL BLUFFS,51503-4658,Medical Doctor,Other Service Providers/ Specialist,Valeant Pharmaceuticals International,100000010935,Valeant Pharmaceuticals North America LLC,NJ,185.00,04/24/2015,Cash or cash equivalent,294364916,PROVENGE,,A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1926.00,05/04/2015,Cash or cash equivalent,338412990,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,963.00,07/20/2015,Cash or cash equivalent,338412998,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,6585.60,07/30/2015,Cash or cash equivalent,338413004,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,32.39,12/16/2015,In-kind items and services,338413010,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,45.14,06/01/2015,In-kind items and services,338412412,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,22.57,09/30/2015,In-kind items and services,338412416,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1064.70,02/02/2015,Cash or cash equivalent,260236708,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1148.40,05/05/2015,Cash or cash equivalent,260236712,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Non-covered Recipient Entity,,,,,,,1215 DUFF AVE,,AMES,50010,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1828.00,05/29/2015,Cash or cash equivalent,260236716,,,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (>=16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1400.00,01/23/2015,Cash or cash equivalent,260236718,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,1400.00,10/23/2015,Cash or cash equivalent,260236722,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,2000.00,04/29/2015,Cash or cash equivalent,260236728,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Non-covered Recipient Entity,,,,,,,2024 NW 92ND CT,STE 8,CLIVE,50325,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,5000.00,07/24/2015,Cash or cash equivalent,260236732,Cimzia,,"A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,3060.90,11/20/2015,Cash or cash equivalent,260236774,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,10256.00,01/29/2015,Cash or cash equivalent,338411668,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,600.00,04/14/2015,Cash or cash equivalent,338411674,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1750.00,10/15/2015,Cash or cash equivalent,338411680,SOLIRIS,,Safety ond Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,
Non-covered Recipient Entity,,,,,,,B5 JESSUP HALL,,IOWA CITY,52242,,,"UCB, Inc.",100000010780,UCB Biosciences Inc.,NC,567.90,05/05/2015,Cash or cash equivalent,260232592,,,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,642.00,08/18/2015,Cash or cash equivalent,338412792,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,6272.80,08/27/2015,Cash or cash equivalent,338412800,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1284.00,09/09/2015,Cash or cash equivalent,338412806,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,2395.20,10/07/2015,Cash or cash equivalent,338412814,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1605.00,11/10/2015,Cash or cash equivalent,338412818,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",CT,1284.00,12/22/2015,Cash or cash equivalent,338412826,SOLIRIS,,ECU-MG-302  An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis,,"A Phase III, Open-Label, Extension Trial OF ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis  gMG"
Non-covered Recipient Entity,,,,,,,85 JESSUP HALL,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,11446.00,01/01/2015,Cash or cash equivalent,300314710,TRIUMEQ,,"A phase IIIb, randomized, open label study of the safety, efficacy and tolerability of switching to a fixed dose combination of dolutegravir abacavir lamivudine from current antiretroviral regimen compared to continuation of the current antiretroviral regimen in HIV 1 infected adults who are virologically suppressed.",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,357.00,03/02/2015,Cash or cash equivalent,300314728,TRIUMEQ,,"A phase IIIb, randomized, open label study of the safety, efficacy and tolerability of switching to a fixed dose combination of dolutegravir abacavir lamivudine from current antiretroviral regimen compared to continuation of the current antiretroviral regimen in HIV 1 infected adults who are virologically suppressed.",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242,,,ViiV Healthcare Company,100000005550,ViiV Healthcare Company,NC,1799.75,08/11/2015,Cash or cash equivalent,300314738,TRIUMEQ,,"A phase IIIb, randomized, open label study of the safety, efficacy and tolerability of switching to a fixed dose combination of dolutegravir abacavir lamivudine from current antiretroviral regimen compared to continuation of the current antiretroviral regimen in HIV 1 infected adults who are virologically suppressed.",,HCP did not receive direct payment from GSK. HCP was listed as the Primary Investigator in accordance with the Sunshine Act requirements.
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 PLEASANT STREET,,DES MOINES,50309,,,Bristol-Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,973.60,03/12/2015,In-kind items and services,335483206,,,NSR,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,02/10/2015,Cash or cash equivalent,295846046,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,02/10/2015,Cash or cash equivalent,295846048,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,02/10/2015,Cash or cash equivalent,295846050,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,02/10/2015,Cash or cash equivalent,295846052,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,02/10/2015,Cash or cash equivalent,295846054,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,02/10/2015,Cash or cash equivalent,295846056,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,02/10/2015,Cash or cash equivalent,295846058,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,02/10/2015,Cash or cash equivalent,295846060,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,02/10/2015,Cash or cash equivalent,295846062,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,02/10/2015,Cash or cash equivalent,295846064,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,02/10/2015,Cash or cash equivalent,295846066,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,02/10/2015,Cash or cash equivalent,295846068,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/10/2015,Cash or cash equivalent,295844758,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,02/10/2015,Cash or cash equivalent,295844760,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,01/06/2015,Cash or cash equivalent,295841900,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,01/06/2015,Cash or cash equivalent,295841902,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,01/06/2015,Cash or cash equivalent,295841904,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,01/06/2015,Cash or cash equivalent,295841906,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,01/06/2015,Cash or cash equivalent,295841908,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,01/06/2015,Cash or cash equivalent,295841910,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,01/06/2015,Cash or cash equivalent,295841912,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,01/06/2015,Cash or cash equivalent,295841914,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,01/06/2015,Cash or cash equivalent,295841916,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,01/06/2015,Cash or cash equivalent,295841918,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,01/06/2015,Cash or cash equivalent,295841920,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,01/06/2015,Cash or cash equivalent,295841922,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,01/06/2015,Cash or cash equivalent,295841924,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,01/06/2015,Cash or cash equivalent,295841926,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,01/06/2015,Cash or cash equivalent,295842346,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,312.50,02/03/2015,Cash or cash equivalent,295842420,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,71.88,08/20/2015,Cash or cash equivalent,340077420,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,150.94,11/30/2015,Cash or cash equivalent,340077424,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,525.00,01/20/2015,Cash or cash equivalent,340077426,Amitiza,,PEDS 11S1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,1137.57,11/18/2015,Cash or cash equivalent,340077428,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,1688.65,08/13/2015,Cash or cash equivalent,340077430,Amitiza,,PEDS 11S1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,4471.94,02/12/2015,Cash or cash equivalent,340077432,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,5743.13,08/20/2015,Cash or cash equivalent,340077434,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,7383.40,05/08/2015,Cash or cash equivalent,340077436,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,105 Jessup Hall,,Iowa City,52242,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,7762.70,11/11/2015,Cash or cash equivalent,340077438,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1415 Woodland Avenue,Suite 218,Des Moines,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,683.80,11/18/2015,Cash or cash equivalent,340077554,Amitiza,,PEDS 11S1,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1415 Woodland Avenue,Suite 218,Des Moines,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,1351.42,08/20/2015,Cash or cash equivalent,340077556,Amitiza,,PEDS 11S1,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1415 Woodland Avenue,Suite 218,Des Moines,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,2041.37,08/19/2015,Cash or cash equivalent,340077558,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1415 Woodland Avenue,Suite 218,Des Moines,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,2735.96,05/08/2015,Cash or cash equivalent,340077560,Amitiza,,PEDS 1131,,
Covered Recipient Teaching Hospital,2939,IOWA LUTHTERAN HOSPITAL,,,,,1415 Woodland Avenue,Suite 218,Des Moines,50309,,,"Sucampo Pharma Americas, LLC",100000010731,"Sucampo Pharma Americas, LLC",MD,5000.00,07/31/2015,Cash or cash equivalent,340077562,Amitiza,,PEDS 11S1,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,01/06/2015,Cash or cash equivalent,295840308,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,01/06/2015,Cash or cash equivalent,295840310,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,01/06/2015,Cash or cash equivalent,295840312,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,01/06/2015,Cash or cash equivalent,295840314,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,01/06/2015,Cash or cash equivalent,295840316,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,01/06/2015,Cash or cash equivalent,295840318,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,281.25,01/06/2015,Cash or cash equivalent,295840320,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,484.38,01/06/2015,Cash or cash equivalent,295840322,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,01/06/2015,Cash or cash equivalent,295840324,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,01/06/2015,Cash or cash equivalent,295840326,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,01/06/2015,Cash or cash equivalent,295840328,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,01/06/2015,Cash or cash equivalent,295840330,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,414.06,01/06/2015,Cash or cash equivalent,295840332,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,421.88,01/06/2015,Cash or cash equivalent,295840334,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,Iowa City,52242,,,bioMerieux,100000000114,bioMerieux,NC,64000.00,12/03/2015,Cash or cash equivalent,339821510,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,Iowa City,52242,,,bioMerieux,100000000114,bioMerieux,NC,850.50,11/23/2015,Cash or cash equivalent,339791586,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353 JCP,,Iowa City,52242,,,bioMerieux,100000000114,bioMerieux,NC,3402.00,11/23/2015,Cash or cash equivalent,339756152,,,,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848012,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848014,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848016,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,03/10/2015,Cash or cash equivalent,295848018,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848020,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848022,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848024,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,03/10/2015,Cash or cash equivalent,295848026,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,03/10/2015,Cash or cash equivalent,295848028,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848030,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848032,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848034,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848036,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,03/10/2015,Cash or cash equivalent,295848038,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,03/10/2015,Cash or cash equivalent,295848040,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,46.88,03/10/2015,Cash or cash equivalent,295848042,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,03/10/2015,Cash or cash equivalent,295848044,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849696,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849698,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849700,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849702,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849704,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849706,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,03/10/2015,Cash or cash equivalent,295849708,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,281.25,03/10/2015,Cash or cash equivalent,295849710,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,03/10/2015,Cash or cash equivalent,295849712,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,03/10/2015,Cash or cash equivalent,295849714,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,03/10/2015,Cash or cash equivalent,295849716,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,03/10/2015,Cash or cash equivalent,295849718,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,03/10/2015,Cash or cash equivalent,295849720,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,03/10/2015,Cash or cash equivalent,295849722,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,03/10/2015,Cash or cash equivalent,295849724,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,03/10/2015,Cash or cash equivalent,295849726,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,03/10/2015,Cash or cash equivalent,295849728,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,03/10/2015,Cash or cash equivalent,295849730,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,03/10/2015,Cash or cash equivalent,295849732,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,03/10/2015,Cash or cash equivalent,295849734,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,03/10/2015,Cash or cash equivalent,295849736,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,03/10/2015,Cash or cash equivalent,295849738,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,03/10/2015,Cash or cash equivalent,295849740,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,03/10/2015,Cash or cash equivalent,295849742,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/14/2015,Cash or cash equivalent,295851094,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/14/2015,Cash or cash equivalent,295851096,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/14/2015,Cash or cash equivalent,295851098,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,85.00,04/14/2015,Cash or cash equivalent,295851100,,,ProMRI,,
Covered Recipient Physician,,,203369,JONATHAN,,ARNOLD,1401 W AGENCY RD,,WEST BURLINGTON,52655-1659,Medical Doctor,Allopathic & Osteopathic Physicians|Preventive Medicine|Undersea and Hyperbaric Medicine,Novadaq Technologies Inc.,100000011117,Novadaq Technologies Inc.,,10710.00,10/05/2015,In-kind items and services,337576726,,,Use of a covered product at no charge,,
Covered Recipient Physician,,,203369,JONATHAN,,ARNOLD,1401 W AGENCY RD,,WEST BURLINGTON,52655-1659,Medical Doctor,Allopathic & Osteopathic Physicians|Preventive Medicine|Undersea and Hyperbaric Medicine,Novadaq Technologies Inc.,100000011117,Novadaq Technologies Inc.,,17850.00,10/29/2015,In-kind items and services,337576728,,,Use of a covered product at no charge,,
Covered Recipient Physician,,,203369,JONATHAN,,ARNOLD,1401 W AGENCY RD,,WEST BURLINGTON,52655-1659,Medical Doctor,Allopathic & Osteopathic Physicians|Preventive Medicine|Undersea and Hyperbaric Medicine,Novadaq Technologies Inc.,100000011117,Novadaq Technologies Inc.,,10710.00,12/22/2015,In-kind items and services,337576730,,,Use of a covered product at no charge,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877432,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877438,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877442,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877446,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877450,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877454,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877457,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,07/14/2015,Cash or cash equivalent,295877462,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877466,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877470,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877474,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877478,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877484,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877488,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877492,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877496,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877500,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877504,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877508,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877512,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877518,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877522,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877526,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,07/14/2015,Cash or cash equivalent,295877534,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877540,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877544,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877548,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877554,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877556,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877560,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877566,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877570,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877574,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877578,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,07/14/2015,Cash or cash equivalent,295877582,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,07/14/2015,Cash or cash equivalent,295877586,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877590,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,07/14/2015,Cash or cash equivalent,295877596,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,07/14/2015,Cash or cash equivalent,295877598,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,05/12/2015,Cash or cash equivalent,295862404,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,05/12/2015,Cash or cash equivalent,295862408,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,05/12/2015,Cash or cash equivalent,295862412,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,05/12/2015,Cash or cash equivalent,295862416,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,05/12/2015,Cash or cash equivalent,295862422,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862426,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862430,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,05/12/2015,Cash or cash equivalent,295862436,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,05/12/2015,Cash or cash equivalent,295862440,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,05/12/2015,Cash or cash equivalent,295862444,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862448,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862450,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,05/12/2015,Cash or cash equivalent,295862454,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,05/12/2015,Cash or cash equivalent,295862460,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,05/12/2015,Cash or cash equivalent,295862464,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862466,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862472,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,05/12/2015,Cash or cash equivalent,295862476,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,05/12/2015,Cash or cash equivalent,295862480,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,05/12/2015,Cash or cash equivalent,295862484,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862490,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,05/12/2015,Cash or cash equivalent,295862492,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,05/12/2015,Cash or cash equivalent,295862494,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,06/10/2015,Cash or cash equivalent,295866064,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,06/10/2015,Cash or cash equivalent,295866070,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,07/14/2015,Cash or cash equivalent,295871005,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,07/14/2015,Cash or cash equivalent,295871010,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,07/14/2015,Cash or cash equivalent,295871012,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,257.36,07/14/2015,Cash or cash equivalent,295871016,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,349.27,07/14/2015,Cash or cash equivalent,295871020,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,349.27,07/14/2015,Cash or cash equivalent,295871022,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868942,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,349.27,07/14/2015,Cash or cash equivalent,295871024,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,07/14/2015,Cash or cash equivalent,295871030,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868948,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868950,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868954,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868958,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,06/10/2015,Cash or cash equivalent,295868962,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,06/10/2015,Cash or cash equivalent,295868966,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,06/10/2015,Cash or cash equivalent,295868970,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2015,Cash or cash equivalent,295868974,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,06/10/2015,Cash or cash equivalent,295868978,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,06/10/2015,Cash or cash equivalent,295868984,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,05/12/2015,Cash or cash equivalent,295863760,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,167.99,05/12/2015,Cash or cash equivalent,295863764,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,05/12/2015,Cash or cash equivalent,295863770,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,05/12/2015,Cash or cash equivalent,295862400,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,05/12/2015,Cash or cash equivalent,295863776,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,05/12/2015,Cash or cash equivalent,295863780,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,167.99,05/12/2015,Cash or cash equivalent,295863784,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,500.00,09/22/2015,Cash or cash equivalent,295891524,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,08/11/2015,Cash or cash equivalent,295883686,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,08/11/2015,Cash or cash equivalent,295883690,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,08/11/2015,Cash or cash equivalent,295883694,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,321.70,08/11/2015,Cash or cash equivalent,295883700,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,450.38,08/11/2015,Cash or cash equivalent,295883704,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,167.99,08/11/2015,Cash or cash equivalent,295883708,,,BIOHELIX-I,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882332,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882336,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,281.25,08/11/2015,Cash or cash equivalent,295882338,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882342,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882346,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882352,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882354,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,08/11/2015,Cash or cash equivalent,295882358,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882360,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882364,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882368,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882372,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,08/11/2015,Cash or cash equivalent,295882376,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/11/2015,Cash or cash equivalent,295882380,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/11/2015,Cash or cash equivalent,295882384,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,08/11/2015,Cash or cash equivalent,295882388,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,08/11/2015,Cash or cash equivalent,295882392,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,08/11/2015,Cash or cash equivalent,295882396,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,08/11/2015,Cash or cash equivalent,295882401,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,08/11/2015,Cash or cash equivalent,295882406,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,08/11/2015,Cash or cash equivalent,295882410,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,08/11/2015,Cash or cash equivalent,295882416,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,08/11/2015,Cash or cash equivalent,295882420,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890670,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890676,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890680,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890684,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890689,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890692,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890698,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,09/10/2015,Cash or cash equivalent,295890702,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,09/10/2015,Cash or cash equivalent,295890708,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,09/10/2015,Cash or cash equivalent,295890712,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,09/10/2015,Cash or cash equivalent,295890718,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/12/2015,Cash or cash equivalent,295860274,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,05/12/2015,Cash or cash equivalent,295860278,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/14/2015,Cash or cash equivalent,295853360,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,04/14/2015,Cash or cash equivalent,295853364,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/14/2015,Cash or cash equivalent,295853368,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/14/2015,Cash or cash equivalent,295853372,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/14/2015,Cash or cash equivalent,295853376,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/14/2015,Cash or cash equivalent,295853380,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,04/14/2015,Cash or cash equivalent,295853386,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/14/2015,Cash or cash equivalent,295853390,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1079.08,04/14/2015,Cash or cash equivalent,295853394,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/14/2015,Cash or cash equivalent,295853399,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,218.76,04/14/2015,Cash or cash equivalent,295853404,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/14/2015,Cash or cash equivalent,295853406,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,04/14/2015,Cash or cash equivalent,295853410,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/14/2015,Cash or cash equivalent,295853414,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/14/2015,Cash or cash equivalent,295853418,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/14/2015,Cash or cash equivalent,295853422,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/14/2015,Cash or cash equivalent,295853426,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,125.00,04/14/2015,Cash or cash equivalent,295853430,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,156.25,04/14/2015,Cash or cash equivalent,295853436,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,710.95,04/14/2015,Cash or cash equivalent,295853438,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,1158.55,04/14/2015,Cash or cash equivalent,295853442,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/14/2015,Cash or cash equivalent,295853446,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,04/14/2015,Cash or cash equivalent,295853451,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,500.00,05/05/2015,Cash or cash equivalent,295859134,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857242,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857246,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857250,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857254,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857258,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857264,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857268,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857272,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857276,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,04/14/2015,Cash or cash equivalent,295857280,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,181.25,04/14/2015,Cash or cash equivalent,295857282,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,04/14/2015,Cash or cash equivalent,295857284,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,04/14/2015,Cash or cash equivalent,295857286,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857288,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857298,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,04/14/2015,Cash or cash equivalent,295857302,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,04/14/2015,Cash or cash equivalent,295857306,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,04/14/2015,Cash or cash equivalent,295857310,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857314,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857318,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,04/14/2015,Cash or cash equivalent,295857322,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,04/14/2015,Cash or cash equivalent,295857324,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,04/14/2015,Cash or cash equivalent,295857326,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857328,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857330,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,04/14/2015,Cash or cash equivalent,295857332,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,137.50,04/14/2015,Cash or cash equivalent,295857334,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,331.25,04/14/2015,Cash or cash equivalent,295857336,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857338,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,100.00,04/14/2015,Cash or cash equivalent,295857340,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,231.25,04/14/2015,Cash or cash equivalent,295857342,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,296.88,05/12/2015,Cash or cash equivalent,295860270,,,ProMRI,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915834,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915838,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915844,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915848,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915852,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915856,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915860,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,12/08/2015,Cash or cash equivalent,295915864,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910644,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910648,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910652,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,293.75,11/10/2015,Cash or cash equivalent,295910656,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910596,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910600,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910606,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910610,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910614,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910618,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910624,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910628,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910632,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,11/10/2015,Cash or cash equivalent,295910636,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,281.25,11/10/2015,Cash or cash equivalent,295910641,,,SIELLO,,
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,375.00,07/08/2015,Cash or cash equivalent,336554068,,,EXCEL,,AV AV 10186723 20150804 0403 AV 10186723 20150804 0403 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,12/07/2015,Cash or cash equivalent,336554078,,,EXCEL,,AV AV 10201280 20160112 0088 AV 10201280 20160112 0088 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,2875.00,12/08/2015,Cash or cash equivalent,336554080,,,COAPT,,AV AV 10201280 20160112 0199 AV 10201280 20160112 0199 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,02/04/2015,Cash or cash equivalent,336554082,,,EXCEL,,AV AV 10380625 20150306 0422 AV 10380625 20150306 0422 0001 EXCEL Clinical Trial
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,01/30/2015,Cash or cash equivalent,336554084,,,COAPT,,AV AV 10669432 20150225 0015 AV 10669432 20150225 0015 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,03/09/2015,Cash or cash equivalent,336554088,,,COAPT,,AV AV 10669432 20150423 0555 AV 10669432 20150423 0555 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1200.00,06/26/2015,Cash or cash equivalent,336554090,,,COAPT,,AV AV 10669432 20150709 0148 AV 10669432 20150709 0148 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,06/25/2015,Cash or cash equivalent,336554092,,,COAPT,,AV AV 10669432 20150709 0207 AV 10669432 20150709 0207 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Non-covered Recipient Entity,,,,,,,3400 Dexter Court,Suite 200,Davenport,52807,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1300.00,01/22/2015,Cash or cash equivalent,336557670,,,EROV 106 ZXRC,,EXP 150504131312690514 DTL 150504131345053172
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1700.00,06/10/2015,Cash or cash equivalent,336554096,,,COAPT,,AV AV 10669432 20150709 0451 AV 10669432 20150709 0451 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,11/17/2015,Cash or cash equivalent,336554098,,,COAPT,,AV AV 10669432 20151230 0046 AV 10669432 20151230 0046 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,650.00,03/03/2015,Cash or cash equivalent,336554100,,,COAPT,,AV AV 10743241 20150407 0600 AV 10743241 20150407 0600 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Covered Recipient Teaching Hospital,2938,MERCY MEDICAL CENTER-DES MOINES,,,,,1111 6th Avenue,,Des Moines,50314,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,250.00,05/18/2015,Cash or cash equivalent,336554104,,,COAPT,,AV AV 10743241 20150623 0304 AV 10743241 20150623 0304 0001 Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Pa
Non-covered Recipient Entity,,,,,,,3400 Dexter Court,Suite 200,Davenport,52807,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,100.00,02/26/2015,Cash or cash equivalent,336557672,,,EROV 106 ZXRC,,EXP 150522154609583666 DTL 150522154642844415
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,04/30/2015,Cash or cash equivalent,336553682,,,CANOPY,,AV AV 10201280 20150519 0203 AV 10201280 20150519 0203 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,200.00,03/27/2015,Cash or cash equivalent,336553686,,,CANOPY,,AV AV 10380625 20150412 0077 AV 10201280 20150402 0077 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1000.00,08/03/2015,Cash or cash equivalent,336553690,,,CANOPY,,AV AV 10380625 20150911 0596 AV 10380625 20150911 0596 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,03/12/2015,Cash or cash equivalent,336553692,,,CANOPY,,AV AV 10669432 20150423 0449 AV 10669432 20150423 0449 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2946,GENESIS MEDICAL CENTER,,,,,1227 E Rusholme Street,,Davenport,52803,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,500.00,05/28/2015,Cash or cash equivalent,336553694,,,CANOPY,,AV AV 10743241 20150623 0049 AV 10743241 20150623 0049 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,1670.00,02/04/2015,Cash or cash equivalent,298896702,INJECTAFER,,A Multi-Center Randomized Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety Effect on Quality Life and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia in an Infusion Center Setting,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,2580.00,04/01/2015,Cash or cash equivalent,298896706,INJECTAFER,,A Multi-Center Randomized Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety Effect on Quality Life and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia in an Infusion Center Setting,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,7480.00,09/23/2015,Cash or cash equivalent,298896714,INJECTAFER,,A Multi-Center Randomized Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety Effect on Quality Life and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia in an Infusion Center Setting,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,60.00,12/09/2015,Cash or cash equivalent,298896718,INJECTAFER,,A Multi-Center Randomized Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety Effect on Quality Life and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia in an Infusion Center Setting,,
Non-covered Recipient Entity,,,,,,,230 Nebraska Street,,Sioux City,51101,,,Luitpold Pharmaceuticals Inc,100000010540,Luitpold Pharmaceuticals Inc,NY,750.00,12/22/2015,Cash or cash equivalent,298896724,INJECTAFER,,A Multi-Center Randomized Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety Effect on Quality Life and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia in an Infusion Center Setting,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,15000.00,01/01/2015,In-kind items and services,336554910,,,Elucidating the role of FOXO3 in restoring the potency of in vitro expanded mesenchymal stem cells,,ADD ADD 7000111163 Grant3 ADD 7000111163 Grant3 REC1
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,600.00,04/29/2015,Cash or cash equivalent,336554912,,,CANOPY,,AV AV 10201280 20150519 0176 AV 10201280 20150519 0176 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,700.00,02/11/2015,Cash or cash equivalent,336554914,,,CANOPY,,AV AV 10380625 20150306 0262 AV 10380625 20150306 0262 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Drive,,Iowa City,52242,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,1200.00,08/04/2015,Cash or cash equivalent,336554916,,,CANOPY,,AV AV 10380625 20150911 0543 AV 10380625 20150911 0543 0001 Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy CANOPY
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896358,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896364,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896368,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896372,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896376,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896380,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896386,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,243.50,10/15/2015,Cash or cash equivalent,295896392,,,SIELLO,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2872.00,02/06/2015,Cash or cash equivalent,340099002,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM-EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1805.00,04/22/2015,Cash or cash equivalent,340099004,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM-EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1906.00,04/22/2015,Cash or cash equivalent,340099006,ORENITRAM,,"AN OPEN-LABEL, LONG-TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,3897.00,06/26/2015,Cash or cash equivalent,340099008,ORENITRAM,,"AN OPEN-LABEL, LONG-TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,2271.00,06/26/2015,Cash or cash equivalent,340099010,ORENITRAM,,"AN OPEN-LABEL, LONG-TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,163.00,06/26/2015,Cash or cash equivalent,340099012,ORENITRAM,,"AN OPEN-LABEL, LONG-TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,13740.00,08/07/2015,Cash or cash equivalent,340099014,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM-EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,1572.00,11/20/2015,Cash or cash equivalent,340099016,ORENITRAM,,TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM-EV,http://clinicaltrials.gov/ct2/show/NCT01560624,NA
Non-covered Recipient Entity,,,,,,,DBA:JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,53.11,01/12/2015,Cash or cash equivalent,325067668,IOL,,Functional Benefit with AcrySof Natural Chromophore,,
Non-covered Recipient Entity,,,,,,,DBA:JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,500.00,04/01/2015,Cash or cash equivalent,325067680,IOL,,Functional Benefit with AcrySof Natural Chromophore,,
Non-covered Recipient Entity,,,,,,,DBA:JONES EYE CLINIC,4405 HAMILTON BLVD,SIOUX CITY,51104,,,Alcon Research Ltd,100000000218,Alcon Research Ltd,TX,2000.00,04/01/2015,Cash or cash equivalent,325067688,IOL,,Functional Benefit with AcrySof Natural Chromophore,,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,Endo Pharmaceuticals Inc.,100000000285,Endo Pharmaceuticals Inc.,PA,1087.50,02/10/2015,Cash or cash equivalent,338766876,SUPPRELIN LA,,"A MULTICENTER, OBSERVATIONAL REGISTRY OF PEDIATRIC FEMALE PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY REVCEIVING SUPPRELIN LA HISTRELIN ACETATE, A HYDROGEL SUBCUTANEOUS IMPLANT",,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,Endo Pharmaceuticals Inc.,100000000285,Endo Pharmaceuticals Inc.,PA,1812.50,07/28/2015,Cash or cash equivalent,338766880,SUPPRELIN LA,,"A MULTICENTER, OBSERVATIONAL REGISTRY OF PEDIATRIC FEMALE PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY REVCEIVING SUPPRELIN LA HISTRELIN ACETATE, A HYDROGEL SUBCUTANEOUS IMPLANT",,
Covered Recipient Teaching Hospital,2940,IOWA METHODIST MEDICAL CENTER,,,,,1200 Pleasant St,,Des Moines,50309,,,Endo Pharmaceuticals Inc.,100000000285,Endo Pharmaceuticals Inc.,PA,362.50,10/27/2015,Cash or cash equivalent,338766888,SUPPRELIN LA,,"A MULTICENTER, OBSERVATIONAL REGISTRY OF PEDIATRIC FEMALE PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY REVCEIVING SUPPRELIN LA HISTRELIN ACETATE, A HYDROGEL SUBCUTANEOUS IMPLANT",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,240.00,01/20/2015,Cash or cash equivalent,340572228,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,240.00,01/20/2015,Cash or cash equivalent,340572232,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,120.00,01/20/2015,Cash or cash equivalent,340572234,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1618.00,01/21/2015,Cash or cash equivalent,340572238,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13031.82,01/21/2015,Cash or cash equivalent,340572240,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4000.00,02/10/2015,Cash or cash equivalent,340572244,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1200.00,02/05/2015,Cash or cash equivalent,340572246,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,500.00,02/05/2015,Cash or cash equivalent,340572250,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,48.79,03/20/2015,Cash or cash equivalent,340572264,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,250.00,03/20/2015,Cash or cash equivalent,340572266,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,248.52,03/20/2015,Cash or cash equivalent,340572268,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1374.36,02/06/2015,Cash or cash equivalent,340572300,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3571.90,05/08/2015,Cash or cash equivalent,340572340,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,421 CHESTNUT ST ATTN GAYLE TURI,,EVANSVILLE,47713,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1050.00,04/24/2015,Cash or cash equivalent,340572214,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"T2 Biosystems, Inc.",100000136424,"T2 Biosystems, Inc.",MA,6000.00,08/20/2015,Cash or cash equivalent,340851486,,,T2Candida Sample Acquisition,,
Non-covered Recipient Entity,,,,,,,TFC BANKING REMITTANCE PROCESS 2400 OGDEN AVENUE SUITE,,LISLE,60532,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5586.25,01/21/2015,Cash or cash equivalent,340589126,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6965.60,01/06/2015,Cash or cash equivalent,340589130,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr C44PGH,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,10.95,01/23/2015,In-kind items and services,340586306,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 WestRsch 151,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,120.45,10/27/2015,In-kind items and services,340586342,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West 151 Attn Sarah Else,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2475.00,08/04/2015,Cash or cash equivalent,340586350,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West 151 Attn Sarah Else,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,988.20,09/25/2015,Cash or cash equivalent,340586357,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,200 Hawkins Dr C44PGH,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,132.90,02/19/2015,In-kind items and services,340586360,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,601 Highway 6 West Iowa City VA Health Care System,,Iowa City,52246,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,102.00,08/03/2015,In-kind items and services,340586398,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1842.00,04/14/2015,Cash or cash equivalent,340583300,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4013.04,04/28/2015,Cash or cash equivalent,340583346,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,TFC BANKING REMITTANCE PROCESS 2400 OGDEN AVENUE SUITE,,LISLE,60532,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4000.00,02/20/2015,Cash or cash equivalent,340588922,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,TFC BANKING REMITTANCE PROCESS 2400 OGDEN AVENUE SUITE,,LISLE,60532,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,803.00,03/13/2015,Cash or cash equivalent,340588972,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4304.40,03/27/2015,Cash or cash equivalent,340588976,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5280.65,05/01/2015,Cash or cash equivalent,340583412,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,8123.64,01/21/2015,Cash or cash equivalent,340583450,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3200.00,01/21/2015,Cash or cash equivalent,340583454,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,160.00,01/20/2015,Cash or cash equivalent,340583458,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,360.00,01/20/2015,Cash or cash equivalent,340583462,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,SPECIALISTS  INC 1800 NATIONS DR STE 115 Attn to Acco,,GURNEE,60031,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,160.00,01/20/2015,Cash or cash equivalent,340583466,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2775.00,05/05/2015,Cash or cash equivalent,340579316,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3423.00,05/26/2015,Cash or cash equivalent,340579320,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2735.00,01/07/2015,Cash or cash equivalent,340579362,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2280.00,01/06/2015,Cash or cash equivalent,340579366,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4564.00,02/05/2015,Cash or cash equivalent,340579396,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1188.36,02/10/2015,Cash or cash equivalent,340579400,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,02/10/2015,Cash or cash equivalent,340579946,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,12416.10,01/06/2015,Cash or cash equivalent,340579980,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4267.60,02/05/2015,Cash or cash equivalent,340579988,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1188.36,02/10/2015,Cash or cash equivalent,340580458,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,589.00,05/05/2015,Cash or cash equivalent,340580478,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1084.68,01/19/2015,Cash or cash equivalent,340580970,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4355.34,07/23/2015,Cash or cash equivalent,340580974,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,210.00,09/03/2015,Cash or cash equivalent,340580978,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,40.00,02/03/2015,Cash or cash equivalent,340580982,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3873.90,02/05/2015,Cash or cash equivalent,340576106,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,04/01/2015,Cash or cash equivalent,340576116,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,02/10/2015,Cash or cash equivalent,340579996,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5135.80,04/24/2015,Cash or cash equivalent,340579998,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,03/24/2015,Cash or cash equivalent,340580002,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,03/24/2015,Cash or cash equivalent,340580006,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,03/24/2015,Cash or cash equivalent,340580008,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1322.50,02/20/2015,Cash or cash equivalent,340580984,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,8314.74,06/30/2015,Cash or cash equivalent,340580988,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4695.97,06/15/2015,Cash or cash equivalent,340580992,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2367.83,06/02/2015,Cash or cash equivalent,340580996,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,929.07,04/17/2015,Cash or cash equivalent,340581000,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel Street Suite 3262,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,11466.00,03/09/2015,In-kind items and services,340581002,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,180.00,03/31/2015,Cash or cash equivalent,340581006,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,04/01/2015,Cash or cash equivalent,340576122,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,04/01/2015,Cash or cash equivalent,340576126,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,04/21/2015,Cash or cash equivalent,340576128,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3170.00,04/10/2015,Cash or cash equivalent,340580516,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3735.00,03/06/2015,Cash or cash equivalent,340580524,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1141.00,03/06/2015,Cash or cash equivalent,340580528,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,03/24/2015,Cash or cash equivalent,340580530,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,650.00,03/24/2015,Cash or cash equivalent,340580534,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,969.07,05/12/2015,Cash or cash equivalent,340581016,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5000.00,02/13/2015,Cash or cash equivalent,340581998,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,280.00,03/02/2015,Cash or cash equivalent,340581056,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,100.00,02/05/2015,Cash or cash equivalent,340582002,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,500.00,02/05/2015,Cash or cash equivalent,340582004,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,300.00,02/05/2015,Cash or cash equivalent,340582008,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,7860.00,02/05/2015,Cash or cash equivalent,340582012,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6647.04,02/05/2015,Cash or cash equivalent,340582016,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2224.00,02/20/2015,Cash or cash equivalent,340582020,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1583.76,08/07/2015,Cash or cash equivalent,340581104,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3500.00,04/21/2015,Cash or cash equivalent,340582042,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,600.00,10/26/2015,Cash or cash equivalent,340581110,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,411 Laurel St,,Des Moines,50314,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2287.83,05/15/2015,Cash or cash equivalent,340581170,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50.00,05/22/2015,Cash or cash equivalent,340582098,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,820.00,05/22/2015,Cash or cash equivalent,340582100,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2577.40,05/01/2015,Cash or cash equivalent,340575796,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,Attn Kiley McGlauchlen 1025 Maine Street,,Quincy,62301,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,05/01/2015,Cash or cash equivalent,340575802,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2100.00,04/10/2015,Cash or cash equivalent,340578834,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1743.00,03/06/2015,Cash or cash equivalent,340578850,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE Attn Rod Raphael,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,100.00,01/06/2015,Cash or cash equivalent,340582150,Uloric,,"Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,13254.50,01/13/2015,Cash or cash equivalent,340582152,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2744.00,01/29/2015,Cash or cash equivalent,340582156,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,10987.00,01/29/2015,Cash or cash equivalent,340582160,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,392.49,01/21/2015,Cash or cash equivalent,340582164,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,5139 BEECH DRIVE,,INDIANAPOLIS,46254,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,392.49,01/21/2015,Cash or cash equivalent,340582168,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTNSHELLY MOORE AD ACCTNG 1025 S SIXTH ST,,SPRINGFIELD,62703,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1270.00,03/06/2015,Cash or cash equivalent,340594574,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,INDIANA LLC 5250 E US 36 Suite 645 attnto Erin Conder,,Avon,46123,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3000.00,02/06/2015,Cash or cash equivalent,340594618,Uloric,,"Phase 3 Evaluation of sUA and flare rates of gout subjects taking febuxostat XR 40 mg, 80 mg, Uloric IR 40 mg and 80mg, and placebo",,
Non-covered Recipient Entity,,,,,,,ATTNSHELLY MOORE AD ACCTNG 1025 S SIXTH ST,,SPRINGFIELD,62703,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6005.00,01/07/2015,Cash or cash equivalent,340594552,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTNSHELLY MOORE AD ACCTNG 1025 S SIXTH ST,,SPRINGFIELD,62703,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,41.80,01/02/2015,Cash or cash equivalent,340594556,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTNSHELLY MOORE AD ACCTNG 1025 S SIXTH ST,,SPRINGFIELD,62703,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,41.80,01/19/2015,Cash or cash equivalent,340594558,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,MEDICINE 675 W NORTH AVENUE SUITE 210,,MELROSE PARK,60160,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,545.00,05/26/2015,Cash or cash equivalent,340594404,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,MEDICINE 675 W NORTH AVENUE SUITE 210,,MELROSE PARK,60160,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1209.80,01/06/2015,Cash or cash equivalent,340594410,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,MEDICINE 675 W NORTH AVENUE SUITE 210,,MELROSE PARK,60160,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3732.20,03/06/2015,Cash or cash equivalent,340594420,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,55 UNIVERSITY DR STE 106,,VALPARAISO,46383,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3981.97,04/10/2015,Cash or cash equivalent,340603404,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,55 UNIVERSITY DR STE 106,,VALPARAISO,46383,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2329.23,04/10/2015,Cash or cash equivalent,340603434,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,55 UNIVERSITY DR STE 106,,VALPARAISO,46383,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4608.20,01/22/2015,Cash or cash equivalent,340603486,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,LTD PO BOX 5247 ATTN SHARON RUGGLES RESEARCH,,ROCKFORD,61125,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2278.25,01/07/2015,Cash or cash equivalent,340604546,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,201 Ridge St Ste 201,,Council Bluffs,51503,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,118.00,08/25/2015,In-kind items and services,340605286,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,201 Ridge Suite 201,,Council Bluffs,51503,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,5292.00,02/16/2015,In-kind items and services,340605300,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3717.96,01/13/2015,Cash or cash equivalent,340601628,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,9.74,01/13/2015,Cash or cash equivalent,340601630,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,01/13/2015,Cash or cash equivalent,340601632,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,201.00,01/07/2015,Cash or cash equivalent,340600630,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3083.69,11/12/2015,Cash or cash equivalent,340600234,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1015 Duff Avenue Medical Arts Bldg,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2646.00,02/23/2015,In-kind items and services,340600236,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,860.00,01/29/2015,Cash or cash equivalent,340600554,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,59.00,02/10/2015,Cash or cash equivalent,340600564,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,172.00,02/10/2015,Cash or cash equivalent,340600566,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,707.00,04/24/2015,Cash or cash equivalent,340600570,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3154.70,03/27/2015,Cash or cash equivalent,340610536,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2802.00,01/22/2015,Cash or cash equivalent,340609278,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1188.37,02/06/2015,Cash or cash equivalent,340609280,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTN CASANDRA SMILELY 5841 S MARYLAND AVENUE N007 MC,,CHICAGO,60637,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6280.00,02/05/2015,Cash or cash equivalent,340610046,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTN CASANDRA SMILELY 5841 S MARYLAND AVENUE N007 MC,,CHICAGO,60637,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6455.00,03/27/2015,Cash or cash equivalent,340610052,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ATTN CASANDRA SMILELY 5841 S MARYLAND AVENUE N007 MC,,CHICAGO,60637,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,03/27/2015,Cash or cash equivalent,340610054,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2081.00,04/10/2015,Cash or cash equivalent,340609290,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,517.00,01/29/2015,Cash or cash equivalent,340609332,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1356.00,05/05/2015,Cash or cash equivalent,340609338,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3210.50,01/29/2015,Cash or cash equivalent,340610392,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4659.20,05/05/2015,Cash or cash equivalent,340607592,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,01/07/2015,Cash or cash equivalent,340607602,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4542.30,01/22/2015,Cash or cash equivalent,340607604,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,250.00,01/19/2015,Cash or cash equivalent,340607606,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1200 Centre West Drive,,Springfield,62704,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1209.80,01/06/2015,Cash or cash equivalent,340594856,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court 8,,Clive,50325,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2513.00,10/14/2015,Cash or cash equivalent,340595644,,,"P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU",,
Non-covered Recipient Entity,,,,,,,2024 NW 92nd Court 8,,Clive,50325,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,750.00,10/14/2015,Cash or cash equivalent,340595646,,,"P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU",,
Non-covered Recipient Entity,,,,,,,1200 Centre West Drive,,Springfield,62704,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4345.40,01/29/2015,Cash or cash equivalent,340594910,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1280.00,04/10/2015,Cash or cash equivalent,340597044,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,640.00,03/06/2015,Cash or cash equivalent,340597046,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,62624 COLLECTION CENTER DR ATTN ACCOUNTS RECEIVABLE,,CHICAGO,60693,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2137.00,02/06/2015,Cash or cash equivalent,340594936,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,62624 COLLECTION CENTER DR ATTN ACCOUNTS RECEIVABLE,,CHICAGO,60693,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1436.00,01/06/2015,Cash or cash equivalent,340594956,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,62624 COLLECTION CENTER DR ATTN ACCOUNTS RECEIVABLE,,CHICAGO,60693,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4532.93,03/24/2015,Cash or cash equivalent,340594974,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,550.14,11/12/2015,Cash or cash equivalent,340596062,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,357.87,05/15/2015,Cash or cash equivalent,340596064,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,160.00,10/26/2015,Cash or cash equivalent,340596066,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,411.25,07/23/2015,Cash or cash equivalent,340596068,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,350.00,09/03/2015,Cash or cash equivalent,340596070,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,411.25,06/30/2015,Cash or cash equivalent,340596072,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1233.75,06/15/2015,Cash or cash equivalent,340596074,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,411.25,06/02/2015,Cash or cash equivalent,340596076,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,715.74,04/17/2015,Cash or cash equivalent,340596078,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,20.00,03/31/2015,Cash or cash equivalent,340596080,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,ADVANTAGE INC PO BOX 4539 ATTN CLINICAL RESEARCH ADVA,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,620.00,05/05/2015,Cash or cash equivalent,340597132,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,800 S WELLS STREET SUITE M15 Attn Dr Danny Sugimoto,,CHICAGO,60607,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,682.45,03/06/2015,Cash or cash equivalent,340595040,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,01/07/2015,Cash or cash equivalent,340595542,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1749.90,01/06/2015,Cash or cash equivalent,340595544,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3573.60,02/05/2015,Cash or cash equivalent,340595562,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,686.00,02/05/2015,Cash or cash equivalent,340595564,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,PO BOX 4539,,CAROL STREAM,60197-4539,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1338.30,04/24/2015,Cash or cash equivalent,340595576,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,1215 Duff Ave,,Ames,50010,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,210.00,03/02/2015,Cash or cash equivalent,340595862,Contrave,,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events MACE in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR-Bupropion SR",,
Non-covered Recipient Entity,,,,,,,1200 Centre West Drive,,Springfield,62704,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3145.20,03/27/2015,Cash or cash equivalent,340594836,Uloric,,Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,4096.15,01/07/2015,Cash or cash equivalent,292427734,BOTOX,,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,8427.52,03/06/2015,Cash or cash equivalent,292427738,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,5289.07,05/29/2015,Cash or cash equivalent,292427740,BOTOX,,Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,1525.95,01/09/2015,Cash or cash equivalent,292427744,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,5067.35,07/07/2015,Cash or cash equivalent,292427748,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,4789.95,07/22/2015,Cash or cash equivalent,292427752,BOTOX,,A Study Evaluating the Efficacy and Safety of Botulinum Toxin Type A and Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,398.20,01/07/2015,Cash or cash equivalent,292443828,ACZONE,,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Non-covered Recipient Entity,,,,,,,"5950 UNIVERSITY AVENUE, SUITE 341",,WEST DES MOINES,50266,,,Allergan Inc.,100000000278,Allergan Inc.,CA,2057.93,03/03/2015,Cash or cash equivalent,292443830,ACZONE,,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,50396.80,03/17/2015,Cash or cash equivalent,340612220,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,6250.00,12/30/2015,Cash or cash equivalent,340612494,Actos,,MCI Convertors from study 301,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,499.50,08/25/2015,In-kind items and services,340612496,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,568.30,12/28/2015,In-kind items and services,340612498,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2860.08,12/18/2015,Cash or cash equivalent,340612518,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,505.00,02/19/2015,In-kind items and services,340612522,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1551.75,03/26/2015,In-kind items and services,340612530,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,42748.31,04/13/2015,Cash or cash equivalent,340612532,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,775.00,04/20/2015,Cash or cash equivalent,340612534,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,249.00,04/27/2015,In-kind items and services,340612536,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,141221.09,06/11/2015,Cash or cash equivalent,340612538,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1373.00,06/25/2015,In-kind items and services,340612540,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,504.00,10/27/2015,Cash or cash equivalent,340612542,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,91049.73,02/18/2015,Cash or cash equivalent,340612544,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,25629.70,09/14/2015,Cash or cash equivalent,340612548,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2810.00,09/29/2015,Cash or cash equivalent,340612550,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1813.02,09/29/2015,Cash or cash equivalent,340612552,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,3275.00,07/30/2015,Cash or cash equivalent,340612554,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,56047.54,07/10/2015,Cash or cash equivalent,340612556,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353,,IOWA CITY,52242,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,1875.00,01/21/2015,Cash or cash equivalent,324740848,,,ACE An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353,,IOWA CITY,52242,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,5000.00,01/21/2015,Cash or cash equivalent,324740852,,,ACE An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353,,IOWA CITY,52242,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,500.00,01/29/2015,Cash or cash equivalent,324740856,,,ACE An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 HAWKINS DRIVE 1353,,IOWA CITY,52242,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,250.00,11/24/2015,Cash or cash equivalent,324740859,,,ACE An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,2906.02,07/30/2015,Cash or cash equivalent,340612558,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,176438.49,01/23/2015,Cash or cash equivalent,340612562,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,81.25,01/07/2015,Cash or cash equivalent,340612564,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,69305.95,08/12/2015,Cash or cash equivalent,340612566,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,249.00,08/25/2015,In-kind items and services,340612568,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,249.00,06/25/2015,In-kind items and services,340612570,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,1850.00,12/18/2015,Cash or cash equivalent,340612472,Actos,,MCI Convertors from study 301,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,250.00,10/14/2015,Cash or cash equivalent,340612476,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,775.00,10/27/2015,Cash or cash equivalent,340612478,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,8992.88,05/14/2015,Cash or cash equivalent,340612480,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,46761.90,05/15/2015,Cash or cash equivalent,340612482,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,7428.25,05/14/2015,Cash or cash equivalent,340612484,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,54211.73,11/13/2015,Cash or cash equivalent,340612486,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,15504.29,11/13/2015,Cash or cash equivalent,340612488,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,4393.60,12/10/2015,Cash or cash equivalent,340612490,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000338,"Takeda Development Center Americas, Inc.",IL,39685.50,10/14/2015,Cash or cash equivalent,340612492,Actos,,Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD,,
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,2964.00,09/28/2015,Cash or cash equivalent,341817666,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Non-covered Recipient Entity,,,,,,,200 HAWKINS DR,,IOWA CITY,52242-1009,,,Actavis Pharma Inc,100000010642,Actavis Pharma Inc,NJ,426.13,06/05/2015,Cash or cash equivalent,335136962,ZENPEP,,Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestines Causing Adverse Intestinal Symptoms Fibrosing Colonopathy,,
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,5952.00,06/25/2015,Cash or cash equivalent,341819328,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,727.19,06/18/2015,Cash or cash equivalent,341819488,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,8226.00,03/25/2015,Cash or cash equivalent,341821024,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,2850.00,03/23/2015,Cash or cash equivalent,341821098,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Non-covered Recipient Entity,,,,,,,28 BBE,,Iowa City,35249,,,"Seattle Genetics, Inc.",100000000279,"Seattle Genetics, Inc.",WA,425.00,03/23/2015,Cash or cash equivalent,341821104,ADCETRIS,,SG0350014,,SG035-0014 -Frontline Mature T & NK Cell Neoplasms
Covered Recipient Physician,,,88578,BRIAN,,OLSHANSKY,4344 MAIER AVE SW,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"On-x Life Technologies, Inc",100000011215,"On-x Life Technologies, Inc",TX,7000.00,10/13/2015,Cash or cash equivalent,342872210,,,Clinical Trial of the On-X Valve Using Low Dose Anticoagulation,,
Covered Recipient Physician,,,88578,BRIAN,,OLSHANSKY,4344 MAIER AVE SW,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"On-x Life Technologies, Inc",100000011215,"On-x Life Technologies, Inc",TX,7375.00,12/01/2015,Cash or cash equivalent,342872218,,,Clinical Trial of the On-X Valve Using Low Dose Anticoagulation,,
Covered Recipient Physician,,,88578,BRIAN,,OLSHANSKY,4344 MAIER AVE SW,,IOWA CITY,52240,Medical Doctor,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,"On-x Life Technologies, Inc",100000011215,"On-x Life Technologies, Inc",TX,695.50,11/05/2015,Cash or cash equivalent,342872222,,,Clinical Trial of the On-X Valve Using Low Dose Anticoagulation,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Actavis Pharma Inc,100000010642,Actavis Pharma Inc,NJ,1377.50,02/23/2015,Cash or cash equivalent,335128158,TUDORZA,,DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD,,
Covered Recipient Teaching Hospital,2948,UNIV OF IOWA HOSP & CLINIC,,,,,200 Hawkins Dr,,Iowa City,52242,,,Actavis Pharma Inc,100000010642,Actavis Pharma Inc,NJ,1520.00,04/21/2015,Cash or cash equivalent,335128160,TUDORZA,,DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ACLIDINIUM BROMIDE ON LONG-TERM CARDIOVASCULAR SAFETY AND COPD EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD,,
